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Disease in the Human Genome
Abstract
This dissertation examines the visual cultures of postwar biomedicine, with a particular focus on how
various techniques, conventions, and professional norms have shaped the `look', classification, diagnosis,
and understanding of genetic diseases. Many scholars have previously highlighted the `informational'
approaches of postwar genetics, which treat the human genome as an expansive data set comprised of
three billion DNA nucleotides. Since the 1950s however, clinicians and genetics researchers have largely
interacted with the human genome at the microscopically visible level of chromosomes. Mindful of this,
my dissertation examines the `observational' approaches of postwar genetics. This is accomplished
through a series of case studies, which examine the visual delineation, diagnosis, and genomic
localization of a number of disorders. My case studies explore various exemplary attempts to associate
particular clinical disorders with specific genetic mutations. This dissertation uses archival resources,
oral histories, and the published biomedical literature to examine the many successes of postwar
biomedicine, and to highlight the contributions made by a wide rage of biomedical professionals. I find
that the visible, tangible human genome, as conceived and depicted at the level of chromosomes, has
become an important work object among a diverse array of practitioners. Chromosomal ideograms, I
argue, provide an important basis for communication and common practices among this community.
While genetic data is becoming increasingly significant to our understanding of human disease,
distinguishing the normal from the pathological remains a task that relies on input from the laboratory
and the clinic. Thus, the success of postwar genetic medicine must be seen in light of the contributions of
biomedical actors from many disciplines, who have agreed to see and communicate about the human
genome - their object of study - in standardized ways.
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ABSTRACT
CHROMOSOMES IN THE CLINIC: THE VISUAL LOCALIZATION AND
ANALYSIS OF GENETIC DISEASE IN THE HUMAN GENOME
Andrew Joseph Hogan
Supervisor: Susan Lindee
This dissertation examines the visual cultures of postwar biomedicine, with a
particular focus on how various techniques, conventions, and professional norms have
shaped the ‘look’, classification, diagnosis, and understanding of genetic diseases. Many
scholars have previously highlighted the ‘informational’ approaches of postwar genetics,
which treat the human genome as an expansive data set comprised of three billion DNA
nucleotides. Since the 1950s however, clinicians and genetics researchers have largely
interacted with the human genome at the microscopically visible level of chromosomes.
Mindful of this, my dissertation examines the ‘observational’ approaches of postwar
genetics. This is accomplished through a series of case studies, which examine the visual
delineation, diagnosis, and genomic localization of a number of disorders. My case
studies explore various exemplary attempts to associate particular clinical disorders with
specific genetic mutations. This dissertation uses archival resources, oral histories, and
the published biomedical literature to examine the many successes of postwar
biomedicine, and to highlight the contributions made by a wide rage of biomedical
professionals. I find that the visible, tangible human genome, as conceived and depicted
at the level of chromosomes, has become an important work object among a diverse array
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of practitioners. Chromosomal ideograms, I argue, provide an important basis for
communication and common practices among this community. While genetic data is
becoming increasingly significant to our understanding of human disease, distinguishing
the normal from the pathological remains a task that relies on input from the laboratory
and the clinic. Thus, the success of postwar genetic medicine must be seen in light of the
contributions of biomedical actors from many disciplines, who have agreed to see and
communicate about the human genome – their object of study – in standardized ways.
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INTRODUCTION
Informational and Observational Approaches to Human Genetics and Biomedicine
This dissertation examines the visual cultures of postwar genetics and
biomedicine. I trace the changing ‘look’ of disease during an era in which an everincreasing number of disorders have come to be understood as having a ‘genomic’ basis.
Since the 1960s, practitioners of biomedicine have sought to move past the variable and
often confusing presentation of disorders in the clinic. Instead, they have increasingly
come to rely on the genomic markers of disease to aid in clinical delineation. As part of
this, a new nosological system was developed in biomedicine, which has sought to
differentiate diseases by locating their causes within the human genome. In this
dissertation, I explore the many successes of this approach to disease classification, while
also highlighting various complications that have arisen.
Throughout the postwar period, clinicians and geneticists have looked to the
genome, at the microscopically visible level of chromosomes, in the hope of improving
the delineation, diagnosis, understanding, and treatment of disease. I examine how
human and medical geneticists have come to see and analyze the human genome – their
object of study – in standardized ways. Scholars have previously highlighted the
‘informational’ approaches of postwar genetics, which treat the genome as an expansive
digital data set. Since the 1950s however, geneticists have largely interacted with the
genome at the microscopically visible level of chromosomes. Mindful of this, this
dissertation explores the ‘observational’ approaches of postwar genetics. Similar to the
heart in cardiology, the human genome has been referred to as the ‘organ’ of medical
1

genetics. Through historical case studies of disorders like Fragile X and Prader-Willi
syndrome, I examine how clinicians and geneticists locate, assess, and develop
confidence in correlations between visible chromosomal markers and likely clinical
outcomes. The human genome, I argue, has a tangible presence in postwar biomedicine
as an anatomical entity and standardized scientific object that can be seen, analyzed, and
dissected. At the same time, the genome is also an important conceptual space in
biomedicine, where the conventions, interests, and questions of basic genetics and
applied clinical research intersect and intermingle.

Examining ‘Mistakes of the Binder’ in Postwar Biomedicine
In 1969, Yale University School of Medicine physician Herbert Lubs reported in
the American Journal of Human Genetics on the identification of an unusual
chromosomal abnormality in a boy affected by intellectual disability. Chromosomal
analysis had been performed, and a ‘secondary constriction’ was identified on one of the
boy’s chromosomes (Figure 1). The secondary constriction, which caused the
appearance of large ‘satellites’ at the end of this chromosome, was also seen in the
patient’s mother and similarly affected brother. This suggested that the marker might be
simply a benign genetic variant. However, analysis of the boy’s extended family
revealed that the secondary constriction was always associated with intellectual disability
when seen in males, but seemed to have no clinical impact on females. This inheritance
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pattern suggested to Lubs that the chromosomal marker, and its physical effects, were Xlinked traits (Lubs, 1969).1

Figure 1 Human chromosome karyotype showing the secondary constriction identified
by Herbert Lubs. This image was published in Lubs (1969), Copyright Elsevier (1969).
Reprinted with permission.

1

X-linked traits are so named because they are inherited on the X chromosome.
Normally, males possess one X chromosome, and females have two. If such a trait is
recessive, it is usually overridden by the other X chromosome in females, but is
expressed in males, who have just one.
3

Perhaps the most clinically significant attribute of this new chromosomal marker
was its heritability. Chromosomal abnormalities – such as trisomy 21, the cause of Down
syndrome – that had been identified over the past decade were most often the result of
random reproductive events, meaning that they were not heritable and could not be traced
through families.2 That this “marker X chromosome”, as Lubs called it (231), was passed
down through a family, and predictive of intellectual disability, was potentially valuable
clinically. With this in mind, Lubs suggested at the beginning on his report that,
“descriptive human cytogenetics [chromosomal analysis] is entering a new and important
phase.” Indeed, identifying smaller, heritable chromosomal anomalies, such as this one,
was important because, “they may permit prevention of clinical disease by identifying
high-risk marriages and allowing subsequent amniocentesis and abortion of abnormal
fetuses if requested by the family” (Lubs, 1969, 231).
Lubs’ chromosomal studies in this 1969 report are representative of a set of
practices and conceptions that have not been adequately addressed among scholars of
postwar genetics and biomedicine. In 1963, human geneticist Lionel Penrose drew a
distinction between gene-level mutations, “mistakes of an imaginary printer,” which are
too small to be seen, and chromosomal aberrations, “mistakes of a binder,” that could be
observed microscopically (Penrose, 1963, 136). Much attention has been paid, in recent
decades, to how researchers study these “mistakes of the printer,” using various
‘informational’ approaches, relying on molecular level techniques. Scholars, for
instance, have highlighted the cracking of the DNA code, the importance of recombinant
2

Most often the abnormal event is non-disjunction, which generally leads to the loss or
gain of one chromosome.
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DNA technology, and the humbling impacts of the Human Genome Project (Lenoir,
1999; Morange, 1998; Kay, 2000; Keller, 2000; de Chadarevian, 2002).
These informational approaches to postwar genetics treat the human genome as an
expansive, and abstract data set, comprised of over three billion DNA nucleotides.
Scientists and scholars alike often describe the DNA code, which consists of four
nucleotides abbreviated A, T, C, and G, as a ‘language’. In its entirety, the human
genome has often been referred to as ‘the book of life’, with obvious religious overtones.
As Lily Kay has described, informational metaphors have driven genetics thinking and
research throughout the postwar period. Even before the demonstration of the double
helical structure of DNA in 1953, information theory and cybernetics were already
central to the practices of molecular biology (Kay, 2000; de Chadarevian, 2002). While
the 1960s marked a move away from explicit informational theory among geneticists,
efforts at ‘cracking’ the DNA code, and learning to read, translate, and edit it, continued
to drive research in the field. Indeed, a shift from more formalistic mathematical
approaches to deciphering the DNA code, to material biochemical techniques did not
undercut the central role of informational metaphors in molecular biology in the 1960s
(Kay, 2000).
Informational approaches to postwar genetics were greatly enhanced during the
1970s by the introduction and development of recombinant DNA technology, which
allowed strands of DNA to be cut up, separated out, and recombined at the molecular
level. These techniques facilitated the large scale copying of specific segments of DNA
through PCR and plasmid cloning, and provided a means for developing a molecular
5

level ‘physical map’ of the human genome (Rabinow, 1997; Gaudilliere and Rheinberger,
2004). Ultimately, these techniques, coupled with increasingly powerful computing,
were harnessed and scaled up, leading to the proposal of the Human Genome Project
during the mid-1980s. By 2000, the first reference sequence of the entire human genome
was finished and made publically available (Kevles and Hood, 1992; Cook-Deegan,
1995; Rabinow and Dan-Cohen, 2005; Garcia-Sancho, 2012).
While these molecular innovations have been central to the development and
successes of postwar genetics and biomedicine, they were not the only tools that
clinicians and geneticists used during this period to analyze the human genome. In
addition to these ‘informational’ methods, in recent years historians of science have
begun to explore the ‘observational’ approaches of postwar human genetics: those that
seek to identify and analyze various “mistakes of the binder”. Rather than molecular
techniques, observational approaches are largely based on the analysis of the
microscopically visible human chromosome set. During the postwar period, despite the
great importance of DNA-level techniques, clinicians and geneticists have largely
interacted with the genome at the visible level of chromosomes. Mindful of this, a
parallel history to that of molecular biology has recently began to be told by scholars
(Martin, 2004; Lindee, 2005; de Chadarevian, 2010; Santesmases, 2010; Hogan 2013).

Observational Analysis of the Human Chromosome Set
Lorraine Daston has recently called for a “turn towards ontology” among
historians and philosophers of science, in particular, “towards ontologies created and
6

sustained by scientific observation” (Daston, 2008, 97). Observation is a collective
practice and the building of visual ontologies is a gradual process, which takes place
among a community that learns and agrees to see objects, both commonplace and
obscure, in particular ways (Fleck, 1979; Daston, 2008). Over the past several years,
historians of science have begun to explore the observational practices of postwar
genetics, in particular chromosomal analysis. Unlike the theoretical, abstract, and submicroscopic underpinnings of DNA code cracking and analysis that has been previously
highlighted by scholars, the study of chromosomes is highly visual, subjective, and
fraught with ambiguous findings.
As Soraya de Chadarevian has noted however, chromosomal analysis was
nonetheless of great value to human geneticists in the 1950s and 1960s because it
“offered a glimpse of the complete genetic make up on an individual” (de Chadarevian,
2010, 180). This observational view of the human genome produced some extremely
persuasive evidence for the genetic cause of disorders like Down syndrome, while at the
same time demonstrating that visible genetic abnormalities are often complex, variable,
and difficult to distinguish with absolute certainty.3 Despite various complications, the
ability to physically ‘see’ the genome revolutionized the practices of postwar human and
medical genetics. The capabilities of chromosomal analysis were greatly improved
during the early-1950s by the introduction of a number of new laboratory techniques.
This included the use of colchicine, for arresting cells when chromosomes were visible,
3

For instance, in some cases of Down syndrome an extra copy of chromosome 21 was
not visually obvious, because the cause was a translocation, involving chromosome 21
(Cowan, 2008; Gaudilliere, 2001; Santesmases, 2010).
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and the recognition that a hypotonic (low salt) medium helped to spread out the 46
chromosomes present in each human cell, thus making them easier to see, distinguish,
and count. Also significant were improvements in cell culture techniques, which allowed
for human tissue samples to be derived from the skin or blood or patients, rather than,
much more invasively and painfully, from their bone marrow (Kottler, 1974; Martin,
2004; Lindee, 2005; Cowan, 2008).
In large part due to these developments, the human chromosome set increasingly
became an object of analysis in human genetics and biomedicine beginning in the mid1950s. Also central to this progress were multiple international standardization meetings
held during the 1960s, which helped to make chromosomes more scientifically and
medically useful objects of study. As scholars have previously noted, the biomedical
value of chromosomes was even further revolutionized in the early-1970s, with the
introduction of chromosomal banding (Lindee, 2005; de Chadarevian, 2010). The impact
of this new technique on how chromosomes were seen, standardized, and used in
genomic research has yet to be fully explored by scholars, despite its central role in
shaping how the human genome has been depicted and communicated about ever since.
As I describe, since the 1970s, internationally standardized representations of the
‘banded’ human chromosome set have been widely used to visually represent and analyze
the organization of various genetic elements within the genome (Hogan, 2013).
My focus in this dissertation is on how these observational approaches to postwar
human genetics and biomedicine have shaped conceptions and depictions of the structure
and function of the human genome since just before chromosome banding was introduced
8

around 1970. In studying this, I am attempting to better understand the ongoing
development of research, thinking, and practices in genetics and biomedicine, during the
decades immediately before the Human Genome Project was completed in 2000. Indeed,
as clinicians and geneticists increasingly looked to the genome, at the microscopically
visible level of chromosomes, they began to see various markers that were reproducibly
associated with particular clinical disorders. Identifying such markers required the
development of standardized ways of seeing, reporting, and reproducing these
chromosomal features. As I show, in the years before large-scale DNA sequencing was
possible, researchers achieved significant, and often overlooked successes, when using
observational approaches to explore the human genome and its role in genetic disease.
During postwar biomedicine, the visual genetic markers of disease have proven to
be of both clinical and biological interest. The association of chromosomal locations and
abnormalities with particular clinical outcomes can be useful diagnostically, but it also
may be seen as an important introductory step in determining biological mechanisms of
causation. Indeed, long before disease genes could be isolated and sequenced,
observational analysis of the human chromosome set was used to locate disease etiologies
in the genome and to explore the causative link between genetic aberrations and clinical
expressions. While “mistakes of the printer” largely could not yet be identified, the
‘binding’ of the genome, as Penrose described it, proved to be more transparent than
anticipated (Penrose, 1963, 136). During the 1970s and 1980s, observational approaches
to genetics and biomedicine increasingly began to reshape understandings of the genome,
leading to the broader recognition of it as a physical entity, and a distinct part of the
9

human anatomy. As I show, accounts of the human genome in the published biomedical
literature around 1980 increasingly began discussing it, less as an informational
abstraction, and instead more frequently as a discrete object, which was suitable for
observational analysis.
Classifying Disease in the Laboratory and the Clinic
Scholars have consistently shown that the value and apparent sensibility of
classification systems are always context dependent (Foucault 1970; Fleck 1979; Latour
1987; Bowker and Star 1999). In The Birth of the Clinic, Michel Foucault suggests that
disease classification has long been influenced by a natural history tradition: since the
18th century, physicians have sought to identify and classify clinical pathologies as
Linnaeus did plants, “to see, to isolate features, to recognize those that are identical and
those that are different, to regroup them, to classify them by species or families”
(Foucault 1973, p. 89). As those experienced in clinical practice recognize however,
approaches to disease classification based on the identification of clinically visible signs,
symptoms, and lesions often lead to uncertain or variant diagnoses. Indeed, while some
patients may present with the ‘classical’ bodily indicators of a particular disorder, the
clinical spectrum of expression, and various “individual idiosyncrasies”, often complicate
and inject uncertainty into the diagnostic process (Aronowitz, 1998, 7).
Clinical practice is heavily influenced by an ‘ontological’ perspective on disease:
one that treats diseases are real entities, which develop within, and impact, all individuals
in a similar way. As Charles Rosenberg has noted, this view of disease is part of a larger
reductive trend in our society, which in this case gives individual diseases legitimate
10

identities (Rosenberg, 1992). The ontological characterization of a disease becomes
particularly persuasive when that disorder is deemed to be genetic. In some cases, a
disease may be considered to be genetic because it appears to be passed down through the
generations of a family, while in others the disorder may became associated with a
particular genomic mutation or visible aberration, as in the case of Down syndrome.
While genetic factors may play a role in nearly all disease, to associate a disorder with a
specific genetic etiology is to provide it with a unique ontological identity.
One of the most influential and demonstrative examples of this ontological
perspective on genetic disease in the postwar period can be found in Victor McKusick’s
catalogs of disorders, Mendelian Inheritance in Man. Beginning in the 1960s, McKusick,
a leading figure in the burgeoning field of medical genetics, who had first-hand
experience with the complexities of clinical diagnosis, promoted a new way of
delineating clinically described genetic disorders. This system, influenced in part by
Linus Pauling’s demonstration that sickle cell anemia was caused by a specific, inherited
protein anomaly (Pauling et al 1949; Stasser 1999; Interview with Kurt Hirschhorn, New
York City, January 26, 2012), sought to link clinical disorders with specific genetic
inheritance patterns (dominant, recessive, X-linked) and genomic mutations. The success
of this ontological system for genetic disease designation is made apparent by the
growing size and scope of subsequent editions of Mendelian Inheritance in Man.
Closely associated with McKusick’s approach to clinical classification is the
‘gene-for’ concept of disease, which is related to the ‘one-gene-one-enzyme’ hypothesis
developed by George Beadle and Edward Tatum in the early-1940s. As scholars have
11

shown, genes are both real physical entities and powerful social concepts (Nelkin and
Lindee; Kay, 2000; Moss, 2003). Throughout the postwar period, clinicians and
geneticists have suggested the presence of a gene-for X often long before one (or two, or
none) was ever identified and sequenced. As I trace in this dissertation, the gap between
suggesting a gene-for-X syndrome and determining its DNA sequence or functionality
was often quite wide in time and technique in the 1970s and 1980s.
Nonetheless, the idea that there was a gene or mutation somewhere in the human
genome that could be used to delineate a particular clinical disorder was, and continues to
be, a significant driver of biomedical research. Along the way, clinicians and geneticists
have discovered however, both to their frustration and professional benefit, that in most
cases the gene-for-X concept of disease is overly simplistic. Indeed, as biomedical
researchers looked to the genome, at the visible level of chromosomes, in order to find
the gene-for-X during the 1970s and 1980s, they increasingly found that the functionality
of the human genome was much more complex and multi-dimensional than many had
previously anticipated.

The ‘Syndrome’ Concept
The case studies that I focus on in this dissertation are all inborn genetic
syndromes. Syndromes are characterized by an array of clinical symptoms, all occurring
together, assumedly due to the same cause. Each of the syndromes described here were
eventually associated with a specific genomic mutation and etiological mechanism,
though syndromes may also be caused by environmental or developmental exposure to
12

toxins. The syndrome concept is generally attributed to 17th century English physician
Thomas Sydenham, who sought to identify distinct disease entities as naturalists did
species (Faber, 1923; Opitz, 1979; Opitz, 1994). Unlike with Linnaean binomial
nomenclature however, there is no standardized, top-down naming and classification
system for syndromes. During the postwar period, some medical geneticists, most
notably McKusick and longtime American Journal of Medical Genetics editor John
Opitz, played an intermediary role in disambiguating disease nomenclature.
Syndromes may be named after those who first described them (Down syndrome,
DiGeorge syndrome), certain clinical features (Kabuki syndrome, Velo-cardio-facial), or
particular chromosomal markers (1p36 deletion syndrome, Fragile X syndrome), among
other possibilities. Many syndromes are known by multiple names, which may differ
over time, by clinical subspecialty, or by city or country of diagnosis. As this dissertation
describes, the stabilization of a common or universal name for a syndrome generally
happens over the course of years, and may be impacted by new genetic findings, the
development of research and support institutes, or the acknowledgement that an existing
name, though descriptive or useful, is offensive to those affected. Indeed, while
clinicians and geneticists may understand a particular syndrome to be a discrete
ontological entity, this does not imply that they can easily agree on what to call the
disorder, or what symptoms are components of its clinical spectrum.
McKusick sought to adjudicate the variable naming and understanding of genetic
disorders in Mendelian Inheritance in Man (MIM) by associated specific syndromes,
often known by multiple designations, with one particular MIM number and, when
13

possible, genetic inheritance pattern, mutation, or genomic location. To this day MIM,
now published exclusively online as OMIM, plays a key role in designating the
ontological existence of disorders by providing them with an OMIM number and entry.
Additional medical texts, such as David Smith’s Recognizable Patterns of Human
Malformation similarly play a role in identifying and easing the diagnosis of genetic
disorders. As I describe in this dissertation, clinicians do not take lightly the application
of the term ‘syndrome’ to a particular disorder. Rather, the proper designation of
syndromes in the clinic has been a hotly contested matter in some instances, for
nosological, professional, and institutional reasons.

Medical Technologies and New Types of People
As many scholars have previously described, the introduction of new technologies
into the clinic alters how physician think about diseases, what they look like, and what
groups of people may be impacted by them. In the early part of the 20th century, new
techniques of examining blood were central to the identification, diagnosis, and treatment
of various disorders (Howell, 1995; Wailoo, 1997). Similarly, the introduction of
visualization technologies into the clinic, such as X-ray and ultrasound, as well as CT,
MRI, and PET scans have greatly impacted the practices of healthcare and diagnosis in
the 20th century (Kevles, 1997). Indeed, new medical technologies, such as PET scans,
have been used in the clinic, as well as the courtroom, to emphasize differences among
people (Dumit, 2003).
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New technologies in the clinic, in addition to enhancing the ‘clinical gaze’, also
have facilitated the development of the ‘molecular gaze’ (Foucault, 1973; Rose, 2007).
In recent years, genetic markers have also been used widely to identify new categories of
people, in some cases who could not be differentiated otherwise (Rabinow, 1992;
Hacking, 20077; Parthasrarthy, 2007; Hogan, 2012). A genetic categorization may
designate a population with an increased risk of particular health consequences, such as
breast cancer, Alzheimer’s disease, or cystic fibrosis. Genomic abnormalities may also
‘designate’ an individual as being part of a particular social group of affected persons
(Navon 2011; Navon 2012). The association of genetic markers with particular clinical
risks and outcomes has led to what some scholars refer to as the ‘geneticization’ and
‘biomedicalization’ of contemporary medical thinking and practice.
In 1991, Abby Lippman pointed to the geneticization of medicine, noting that
human disease and difference was increasingly being reduced to molecular explanations
(Lippman, 1991, 1992). Just as Nelkin and Tancredi (1989) warned a few years earlier,
the development of simple diagnostic tests for genetic conditions represented a
potentially dangerous new form of social power. Such tests carry scientific legitimacy,
and their simplicity makes them broadly applicable, meaning that they be in wide use
before their potential social harms are recognized. In their 1995 book The DNA
Mystique: The Gene as a Cultural Icon (1995) Nelkin and Lindee future demonstrated
the social and scientific power of ‘gene talk’, tracing the prevalence of genetic
essentialism in contemporary society, and its role in defining kinship, disease, and
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responsibility. The gene, they demonstrate, has been transformed into a source for social
difference, with potentially destructive ends.
While Lippman (1991, 1992) originally intended for the term ‘geneticization’ to
have a negative connotation, scholars, following the lead of Hedgecoe (1998, 2001), have
more recently approached the process of geneticization from a more symmetrical
perspective. These studies of geneticization, conducted over the last 15 years, follow one
of two general methodological approaches. The first is ethnographic analysis, focusing
on the day-to-day process of clinical diagnosis. Ethnographers have questioned the
extent to which genetic evidence has impacted clinical practice, arguing that the
evaluation of patients’ bodies continues to provide key evidence for the diagnosis of
disorders, while genetic data is often inconclusive (Shaw, 2003; Featherstone et al, 2005;
Latimer et al, 2006). These ethnographic studies have pushed back against existing
accounts of the pervasiveness of genetic reductionism in medicine (Lippman, 1991;
Keller, 2000; Hedgecoe, 2001).
A more middle-of-the-road ethnographic study responds to the anti-reductionist
perspective by suggesting that clinical diagnosis involves analytic “triangulation” among
mutations, phenotypes, and disease categories (Rabeharisoa and Bourret, 2009, 701).
Rabeharisoa and Bourret also explore the epistemological status of genetic data in the
clinic, and conclude that a certain mutation is not automatically considered “objective
proof” that a syndrome is present. Rather, a mutation’s diagnostic value depends upon
the pre-existing “interpretive model” for a particular disorder (704).
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Ethnographic studies provide valuable analysis of the heterogeneous evidence,
social processes, and inevitable uncertainties associated with the process of clinical
diagnosis. However, while these studies have exposed scholars to the breadth of possible
clinical interpretations and outcomes, they do not provide an in-depth look at the
diagnosis of any one disorder in particular. For instance, though the analysis of
Rabharisoa and Bourret (2009) is broadly insightful, there is still a need to further unpack
the historical development and impact of pre-existing interpretive models for disorders.
For instance, how is a disorder initially associated with a genetic marker, and how is this
correlation stabilized and made diagnostically useful?
The second methodology used recently for studying the impact of geneticization
involves a close analysis of the scientific literature on a particular disorder. Certain
studies have focused on the strategic attempts of researchers to ‘geneticize’ an existing
disorder, such as diabetes and schizophrenia (Hedgecoe, 2001; Hedgecoe, 2002). While,
in other instances, scholars have focused on the impact of geneticization on the clinical
diagnosis of a disease. A few of these studies have looked at cystic fibrosis, and shown
the ways in which the geneticization of a disorder, rather than providing simple and clearcut diagnostic markers, has instead further complicated clinical understandings of
individual risks and likely symptomatic effects (Kerr 2000; Hedgecoe, 2003; Kerr, 2005).
Throughout this dissertation, I examine various instances in which such complications
arose that called into question the reliability of a seemingly straightforward genetic
marker. As I demonstrate, in the course of attempting to resolve these genetic
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complications, clinicians and geneticists came to appreciate new levels of complexity in
genomic function and disease causation.

Perspectives on Biomedicine and ‘Biomedicalization’
This rise of ‘biomedicine’ has similarly been associated with the increasing
centrality of molecular genetic conceptions of disease. Nicholas Rose (2007) has argued
that medical practice has shifted away from the “clinical gaze” that Foucault describes,
towards a “molecular gaze”. Understandings of disease at the molecular level, argues
Rose (2007, p. 8), as well as Clarke et al. (2010), have led to new conceptions of “life
itself”, and a novel “somatic ethics” of individualized biomedical knowledge,
responsibility, and intervention. Jean-Paul Gaudilliere (2002) has similarly pointed to the
central role of molecular analysis in the rise of biomedicine, and has argued that the
biological laboratory has replaced the pathology clinic as the primary location and focus
of medical practice. For Gaudilliere, and other scholars, this suggests that there is a
largely unidirectional flow of knowledge in biomedicine from the basic biological
laboratory to the clinic (Gaudilliere, 2002; Fujimura, 1992).
Other scholars however, have pushed back against this perspective on
biomedicine in which knowledge in the laboratory supersedes and directs clinical
diagnosis and understanding of disease. Keating and Cambroiso (2000, 2003, 2004) have
repeatedly argued that, in contemporary biomedicine, pathology has not been reduced to
biology. Rather, they suggest that biomedicine represents a realignment of the ‘normal’
and the ‘pathological’ (Canguilhem 1991), not a fusion of the two, or a reduction of one
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into the other. Biomedical practice, they argue, takes place in intellectually and
institutionally collaborative spaces or ‘platforms’, which are, “benches upon which
conventions concerning the biological or normal are connected with conventions
concerning the medical or pathological” (Keating and Cambrosio 2000, p. 386).
Still other scholars have expressed doubt about the transformative nature of
biomedicine. Based largely on ethnographic analysis of the practice of dysmorphology,
the identification of genetic disorders through bodily characteristics, these researchers
maintain genetic results are often quite uncertain, necessitating a return to the clinic.
Indeed, as these scholars suggest, clinicians do not simply rely on genetic testing to slot
patients into pre-existing and discrete categories. Nor does genetic testing always make
diagnosis a simple and immediate process. Rather, the clinic has always been, and
continues to be, central to medical knowledge production: genetic testing may
supplement clinical judgment, but certainly has not supplanted it, as Rose (2007)
suggested (Shaw, 2003; Latimer et al. 2006; Featherstone and Atkinson 2012). In this
dissertation, I explore how clinicians and geneticists locate, assess, and develop
confidence in correlations between genomic markers and clinical outcomes. The
genome, I argue, has become an important conceptual space in biomedicine, where the
questions, interests, and conventions of basic genetics and applied clinical research
intersect and intermingle.
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Outline for this Dissertation
This dissertation draws on archival resources, informational interviews, and a
thorough analysis of the published medical literature to examine the evolving look and
‘genomic‘ understanding of a number of inborn genetic disorders. Because of the
contemporary focus on this research, available archival collections for this project are
relatively limited. As a result, I draw heavily on journal articles and medical textbooks
relevant to my case study disorders, and medical genetics more broadly. In line with
Hannah Landecker’s Culturing Life (2007), this dissertation draws on the published
biomedical literature to examine the broad impact of a specific concept: the genomic
basis of disease. I also rely on interviews with over 30 biomedical professionals. These
interviews helped to clarify the published literature, and often revealed what was thought
and debated by clinicians and researchers, but not published in journals. In some cases,
these individuals also provided relevant materials that are not yet archived, including
meeting minutes and correspondence concerning professional committees or joint
publications.
In chapter one of this dissertation, I explore the development of human
cytogenetics in the postwar period. Multiple scholars have thoroughly examined the
early decades of human cytogenetics (Martin, 2004; Lindee, 2005; de Chadarevian, 2010;
Santesmases, 2010), so my research primarily focuses on the 1970s and 1980s. Over this
period, I trace the parallel evolution of standardized chromosomal depictions and
changing conceptions of the human genome. I argue that, during this period, conceptions
of the human genome shifted from abstract references to ‘all the human genes or genetic
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material’ to more physical and bounded descriptions, physically embedded in the visual
representations of the human chromosome set.
I explore how the nomenclature system, initially developed to help standardize the
laboratory and clinical analysis of banded chromosomes, was also adopted for gene and
disease etiology mapping. As part of this, I demonstrate how descriptions of the human
genome became increasingly anatomical during this period. Like heart in cardiology, the
genome was described as the ‘organ’ of medical genetics, and the mapping of it as a
‘neo-Vesalian’ revolution. All of this together provided the basis for new ways of
delineating, diagnosing, and understanding human disease. Medical geneticists were now
no longer dependent on clinical signs of disease alone: they could also rely on genomic
locations to identify unique disorders.
Chapter 2 offers a case study of the clinical and laboratory history of Fragile X
syndrome. I begin with a discussion of the debate over X-linked intellectual disability in
the 20th century, and then address the first clinical description, in 1943, of what was later
termed Martin-Bell syndrome, and eventually Fragile X syndrome. From there, I discuss
the identification of a cytogenetic marker, initial confusion over its laboratory expression,
and its ultimate use as a diagnostic basis for delineating and naming Fragile X syndrome
in the late-1970s and early-1980s. Next, I explore the challenges of using this
cytogenetic marker to identify carriers of the disorder, and attempts to identify treatments
for Fragile X syndrome based on a limited cytogenetic understanding on the fragile X
site.
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During the mid-1980s, clinicians and researchers were perplexed by the unusual
inheritance pattern of Fragile X syndrome in families. I explore the various theories
developed to explain the abnormal pedigrees, and the experimental demonstration of one
of these theories based on observational chromosomal analysis in 1986. This cytogenetic
research was done five years before the fragile site could be molecularly characterized,
and offered important evidence that a novel genomic mechanism was at play in causing
Fragile X syndrome and other disorders with similar inheritance patterns. This chapter
explores how clinicians and researchers took advantage of chromosomal analysis in the
years before large-scale DNA sequencing was possible to delineate, diagnose, prevent,
treat, and explain Fragile X syndrome, while at the same time exploring unanticipated
structural and functional characteristics of the human genome.
In chapter 3, I explore the genetic characterization of another clinical disorder,
based upon chromosomal analysis. Prader-Willi syndrome was first described in 1956,
and mounting cytogenetic evidence suggested a genomic basis during the 1970s. In
1981, Prader-Willi syndrome became one of the first genetic disorders to be associated
with a microscopically visible, de novo deletion on a human chromosome. As a result,
during the early-1980s, Prader-Willi syndrome was seen as an exemplar of a new type of
disorder, which could be delineated and diagnosed based on a discrete cytogenetic
marker. It became associated with a discrete genomic abnormality and location, on the
long arm of chromosome 15.
To the surprise of researchers and clinicians however, in 1987 another clinically
and historically distinct genetic disorder was associated with the same exact visible
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chromosomal deletion. Angelman syndrome looked nothing like Prader-Willi syndrome
in the clinic, and yet it seemed to be caused by the same exact genomic etiology. This
posed a problem for medical geneticists, who had argued that genetic diseases could be
thought of as either the same or different based on the mutation that caused them.
Clinicians and researchers never suggested that Prader-Willi and Angelman syndromes
might in fact be the same, but instead began to explore alternative explanations.
Cytogenetic analysis provided the first evidence for the mechanistic different between
them. It was demonstrated chromosomally, and later molecularly, that which parent a
patient inherited the deletion from made the difference in terms of which syndrome
affected them. This finding revolutionized the ways in which clinicians and researchers
thought about the structure and functionality of the human genome. In 1989, this was the
first demonstration in humans of an ‘epigenetic’ phenomenon known as genetic
imprinting. This history offers a window into the continuing development of
biomedicine during this period, as the interests and aims of basic and clinical researchers
became closely aligned.
Chapter 4 looks at a second case of what one might call ‘genetic intersection’: an
unusual instance in which two clinically and historically distinct disorders are found to be
associated with the exact same genomic abnormality. DiGeorge and Velo-Cardio-Facial
syndromes were both independently described and named, in distinct times and places,
based on clinical analysis alone. During the 1980s, chromosomal analysis suggested a
genomic cause for DiGeorge syndrome, which was eventually determined to be a small
deletion on chromosome 22. Similar to the case of Prader-Willi and Angelman
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syndromes, DiGeorge and Velo-Cardio-Facial syndromes became associated with the
exact same genomic deletion in the early-1990s. Unlike the previous case however, this
finding was widely pointed to as evidence that these two disorders were in fact two
historically distinct forms of the same clinical disorder.
In making this argument, some clinicians and geneticists pointed to the parable of
the blind men and the elephant. As they described it, researchers had been distracted all
along by their own specialties and interests, and overlooked what this instance of genetic
intersection had finally made apparent to them. DiGeorge and Velo-Cardio-Facial
syndrome were the same exact disorder: there had always been just one elephant in the
room. Following the association of these two disorders with the same genomic deletion,
debates have been ongoing over the appropriate name for this syndrome. Some have
promoted 22q11 deletion syndrome, a designation that directly links that clinical disorder
to a genomic location and chromosomal band. The distinctions between this story, and
the one presented a chapter early offer a useful opportunity to reflect on the constantly
evolving relationship between clinical and laboratory findings in medical genetics as well
as the professional and institutions implications of disease nosology.
My concluding chapter examines how and why chromosomal depictions continue
to shape the ways in which biomedical professionals interact with the genome in the postHuman Genome Project era. Indeed, even with a complete DNA reference sequence at
their fingertips, clinicians and geneticists have persisted in thinking and communicating
about the human genome using a visual nomenclature originally developed for
chromosomal analysis in the 1970s. An excellent example of this is the prominent place
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that standardized depictions of the human chromosome set continue to have as signposts
and navigation tools in online genomic databases, such as the University of California,
Santa Cruz Genome Browser. Mindful of this, I examine how and why older, less
exacting – and often incommensurable – languages of description are maintained, and
relied upon, for the analysis and presentation of results in science and medicine. In doing
so, I explore how clinicians and researchers use techniques of visualization to help make
the genome, more legible for themselves and their colleagues.
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CHAPTER 1
Seeing and Analyzing the Human Genome at the Level of Chromosomes
In 1982, Victor McKusick, Physician-in-Chief of the Johns Hopkins University
School of Medicine, published a commentary entitled, “The Human Genome Through the
Eyes of a Clinical Geneticist.” At the time, McKusick was a central figure in the
burgeoning field of medical genetics, a discipline populated by both Ph.D. trained
geneticists and physicians interested in the role of genetics in human disease. In his
article, which reflected on the previous 25 years of advancement in medical genetics,
McKusick noted,

The advances which started in 1956 have provided the clinical geneticist
with his organ. Now the clinical geneticist is in the same position as the
nephrologist with his kidney, the cardiologist with the heart, and so on.
He has an organ that he can biopsy, of which he can analyze disordered
structure and function, and which he can attempt to repair (McKusick,
1982, 7).
As the title of his paper suggests, the organ that McKusick was referring to is the human
genome. During the early-1980s, McKusick, and other prominent figures in the genetics
community, increasingly began discussing the human genome using anatomical points of
reference. As McKusick put it in his 1982 paper, genomic analysis provided the field of
medical genetics with a “neo-Vesalian model” for identifying and understanding genetic
diseases (McKusick, 1982, 22). In this chapter, I explore how the human genome was
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visualized, conceptualized, dissected, and mapped at the level of chromosomes during the
1970s and 1980s.
The human genome is often referred to as an abstract informational database,
comprised of billions of DNA nucleotides. Indeed, it has widely been presented in the
postwar period as a code to be ‘cracked’, as well as scanned and analyzed, at the
molecular level. Analysis of the human genome however, frequently has also taken place
at the level of its most basic, and visible, components: the human chromosomes. Since
the 1960s, the observational approach of chromosomal analysis has provided human and
medical geneticists with the opportunity to look for and locate various genes and disease
etiologies within the human genome. Throughout the 1970s and 1980s, McKusick
maintained and updated a visual depiction of this process, which was based upon
standardized depictions of the human chromosome set (McKusick and Ruddle, 1977;
McKusick, 1982, 1984, 1986a, 1988).
As I will demonstrate throughout this chapter, during the 1970s and 1980s, the
human genome became an important, an increasingly well-defined, object of both
scientific and anatomical investigation. While descriptions of the genome in the 1970s
often referred to it quite abstractly as being composed of ‘all the human genes or genetic
material’, by the early-1980s, medical textbook definitions of the human genome were
becoming increasingly bounded by, and literally ‘embodied’ within the human
chromosome set. Over this time, conceptions of the human genome, among clinicians
and biomedical researchers, became increasingly chromosomal and anatomical, at the

27

same time that standardized depictions of the human chromosome grew more-and-more
linearized and ‘genomic’.
Conceptions and representations of genetic disease paralleled these developments.
In this chapter, I also explore the making of a new system of disease nosology within the
field of medical genetics. Rather than being dependent on clinical presentations to
delineate, diagnose, and classify genetic disorders, during the postwar period, medical
geneticists increasingly looked to the genome as a new and valuable arbiter. It was
assumed that mutational analysis could provide a more accurate and reliable means of
distinguishing different diseases, compared to the diverse and often confusing array of
signs and symptoms seen in the clinic. Indeed, embedded within depictions of what
McKusick called the ‘morbid anatomy’ of the human genome was the idea that every
genetic disease could be associated with a unique location in the genome, thereby giving
it a distinct identity.
Throughout this dissertation, I explore the application of this nosological system
in postwar biomedical thinking and practice. My case studies highlight various problems
and complications that arose over this time, issues that transformed chromosomal
analysis into an unexpectedly productive experimental system for geneticists more
broadly. A historical analysis of these cases offers a window into the evolving ways that
clinicians and biomedical researchers have thought about the human genome, and its role
in human disease, since the late-1960s.
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Counting Chromosomes in the 1950s
1953 is often pointed to as a landmark year in the history of genetics, because it
marked the proposal of a double helical structure for DNA. This important finding
shaped the trajectory of molecular biology for years to come, by helping to explain DNA
replication and facilitating the cracking of the DNA code over the next decade, thus
adding to the informational basis of genetics research. While the identification of the
DNA double helix is also regarded as an important moment in the history of medical
genetics, Victor McKusick often pointed to another event, three years later, as being
central to the origin of the field, “medical genetics has become established as a clinical
specialty, as the culmination of developments that began in 1956 with the description of
the correct chromosome number in man” (McKusick, 1997a, 1).
Until the early-1950s, the chromosome number in man was believed to be 48, not
46 (Kottler, 1974; Martin, 2004). Identifying the correct chromosome number is widely
regarded as a significant finding in medical genetics, because in the years after its
stabilization, a variety of syndromes associated with abnormal numbers of chromosomes
were identified. The most notable among these, Down, Turner, and Klinefelter
syndromes, were each linked to specific chromosomal abnormalities within five years of
1956. As McKusick put it in his 1997 history of medical genetics, “With the discovery of
specific microscopically visible chromosomal changes associated with clinical disorders,
beginning with Down syndrome in January 1959, medical genetics acquired an anatomic
base. Medical geneticists now had their specific organ – the genome – just as
cardiologists had the heart and neurologists had the nervous system” (McKusick, 1997a,
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1). Indeed, the year 1956 matters for medical geneticists because it marks the moment at
which the size and scope of the human genome, the field’s organ, was for the first time
concretely defined.
Histories of medical genetics often highlight the 1956 demonstration, by Joe-Hin
Tijo and Albert Levan, that humans normally possess 46 chromosomes (Tijo and Levan,
1956). As Aryn Martin has pointed out however, while “communal closure around the
new number,” did not occur until 1956, the revolution in medical genetics associated with
1956 actually began with the introduction of a number of new techniques beginning in
the early-1950s (Martin, 2004, 936). Foremost among these was the uptake of the
chemical colchicine, which arrests cells at a point in their reproductive cycle when
chromosomes are visible (they usually are not), and the use of a hypotonic (low salt)
solution to spread out the chromosomes in a cell, thus making them easier to differentiate
and count (Martin, 2004).
As Martin has suggested, the introduction of these new techniques began to
change the way that human geneticists thought about chromosomes, even before 1956.
Referencing a paper by American cytogeneticist T.C. Hsu (1952), in whose lab the
hypotonic technique was first (accidently) identified and used,4 Martin notes that Hsu,

Also lined up the chromosomes in pairs by length and named them (by
number). This, I suggest, changed the counting game from the question
‘How many?’ to the question ‘Are all members accounted for?’ An
4

As Martin (2004) notes, an ‘invisible technician’ was initially responsible for ‘the
hypotonic miracle’, having made a ‘mistake’ in mixing solutions.
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analogy would be counting how many people are in a room versus taking
attendance (Martin, 2004, 935-6).

Establishing the correct human chromosome number therefore, was an important step in
bounding the human chromosome set, allowing for ‘normal’ versions of it to be
distinguished from various ‘pathological’ ones (Canguilhem, 1991).
During the early-1950s, human geneticists developed new expectations for the
counting of chromosomes. And, by the end of the decade, the number of chromosomes
that an individual was seen to possess became much more meaningful medically, “A
count of 47 is no longer indicative of a poor counting methodology or a challenge to the
established count, but of a body marked by genetic difference” (Martin, 2004, 938).
Indeed, by the close of the 1950s, abnormal chromosomal counts were seen as very
significant observational findings in the clinic. And, as I explore here, over the coming
decades, the human chromosome set would be further transformed into a standardized
object for biomedical thinking and research, thereby creating various new methods for
‘doing’ genetics that were based on the observational approaches of cytogenetics.
In 1959, French clinician Jerome Lejeune famously reported that patients with
Down syndrome appeared to possess one additional chromosome: for a total of 47 instead
of 46 (Lejeune et al, 1959). Once it was recognized that chromosomal abnormalities
could be associated with particular clinical syndromes, a call went out for the
establishment of a system for naming individual chromosomes. The development of an
internationally standardized chromosomal nomenclature system was undertaken at a 1960
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meeting of cytogeneticists in Denver. After much social and technical negotiation, the
participants decided upon a system in which each of the non-sex chromosomes (the
autosomes) would be numbered by their relative size, with the largest becoming
chromosome one. The sex chromosomes remained named X and Y, even though the X
chromosome is closer in size and shape to chromosome 7 and the Y is most similar to
chromosome 22 (Denver Study Group, 1960; Lindee, 2005).
This standardized nomenclature system has, since 1960, frequently been the basis
for constructing human karyotypes, where all of the chromosomes in one cell are
represented together in one picture. During the 1950s, karyotypes were often drawn by
hand with the assistance of a camera lucida. However, as cytogeneticist Malcolm
Ferguson-Smith has described, by the end of the decade, photographic cameras were
being affixed directly to microscopes (Interview with Malcolm Ferguson-Smith, 5
December 2003, conducted by Peter Harper).5 When a karyotype is constructed in this
way, a photograph is taken of a cell is in which all of the chromosomes appear to be
visible and out enough to be differentiated. After the photograph is developed, each
individual chromosome is cut out and rearranged by its relative size. Karyotyping is used
to help identify and systematically name abnormalities in the chromosome set, for
instance an extra copy of chromosome 21, the cause of Down syndrome.

5

Interview with [Malcolm Ferguson-Smith, 5 December 2003]. Interviews with Human
and Medical Geneticists series, Special Collections and Archives, Cardiff University,
Cardiff, UK.
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Creating a Standardized Representation of the Human Chromosome Set
The human chromosome set may be visually represented in a variety of ways.
While karyotypes involve the direct cut-and-paste organization of microscopic
photographs, chromosomes have also been represented throughout the postwar period
using idealized drawings called ‘ideograms’. Chromosomal ideograms depict the
distinctive features of each human chromosome, including two arms (each chromosome
has a long and a short arm), a centromere, which separates the two arms, and ‘satellites’
(additional material at the end of certain chromosomes). Chromosomal locations are
always identified relative to the centromere: those close to the centromere are ‘proximal’
and those further away are referred to as ‘distal’.
In 1960, the Denver Study Group individually numbered each chromosome, and
developed ideograms to represent the human chromosome set (Denver Study Group,
1960). Throughout the 1960s however, it remained quite difficult, if not impossible, to
distinguish various chromosomes that were of similar size and shape. Reflecting this
reality, cytogeneticists often referred to the human chromosomes as being members of
seven visually distinguishable groups: A (1-3), B (4, 5), C (6-12, X), D (13-15), E (1618), F (19, 20), and G (21, 22, Y). These groupings were officially recognized during a
follow-up meeting to the Denver Study Group, held in London in 1963 (London
Conference, 1963). Within each group, individual chromosomes were very difficult to
tell apart, a situation that was particularly problematic for the C group, which is made up
of eight members, including the X chromosome.
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The inability to differentiate individual chromosomes greatly limited the
specificity with which chromosomal abnormalities could be identified and
communicated. For example, one could report that a ‘B group’ chromosome was lacking
its short arm in patients with a certain clinical disorder. However, one could not say for
certain if the impacted chromosome was 4 or 5. Later, another cytogeneticist might find
a similar aberration in a different group of patients, but not know if the same
chromosome was affected. Indeed, as the 1960s went on, this inability to differentiate
chromosomes greatly limited the capability of medical geneticists to associate clinical
disorders with particular, visible chromosomal aberrations (Hirschhorn et al, 1973).
Following the Third International Congress of Human Genetics meeting, held in
Chicago in 1966, a committee similar to the Denver Study Group met to further improve
the existing cytogenetic nomenclature (Chicago Conference, 1966; Lindee, 2005). One
of the most significant outcomes of this 1966 gathering was the designation of a standard
abbreviation for the long and short arms of each human chromosome. It was quickly
agreed upon that the short arm of each chromosome should be abbreviated ‘p’ for petit.
According to American cytogeneticist Kurt Hirschhorn however, the debate over what to
call the long arm of each chromosome was extended and contentious. Multiple
participants at this, and other, nomenclature meetings have suggested to me that much of
the disagreement took place along national lines, particularly among French and German
members (Interviews with Uta Francke, February 27, 2012; Kurt Hirschhorn, January 26,
2012; Dorothy Warburton, May 11, 2011).
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At the 1966 meeting, a debate lasted late into the night over what to call the long
arm of chromosomes, particularly given that a francophone designation had already been
attached to the short arm. As Hirschhorn tells the story, sometime after midnight, Lionel
Penrose, that year’s Congress president, walked into the room where the meeting was
being held, and was surprised to find that the discussion was ongoing. Informed that the
designation ‘p’ had been decided upon for the short arm of chromosomes, Penrose
immediately suggested that the long arm should be called ‘q’. This was not because ‘q’
had any sort of linguistic significance, but instead because ‘p + q = 1’ was a well-known
equation (named after Hardy and Weinberg) in population genetics. Hirschhorn
paraphrased Penrose’s successful argument in this way, “If you have ‘p’ for the short
arm, use ‘q’ for the long arm: ‘p + q = 1’, you got the whole chromosome” (Interview
with Kurt Hirschhorn, January 26, 2012).6 Apparently, this settled the debate.
Ultimately, this decision was just one of many compromises in an ongoing international
discussion about how to divide the human chromosome set into standardized subsections.

Moving Out of “The Doldrums” in the Early-1970s
As the 1960s went on, the “golden age” of cytogenetics, during which a number
of clinical disorders were associated with visible chromosomal abnormalities, came to
close. The continued inability to distinguish individual human chromosomes greatly
limited the potential specificity of cytogenetic diagnosis. In reference to this very
6

Peter Harper offers a similar account involving ‘p + q = 1’ during his interview with
David Harden. Interview with [David Harnden, 18 March 2004]. Interviews with Human
and Medical Geneticists series, Special Collections and Archives, Cardiff University,
Cardiff, UK.
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problem, McKusick, quoting his colleague Margery Shaw, has referred to the late-1960s
as a time when clinical cytogenetics was “in the doldrums” (McKusick, 1997a, 8). The
1970s, on the other hand, proved to be a revolutionary time for the field, with the
development new chromosome staining techniques.
Quinacrine (Q) banding was introduced in 1968 (Caspersson et al, 1968),
followed by Giemsa (G) banding and reverse (R) banding around 1970 (Seabright, 1971).
These new techniques produced distinguishable banding patterns on each human
chromosome, allowing for them to be visually differentiated under the microscope. The
banding techniques take advantage of the differential condensation of DNA within each
chromosome. On G-banded chromosomes, more densely compacted regions stain more
darkly, while on R-banded chromosomes the ‘reverse’ happens. The density of a
chromosomal region often reflects the number of genes present within it: less dense
regions usually have more genes (Sumner, 1990).
The ability to concretely differentiate each chromosome was a key contribution of
new banding techniques, but this was only the beginning. These chromosomal bands also
created visible and reproducible landmarks on each chromosome, meaning that they
could be broken down into additional regions and sub-regions based on their bands. This
advance was very important in that it allowed cytogeneticists to speak reliably in terms of
much more than just the long or short arm of a certain chromosome. Now, a
chromosomal aberration, such as the deletion, duplication, or translocation of genetic
material, could be defined by its specific physical band location along a chromosomal
arm. This improved the visual resolution of chromosomal analysis, made laboratory
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results more reliable and reproducible, and represented a first important step towards
creating a genomic map at the visual level of human chromosomes.
In order to make use of banding, cytogeneticists once again had to agree on a
nomenclature system. An international committee was convened to do so in 1971
following the Fourth International Congress of Human Genetics meeting in Paris. The
1971 meeting featured many of the same members as the one five years earlier in
Chicago, and similar international tensions. At the time, G-banding and R-banding were
the two most common methods for creating chromosomal bands. Mary Seabright (1971),
a British cytogeneticist, had developed the most commonly used technique for Gbanding, which was widely adopted in the US and much of Europe. R-banding was a
French innovation, and its use was largely exclusive to France (Interview with Dorothy
Warburton, July 21, 2011).
The Paris Committee’s primary challenge was to create a nomenclature system
that incorporated both G and R banding. As American participant Dorothy Warburton
has told me about coming to a consensus, “it wasn’t easy”. The patterns created by G
and R bands were essentially exact opposites: dark G-bands went unstained by Rbanding, and dark R-bands were not stained by G-banding. As a result, the debate was
over which regions of each chromosome were banded and which were not. Those who
did R-banding wanted to number the visible bands down each chromosome as 1, 2, 3. Gbanding proponents wanted the same numbering system, but with the dark bands that
they saw (Interview with Dorothy Warburton, July 21, 2011).
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A breakthrough came, according to Warburton, when committee chairperson John
Evans suggested a compromise: chromosomes should not be thought of as having regions
that were either banded or not, but instead, the bands on each chromosome should be
understood as continuous: light then dark then light again. This way, a standard
numbering system could be adopted, and the darkness or lightness of a band would
simply depend on which banding method was used. So, following the 1960 chromosome
numbering system and the 1966 arm-lettering compromise, members of the 1971
committee created a consensus nomenclature that named each visible chromosomal band,
whether dark or light. Chromosomal arms were broken down into anywhere from one to
four regions, which were then further divided by the bands visible in each. The
committee worked in groups to decide how many bands could be seen on each
chromosome and to draft representative ideograms (Interview with Dorothy Warburton,
July 12, 2011).
Each band was identified by the chromosome (1-22, X, Y) and arm (p or q) on
which it was located, followed by a number identifying the region (beginning with 1 at
the centromere), and finally with a second number to designate the specific band. For
example, the band 15q12 (pronounced 15 – q – 1 – 2) is located on the long (q) arm of
chromosome 15, and is the second visible band (2) in the first region (1) from the
centromere. Ideograms showing all of the (about 400) visible chromosomal bands in the
human chromosome set were included in the conference report (Paris Conference (1971),
1972) (Figure 2). This standardized nomenclature provided the basis for the system that
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geneticists use to the present day, for identifying the genomic location of various
chromosomal abnormalities, genes, and disease etiologies.

Figure 2 X-shaped, banded chromosomal ideograms, first developed in 1971. This
image was originally published in Paris Conference, 1971 (1972). Reprinted with
permission from the March of Dimes.

Visualizing ‘High-Resolution’ Chromosomes
During the 1970s, cytogeneticists began to experiment with capturing
chromosomes in a somewhat less condensed state under the microscope, in the hope that
they would reveal additional, visible bands. This new technique, known as ‘highresolution’ chromosomal banding, began to spread by the end of the decade (Yunis,
1978). High-resolution chromosomes had more than double the number of visible bands,
and with this technique in place, another international standardization meeting was held
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in Paris in 1980 to update the existing nomenclature. Committee members maintained
the 1971 system, and divided existing bands into sub-bands by adding a decimal to the
end of the current designation. For instance, the second sub-band of 15q13 became
known as 15q13.2 under the revised nomenclature (ISCN, 1981).
Debates arose once again however, over which original band was being divided
into new sub-bands. In G-banding, light bands are understood to be less condensed than
dark bands. Therefore, it did not make logical sense that a new high-density dark band
could be derived from an existing, low-density light band. Because of this and other
ongoing debates (which continued in correspondence afterwards), the meeting turned into
what participant Uta Francke described to me as a “shouting match” (Interview with Uta
Francke, February 27, 2012). As a result, the report from this meeting, held in May of
1980, was not published until well into the next calendar year. Ultimately, the goal of
what was now formally called the ‘International System for Cytogenetic Nomenclature
(ISCN)’ Standing Committee was to maintain an internationally acceptable and
standardized system for identifying chromosomal bands. To accomplish this, small or
theoretical discrepancies and disagreements had to be sidelined in favor of having one
system that everyone, whether they primarily practiced G or R-banding, could use.
In a 1982 letter sent to ISCN committee member David Harnden, one committee
member, a human geneticist, commented on the continuing disagreements among
committee members concerning band standardization by noting, “The guiding principle
of ISCN is clearly the written word, not the ideogram. To worry about minor artistic
inaccuracies in such a highly stylized diagram is pedantic” (From the ISCN Papers, May
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1980 meeting records).7 Indeed, the ideograms were not necessarily meant to capture the
most accurate or logical description of what chromosomes looked like. Instead, they
depicted a nomenclature system that was created through compromise. The most
important goal of the standardization committee was to promote a single naming system,
and not necessarily the most theoretically accurate one.
This said, with the advent of high-resolution chromosomal banding, it had
become increasingly clear that the black-and-white limitations of the 1971 compromise
failed to capture what cytogeneticists were actually seeing under the microscope. While
the official ISCN report in 1981 maintained the all black-and-white banding pattern,
committee member Uta Francke was allowed to publish, as part of the report, a separate
set of G-banded ideograms. These high-resolution ideograms had the same nomenclature
as the official ISCN bands, except that instead of being exclusively black and while, they
showed multiple shades of gray. Francke’s goal was to more accurately represent what
cytogeneticists actually saw under the microscope, so as to improve the visibility of small
chromosomal aberrations (Francke, 1981; ISCN, 1981) (Figure 3).

7

The ISCN papers are currently privately held, and were made available to me, by
geneticist Uta Francke. The collection is located at the Stanford University School of
Medicine, Palo Alto, CA.
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Figure 3 Rod-shaped ideogram of chromosome 1 showing shades of grey. This series of
ideograms was published in the same report as the ISCN (1981) ideograms and largely
looks the same, except for the differential coloring (Francke, 1981). Reprinted with
permission from Uta Francke.
The cytogeneticists involved in creating and maintaining this chromosomal
nomenclature system clearly recognized that they were working with fluid entities, which
were in a constant state of flux during the life of a cell. Any drawing of a chromosome
only captures it at one brief moment and cannot necessarily be directly and logically
related to how that same chromosome looks at a different point of condensation.
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However, the intention of ideograms was not demonstrate or explain the physiological
process of chromosome condensation, but instead to identify and designate the most
reliable, and therefore useful visual landmarks that could be used for analyzing, and
communicating about, the human chromosome set in a standardized manner.
While standardization committee meetings were often contentious and drawn out
affairs, in the end cooler heads had to, and did, prevail in favor of compromise and
consistency. The ideograms produced by these meetings were important for the
exchange of clinical and scientific findings. In addition, these ideograms became an
internationally shared representation of what the human genome looked like, and an
important basis for its physical mapping, as well as for increasingly commonplace efforts
to ‘locate’ genetic disease etiologies within the genome.

The Changing Look of the Human Chromosome Set
Since the first set of human chromosomal ideograms were proposed by the 1960
Denver Study Group, ten standardization committee updates have been published, with
the most recent coming in 2009. Many of these revised editions suggested only small
adjustments to the existing system, but a few provided a significant overhaul of the
previous edition, most noticeably in the form of chromosomal ideograms with new
banding patterns. Such major revisions occurred in 1971, 1981, 1995, and 2005. While
each of these updates revealed the impact of novel cytogenetic techniques on
chromosomal analysis, I argue that the new sets of chromosomal ideograms also offered
novel ways of seeing the human genome. In addition, they reflected new conceptions of
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how genes and disease etiologies could be located and analyzed within it. Here I focus
on the changes that were made to chromosomal ideogram depictions in 1971 and 1981.
The chromosomal ideograms developed by the 1960 Denver Study Group have
two distinguishing features when compared to those produced in later decades. First, the
chromosomes are depicted as solidly colored bodies: no banding techniques were yet
available to provide each ideogram with a distinctive pattern. Secondly, each
chromosome looks like some variation of the letter X (Figure 2). In a 1963 follow-up
meeting held in London, the chromosomes were officially broken down into seven,
lettered groups, as described above. These groupings were based on variations in the
chromosomes’ X-like shapes, as well as their relative size. Group A chromosomes are
large and ‘metacentric’, meaning that their centromere is centrally located, making their
long and short arms close to the same size. Group B and C chromosomes, on the other
hand, are among those called ‘submetacentic’, since their long arms are significantly
larger than their short arms. Group D and G chromosomes are ‘acrocentric’, meaning
that the short arm is too small to easily be seen (London Conference, 1963).
In 1971, the chromosomal ideograms went from being solidly colored to banded,
reflecting the development of Q, G, and R banding techniques. Otherwise, these
ideograms remain X-shaped, like those published by the Denver Study Group (Paris
Conference (1971), 1972) (Figure 2). An entirely new set of ideograms, with new
banding patterns, was not published again until the 1981 ISCN report (ISCN, 1981).
However, two intervening updates in 1975 and 1978 included human chromosomal
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ideograms that were not X-shaped, but rather looked like long, narrow rods (Paris
Conference (1971), Supplement (1975), 1975; ISCN, 1978).
These ideograms were created to facilitate comparisons among the banding
patterns of human and other primate chromosomes (Interview with Uta Francke,
February 27, 2012; Paris Conference (1971), Supplement (1975), 1975) (Figure 3). The
revisions were regarded at the time as supplements to the 1971 Paris conference, as
opposed to a full overhaul (ISCN, 1985). However, this new way of depicting
chromosomal ideograms makes it clear that, in the mid-1970s, geneticists were beginning
to think differently about what chromosomal analysis could reveal about the physical
organization of the genome, and about how standardized ideograms of the human
chromosome set could be used to depict these findings.
Undoubtedly, there were multiple reasons for this move from depicting
chromosomal ideograms as X-shaped to rod shaped. As Uta Francke, who was a
consultant to the 1981 Paris committee, has explained to me, part of the reason to switch
from X-shaped to rod-shaped ideograms was for efficiency: more ideograms could be fit
on one page (Personal Communication with Uta Francke, via email, March 28, 2012).
Indeed, during the mid-to-late-1970s, when comparing the chromosomal ideograms from
different primates was a major feature of the nomenclature committee’s publications, this
made a lot of sense because rod-shaped chromosomes were easier to line up next to each
other (Paris Committee (1971), Supplement (1975), 1975; ISCN, 1978). Another factor
by the late-1970s was the introduction of high-resolution chromosome banding, described
in the previous section. Because high-resolution chromosomes were captured in a less
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dense state, they tended to look more rod-like than X-shaped. Indeed, by 1980 rodshaped chromosomes were closer to what geneticists actually saw under the microscope.
I want to suggest however, that this incremental shift from X-shaped to rod-like
ideograms between 1971 and 1981 also reflected new conceptions of the sort of
knowledge that chromosomal analysis could provide to human and medical geneticists.
X-shaped chromosomal ideograms, as they were depicted up through 1971, represented
important functional units of cellular reproduction. These ideograms appeared X-shaped
because they were actually depicting two exact copies of the same chromosome (joined at
the centromere), which were about to split apart in the formation of two genetically
identical cells. Chromosomal analysis up to this point was mostly focused on identifying
large chromosomal abnormalities. With the wider uptake of chromosomal banding in the
early-to-mid-1970s however, the aims of cytogenetic analysis began to shift. It was now
possible to identify, and communicate about, more specific locations than entire
chromosomes, or large portions of them. As a result, the human chromosomes were
coming to be understood as more than just units of cellular reproduction: they were also
increasingly seen as the basic, observable, and map-able subsections of the genome.
This facilitated early attempts to produce a ‘physical map’ of the human genome,
which involves the direct association of genetic characteristics with distinct landmarks in
the genome. This is different from, but often closely associated with, the older technique
of ‘linkage’ or ‘genetic’ mapping, famously practiced in T.H. Morgan’s fly lab to identify
the relative location of genes or other traits on individual chromosomes.8 Rather than
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For more on mapping in the Morgan Lab see: Kohler (1994).
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determining the relative distance between genes, physical mapping seeks to associate
genetic traits not with fixed genomic locations, which in the 1970s and 1980s were often
defined by visibly distinct chromosomal bands (McKusick, 1988).
The human genome is generally conceived of at the molecular level as being a
linear chain of DNA. As the medical genetics textbook The Metabolic Basis of Inherited
Disease put it in 1978, “All genetic mapping data are consistent with the hypothesis that
the genome is a linear unbranched structure” (Stanbury et al 1978, 41). With this
conception of the human genome in mind, it would not have made much visual or logical
sense to map genes and other genetic traits onto X-shaped chromosomes. This said, there
was no indication in the reports of the standardization committee published in 1975,
1978, or 1981 that this shift from X-shaped to rod-like chromosomes was meant to make
the human genome more map-able. Nor is it my intention to argue for a causal link in
either direction between ideogram linearity and genome map-ability.
Rather, I suggest that this alteration in depiction reflects a shift in how geneticists
conceptualized the relationship between the assumed linearity of the human genome and
the associated observational characteristics of the human chromosome set.
Chromosomes went from being countable entities, with which certain clinical disorders
could be associated, to visibly comparable and ‘dissectible’ linear units of the human
genome, within which the etiologies of disease could be definitively located. In the next
section, I demonstrate this same shift in another way: by tracing evolving definitions of
the term ‘genome’ within the published biomedical literature specific to human genetic
disease. I argue that, during the 1970s and 1980s, the human genome was being
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conceptually and visually remade, at the level of chromosomal analysis, into a clinically
and biologically important, physical part of the human anatomy.

Evolving Conceptions of the Human Genome
It is commonly held that German botanist Hans Winkler coined the term
‘genome’ in 1920 as a hybrid of the words ‘gene’ and ‘chromosome’ (McKusick and
Ruddle, 1987). However, an alternative interpretation, offered by Joshua Lederberg and
Alexa McCray in 2001, holds that the suffix ‘ome’, used by Winkler in 1920, instead
referred to, “a holistic abstraction, an eventual goal, of which only a few parts may be
initially at hand,” as in the use of “biome” to refer in a general sense to all life in a
particular earth environment (Lederberg and McCray, 2001, 9).9 In this section, I trace
the term ‘genome’ in biomedical textbooks from the late-1960s through the 1980s. My
findings suggest a shift in the use of ‘genome’: from being an abstract way to identify all
of an individual’s genetic material or genes, to a term referring more specifically to a
physically embodied and discretely bounded anatomical entity.
A number of texts aimed at geneticists interested in human disease were in print
during the 1970s. ‘Genome’ only appears in a couple of these texts, and when it does, it
is described in quite abstract terms. The glossary of McKusick’s text Human Genetics
(1969), defines the genome quite simply as, “The total genetic endowment” (203), while
the 1973 edition of Genetics in Medicine, a textbook by physician James S. Thompson
and Ph.D. geneticist Margaret W. Thompson, defines genome in its glossary as, “The full

9

All of the world’s deserts or oceans constitute a biome.
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set of genes” (361). Beyond this, the term genome does not appear in the index or the
main text of other medical genetics texts available during the 1970s such as, An
Introduction to Medical Genetics (Roberts, 1973), and Medical Genetics: Principles and
Practice (Nora and Fraser, 1974).10
Discussions and definitions of the human genome were equally absent in more
general medical texts during the 1970s. The term genome is not used in either the 1971
or 1975 editions of the Cecil Textbook of Medicine (Beeson and McDermott, 1971;
1975). In the 1979 update, genome is not listed in the textbook’s index. However, in a
chapter on genetics, physician Alexander G. Bearn does muse, quite abstractly, “It is
apparent that despite the acceleration in discovery of new genetic entities 90 per cent of
the human genome remains to be discovered” (Beeson et al, 1979, 31). Genome does, in
fact, appear the 1970 and 1974 editions of another prominent general medical text,
Harrison’s Principles of Internal Medicine. The term can be found in a chapter
contributed by McKusick, which refers to the genome in 1970 as “the rest of the genetic
make-up”, and in 1974 as “the genetic background” (Wintrobe et al, 1970, 14; Wintrobe
et al, 1974, 323). Following McKusick’s departure as author of this chapter however,
genome completely disappears from the 1977 and 1983 editions of Harrison’s, in which
physicians Joseph L. Goldstein and Michael S. Brown contributed a similar chapter on
genetics and disease (Thorn et al, 1977; Petersdorf et al, 1983).
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The medical texts chosen for this survey were influenced in large part by a list, meant
for small medical libraries, of recommended selections by topic (Brandon and Hill,
1979).
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During the 1980s, the term genome became both more prominent and more
precisely defined in medical genetics and general medicine textbooks. The 1986 edition
of Thompson and Thompson’s Genetics in Medicine states, “The term genome refers to
the full DNA content of the chromosome set” (Thompson and Thompson, 1986, 6). An
Introduction to Medical Genetics (1985) by physicians J.A. Fraser Roberts and Marcus
Pembrey refers to genomic DNA as, “the nuclear DNA of the chromosomes” (Roberts
and Pembrey 1985, 104). Physician James J. Nora and Ph.D. geneticist F. Clarke Fraser
define genome as, “The complement of genes found in a set of chromosomes”, in the
1981 edition of Medical Genetics: Principles and Practice (Nora and Fraser 1981, 497).
In the 1985 update of the Cecil Textbook of Medicine, contributor John L. Hamerton, a
human geneticist, notes, “The term genome refers to the full DNA content of the
chromosome set” (Wyngaarden and Smith 1985, 138). Genome also appears once again
in the 1987 edition of Harrison’s Principles of Internal Medicine, in which physician and
cell biologist Arthur Beaudet compares the genome to a series of books which, “can be
envisioned as being bound into 46 volumes, each the equivalent of one chromosome”
(Braunwald et al 1987, 296).
While the human genome was certainly associated with the human chromosome
set by geneticists before 1980, the findings from these medical textbooks clearly shows
that there was a shift in the importance and meaning of the term genome for medical
geneticists, and physicians more broadly, between the early-1970s and mid-1980s. When
used in the 1970s, genome generally referred to the abstract concept of ‘all the genetic
material or genes’ possessed by an individual. By the mid-1980s however, as the term
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became increasingly commonplace, it was more often defined in the context of the human
chromosome set. Indeed, during 1980s, the human genome came to be understood as a
discrete object of scientific interest among human and medical geneticists, and one that
was physically and conceptually embodied within a visible part of the human anatomy:
the chromosomes.

Victor McKusick and Postwar Medical Genetics
This chapter has, so far, described how the genome became increasingly
understood as embodied by the human chromosome set during the 1970s and 1980s, and
in turn how standardized representations of chromosomes themselves became
increasingly linearized and ‘genomic’ over this time. My focus now shifts to how
chromosome level depictions of the human genome were used to shape conceptions of
genetic disease at this time. Central to this story is the work of Victor McKusick, and his
influence on the field of medical genetics during the postwar period. After a brief
overview of McKusick’s biography, I turn to a discussion of the new basis for genetic
disease noslogy, which he helped to create and promote through his well-known catalog
of human genetic disorders, Mendelian Inheritance in Man.
McKusick has frequently been referred to as the ‘father’ of postwar medical
genetics. Obituaries of McKusick appearing in Science, Nature Genetics, and the Lancet
after his death in 2008 highlight his status in the field, as does the Award Description
provided for the Lasker Award for Special Achievement in Medical Science, which
McKusick received in 1997 (Lasker Foundation, 1997; Collins, 2008; Oransky, 2008;
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Rimoin, 2008). Reed Pyeritz, a student of McKusick’s, has told me that he was a “pretty
towering figure” in the field of medical genetics, even in the mid-1970s, and that he is
among a group of just four or five individuals who could be considered as having
founded this medical specialty in America (Interview with Reed Pyeritz, April 18, 2012).
Indeed, McKusick was heavily influential in the fields of human and medical genetics
during the last five decades of this life, and certainly one of the most important figures
who shaped conceptions of the human genome, including its size, scope, functionality,
and impact on biology and medicine in the postwar period.11
Born in Parkman, Maine in 1921, McKusick received an M.D. from Johns
Hopkins University School of Medicine in 1946, where he became a faculty member a
year later, specializing in cardiology. As part of his cardiology research, McKusick
became interested in Marfan syndrome, a genetic disorder associated with heart defects.
McKusick tracked the inheritance pattern of this disorder in his patients, ultimately
leading to a wider interest in other inherited disorders (McKusick, 1980, 2006; Stafford,
2008). As he recounted in a 2006 autobiography, McKusick was surrounded by multiple
other, more senior, faculty members at Hopkins, during the 1950s, who were also
interested and knowledgeable in genetics, including Bentley Glass and Barton Childs.
Additionally, he suggested that he was heavily influenced by Curt Stern’s 1949 textbook
Principles of Human Genetics. In 1957, McKusick was installed as director of the J. Earl
Moore Clinic at Johns Hopkins, where he developed a Division of Medical Genetics. As
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2005; Comfort, 2012.
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McKusick has told it, colleagues warned him about shifting focus from cardiology to rare
genetic disorders, calling the move “professional suicide” (McKusick, 2006, 5).
During the late-1950s and 1960s, McKusick went on to train a number of major
figures in the field of medical genetics, including David Rimoin and Alan Emery, editors
since 1983 of the text Principles and Practice of Medical Genetics, as well as David
Weatherall, author of The New Genetics and Clinical Practice, Malcolm Ferguson-Smith,
long-time editor of the journal Prenatal Diagnosis, and Peter Harper, author of A Short
History of Medical Genetics (2008). McKusick also helped to develop the Short Course
in Medical and Experimental Mammalian Genetics, which is held annually at the Jackson
Lab in Bar Harbor, Maine. This two-week course has been responsible for educating
thousands of clinicians about the research and practices of medical genetics since it began
in 1960 (Stafford, 2008; Comfort, 2012).
Victor McKusick however, is perhaps best known for his catalog of genetic
disorders, Mendelian Inheritance in Man (MIM). First published in 1966, MIM grew out
of a series of annotated reviews of medical genetics that McKusick and colleagues had
been compiling since 1958. Ultimately, these were organized into catalogs on X-linked,
recessive, and dominantly inherited disorders, which were put into a computer database
beginning in 1964. Successive editions of MIM were published in 1966, 1968, 1971,
1975, and so forth until the final print edition in 1998. The catalog expanded with each
edition, providing a visible demonstration of the growth and success of the field of
medical genetics. Students occasionally referred to the brightly colored books as “green
genes” and “blue genes” when distinguishing among 1970s era editions (McKusick,
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1981, 67). In 1987, MIM became available electronically as Online Mendelian
Inheritance in Man (OMIM) (McKusick, 2006).
In MIM, McKusick offered a particular conception of and perspective on human
genetic disorders. He argued that the study of genetic disorders provided valuable
insights concerning the normal human genetic make-up,

Genetic disorders give us insight into the normal. These catalogs of
hereditary traits are like photographic negatives from which a positive
picture of man’s genetic constitution can be made . . . Physicians have a
unique opportunity to contribute to knowledge of what Richard Lewontin
referred to as ‘man’s mutational repertoire’ (McKusick, 1968, ix).

Additionally, McKusick emphasized the direct correlations that medical genetics
expected to find between genetic mutations and specific clinical disorders,

In medical genetics there is little place for expressions such as ‘spectrum
of disease,’ ‘disease A is a mild form, or a variant, of disease B,’ and so
on. They are either the same disease, if they are based in the same
[genetic] mutation, or they are different diseases. Phenotypic [clinical]
overlap is not necessarily any basis for considering them fundamentally
the same or closely related (McKusick, 1968, xi).
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A major goal of medical genetics was to help clarify the delineation of particular
disorders, whose identity was confused by variable or overlapping clinical expression.
Indeed, if every genetic disorder could be mapped to one discrete location (or perhaps
multiple locations) in the genome, this could greatly improve diagnosis, clinical
understanding, and potentially treatment. McKusick’s contribution to this process was in
the collection and organization of diseases and other genetic traits in MIM. As I describe
in the next section, this also included participation in workshops, which facilitated the
mapping of genes and disease etiologies in the human genome.

Mapping the Human Genome at the Level of Chromosomes
In her book, Moments of Truth in Genetic Medicine (2005), which looks at the
first decade of medical genetics, Susan Lindee argues,

[McKusick] was an early and eloquent proponent of what I call the
cataloging imperative: the increasingly powerful idea among medical
geneticists that the compilation of a list (or, later, map) of genetic traits,
birth defects, and diseases in human populations could transform medical
practice and patient care (Lindee, 2005, 81).

Lindee suggests further that McKusick was, “collecting with a remarkable passion and
with an explicitly medical agenda that has been fully realized in the international effort to
map and sequence human genes, the Human Genome Project” (Lindee, 2005, 81).
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McKusick’s interest in ‘collecting’ genetic diseases, and mapping their etiologies
to particular genomic locations, in many ways defined, throughout the 1970s and 1980s,
the way that human and medical geneticists thought about the geography and scope of the
human genome. McKusick himself was not among the first researchers to propose what
became the Human Genome Project (HGP) during the mid-1980s (McKusick, 1997a).
However, he did feel that the Gene Mapping workshops, which he helped to found, lead,
and promote during the 1970s and 1980s, represented an important foundational basis for
the HGP.
In a draft history of the HGP, written in 1998 McKusick suggested, “Since
mapping all the genes in the human is a goal of the Human Genome Project, the Human
Genome Project (HGP) can be said to have begun in the summer of 1973 when the first
human genome mapping workshop was convened in New Haven by Frank Ruddle”
(McKusick Papers, Box 509623, ‘Hx of HGM 98’ folder, 1). Indeed, McKusick’s
leadership, in the 1970s and 1980s, of the Human Gene Mapping workshops, offered
geneticists with an early glimpse of what mapping the genome would look like and mean
for the study of human genetics and disease.
In 1986, at a Cold Spring Harbor symposium on mapping and sequencing the
human genome, Victor McKusick gave a presentation about the status of the human gene
map. At the time, approximately 900 genes had been mapped to specific human
chromosomes and chromosomal locations (McKusick, 1986b). McKusick later described
this presentation as being “an eye-opener to the molecular geneticists present”
(McKusick, 1997a, 18). Indeed, as McKusick notes, and in line with the history of
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Robert Cook-Deegan (1994), the initial impetus for the Human Genome Project came not
from the human or medical genetics community, but rather from molecular biologists
(McKusick, 1997a). As it turned out however, these molecular biologists were largely
unaware of the extensive human genome mapping that had already been taking place
since 1968, and in an organized manner since 1973 (McKusick, 2006).
The first genes mapped in man were located on the X chromosome, for the simple
reason that X-linked disorders could be identified based on pedigree analysis because
they generally only affected males, as in the case of hemophilia and color blindness.
Roger Donahue, a student of McKusick’s, linked the first gene to an autosomal
chromosome in 1968. Donahue traced a visible abnormality that he had identified in his
own karyotype through various other members of his family. He was eventually able to
link this visible marker, located on chromosome 1, to a set of genes known as the Duffy
Blood group, which code for red blood cell molecules. Reflecting on Donahue’s
research process, McKusick later mused, “As every good graduate student in genetics
should, Donahue studied his own chromosomes” (McKusick, 1981, 67).
Donahue’s finding happened around the same time as other significant
innovations that contributed significantly to human gene mapping in the 1970s. The first,
as I have already discussed, was the development of chromosomal banding techniques,
which offered hundreds of unique and reproducible chromosomal locations (Caspersson
et al, 1968; Seabright, 1971). Another was the development of somatic cell hybridization
techniques involving the fusion of rodent and human cells. The formation of these hybrid
cells, which initially contain full human and rodent genomes (usually mouse or hamster),
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occurs very rarely, but can be facilitated by chemical manipulation and particular viruses.
As the hybrid cells go through continuous rounds of reproduction, most of the human
chromosomes are lost, while all rodent chromosomes remain. Some human
chromosomes however, may be retained, especially if they contain a gene that is
necessary for cell survival in a particular selective medium (Harris and Watkins, 1965).
Somatic cell hybridization proved to be of great value to human gene mapping
because researchers could test for hybrid cells that continued to express a particular
human protein (Weiss and Greene, 1967). If a human protein was still produced by a
hybrid cell, this meant that its gene must be on one of the human chromosomal fragments
still present. In combination with the uptake of G-banding in the early-1970s, somatic
cell hybridization helped to facilitate the mapping of hundreds of human genes to certain
chromosomal locations over the next decade. Because it brought about the mixing and
recombination of chromosomes from different cells, a cellular process that generally only
occurs as part of sexual reproduction, J.B.S. Haladane famously referred to cell
hybridization as “an alternative to sex” (McKusick, 1981, 76).
In 1973, the first Human Gene Mapping workshop was held in New Haven,
Connecticut under the leadership of Frank Ruddle, a Yale geneticist and early adopter of
somatic cell hybridization for gene mapping. The gathering was funded by the March of
Dimes organization, which already had a longstanding relationship with McKusick, and
role in the funding education of medical geneticists through supporting the annual Short
Course in Medical and Experimental Mammalian Genetics. At the time of the first
workshop, very few genes had been mapped to specific chromosomes. However, by the
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fourth workshop held in Winnipeg in 1977, at least one gene had been mapped to each
human chromosome (McKusick, 2006).
This was a significant intellectual accomplishment for those involved in gene
mapping, even if it was only the tip of the iceberg as far as the entire human genome was
concerned (McKusick, 1980). Why was it so meaningful to have associated at least one
gene with every chromosome? Part of the answer to this question can be found in a
lecture that McKusick had given in 1969 at the 3rd International Conference on
Congenital Malformations. It was in this forum that he first publically proposed that the
entire human genome should be mapped on a detailed level. In this talk, he spoke about
human chromosomes metaphorically as continents,

The chromosomes of man are still largely terra incognita. The
developments in human cytogenetics in the last 10-15 years have shown
us the gross outlines of the continents . . . In a pitifully small number of
instances we know pairs of neighbors residing somewhere on one of the
continents, which are the chromosomes in this geomorphic anatomy. But
in few instances do we know which chromosomes continent carries which
gene . . . Combined with a mapping of the fine structure of the gene should
be an all-out effort at mapping the chromosome continents (McKusick,
1970, 408).
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By mid-1976, human geneticists had succeeded in at least planting a flag on every
continent in the human genome, and from there would further explore the landscape of
each. Indeed, by identifying at least one gene on each human chromosome, human
geneticists had expanded the reach of their knowledge and capabilities to the entirety of
the human genome.
The next year, McKusick and Frank Ruddle published a report on the status of the
human gene map in Science. Included in this paper was a map of the human genome,
depicted at the level of banded chromosomes. The chromosomes were each represented
by an ideogram, based on the rod-shape ideogram drawings provided by the 1975
supplement to the 1971 Paris conference. Each chromosome had one or more genes
mapped to it, designated most often by a three-letter abbreviation, placed at the
approximate location on the chromosome to which that gene had been mapped. The
result is a one-page, schematic view of the human genome, divided into 24 chromosomes,
with one or more genes mapped to each. As depicted in the image, the genome is
‘haploid’ and male: only one copy of each chromosome is shown and both an X and Y
chromosome are present (McKusick and Ruddle, 1977; McKusick, 1980) (Figure 4).
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Figure 4 Map of human genes with known genomic locations, depicted on ideograms
similar to those from the 1975 supplement to the 1971 Paris conference. This image was
initially published in McKusick (1980). Reprinted with permission from The Alan
Mason Chesney Medical Archives of The Johns Hopkins Medical Institutions.
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A similar one-page image of the human gene map was also published in the 1978
and 1983 editions of MIM as well as various papers that McKusick published on the
anatomy of the human genome in the early-1980s (McKusick, 1978, 1980, 1981, 1982,
1983). The density of genes on each chromosome expanded quickly over this time, and
by 1986 the gene map depiction spanned four pages instead of just one (McKusick,
1986a). Why represent the human gene map in this way? I would suggest that the
depiction of genes laid out on chromosomal ideograms quite successfully represents the
human genome visually as both a cartographic and anatomical object. As Sismondo
(2004, 215) has argued in reference to the Human Genome Project, the practice of
cartography has a “fiction of completeness . . . Maps ask to be completed” through the
filling in of missing information. The growing gene map as depicted on chromosomal
ideograms had a similar effect: it showed which areas of the genome were well
represented, and what regions remained largely unexplored.
One set of genes that were of particular interest to McKusick, and other medical
geneticists, were those directly involved in the etiology of various genetic diseases.
During the 1970s, McKusick’s maps were largely limited to specific gene designations.
However, in the early-1980s, McKusick began creating separate maps, which he called
the “Morbid Anatomy of the Human Genome,” depicting the genomic location of disease
etiologies as well. As I describe in the next sections of this chapter, these maps were part
of McKusick’s larger interests in making geneticists and clinicians see and understand the
genome as part of the human anatomy.
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The Human Genome as an Anatomical Entity
I began this chapter by noting that Victor McKusick often spoke of the human
genome (and alternatively the human chromosomes) as being the “organ” of molecular
genetics, equating it with the heart for cardiologists and the kidneys for nephrologists
(McKusick, 1982, 1997a, 2001). This fit into McKusick’s larger conception of the
genome as being part of the human anatomy, “The chromosomes and the linear
arrangement of the genes they carry are part of human anatomy” (McKusick, 1981, 78).
McKusick cites multiple sources for this conception of the genome, including the
influential human geneticist Curt Stern and biochemical geneticist Charles Scriver
(McKusick, 1997b, 2001). Clearly McKusick found the reference to be of great
descriptive and rhetorical value, as he used it in most every paper he published on the
human genome between 1980 and his death in 2008.
McKusick was not alone in his use of anatomical analogies when speaking about
the human genome in the early-1980s. In this Nobel lecture, the molecular biologist Paul
Berg also made a similar anatomical reference in talking about the genome and its
relevance to medicine,

Just as out present knowledge and practice of medicine relies on a
sophisticated knowledge of human anatomy, physiology, and
biochemistry, so will dealing with disease in the future demand a detailed
understanding of the molecular anatomy, physiology, and biochemistry of
the human genome . . . We shall also need physicians who are as
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conversant with the anatomy and physiology of chromosomes and genes
as the cardiac surgeon is with the structure of the heart and the circulatory
tree (Berg 1981, 285).

Charles Scriver also adopted an anatomical metaphor in speaking about the
genome during the early-1980s, referring to genomic mapping as akin to a “neo-Vesalian
anatomy” (Scriver, 1982, 496). In the early-1980s, McKusick also picked up on this
concept, publishing a paper entitled “The Human Genome Through the Eyes of Mercator
and Vesalius”. The article looked at the use of both cartographic and anatomical
metaphors for thinking and speaking about the genome. In terms of the cartography of
the genome, McKusick states, “The landmarks in the maps are the [chromosomal] bands
revealed by special staining” (McKusick, 1981, 77). However, as he goes on to explain
in the paper, “This is a cartographic metaphor, but an anatomic metaphor is equally apt”
(McKusick, 1981, 78).
Indeed, analyzing the human genome was not just as a mapping project, but also
as an anatomical exercise, in the tradition of Vesalius. Adopting the same phrasing as
Scriver in a 1986 paper, McKusick noted, “Knowledge of the chromosomal and genic
anatomy of Homo sapiens has given clinical genetics (and medicine as a whole) a neoVesalian basis” (McKusick 1986b, 19). In his account of the early history of the Human
Genome Project, Gene Wars (1994), Robert Cook-Deegan recounts that such references
to the neo-Vesalian nature of genome mapping were quite successful in attracting funding
sources for the project, particularly from the Howard Hughes Medical Institute (Cook64

Deegan 1994, 120). Seemingly, these historical and anatomical references made
mapping the human genome more legible to a wider audience.
When pointing to the ‘neo-Vesalian’ basis of human genetics, McKusick and
Scriver were referencing the work of Andreas Vesalius, a 16th century physician, famous
for his anatomical images published in On the Fabric of the Human Body (1543). The
frontispiece of this text, which McKusick published as part of his 1981 paper, “The
Human Genome Through the Eyes of Mercator and Vesalius”, depicts Vesalius teaching
human anatomy by directly pointing to a newly dissected human body. This was in
contrast to the existing norm during the 16th century, when an instructor would read
directly from the fourteen hundred year-old text of Galen, while standing apart from the
dissected body (Carlino, 2001).
To the present day, Vesalius is remembered in the western medical community as
having brought direct observation of the dissected human body back to the forefront of
research and teaching in human anatomy. In The Secrets of Women: Gender, Generation,
and the Origins of Human Dissection (2006) however, Katherine Park counts Vesalius
among various 15th and 16th century figures who have been inaccurately remembered as
heroes because they, “braved persecution and censure in the service of art and science”
(21). As Park suggests, continued reference to these individuals does, “important cultural
work”, providing, “foundation stories that confirm deep-seated Western institutions about
the scientific origins of modernity – institutions that continue to inform the writing of
even specialists in the field” (Park 2006, 21).

65

Indeed, late-20th century physicians like McKusick and Scriver regarded Vesalius
as a revolutionary figure, who had an impact on future centuries of medical thinking and
practice. References to the ‘neo-Vesalian’ nature of late-20th century human genetics
were rhetorically valuable for making the argument that the genome mattered to medical
practice because it was physically and visually a part of the human anatomy. In addition,
just as the work of Vesalius was seen as reshaping medicine in the 16th century and
beyond, during the 1980s, anatomical exploration of the human genome was similarly
presented by McKusick and Scriver as being likely to have revolutionary implications for
medicine in the decades to come.

The ‘Morbid Anatomy’ of the Human Genome
As part of addressing the anatomy of the human genome in his 1981 paper,
McKusick commented on the localization of disease genes,

For an ever increasing number of diseases the chromosomal location of
the mutant gene responsible is known. In many of these instances this
location is known because the enzyme which is deficient has been
assigned to a specific location. In most of these disorders the evidence is
strong that it is indeed the structural gene for the enzyme that is mutant in
the given disease (McKusick, 1981, 79).
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Similar to the ways in which diseases may be located in the bodies of patients, their
etiological cause may also be located in the human genome. McKusick referred to this
practice as looking at the ‘morbid anatomy’ of the human genome, pointing to the 18th
century work of Giovanni Morgagni in locating the ‘clinical pathology’ of a disease in
certain bodily organs (McKusick, 1997a, 422; McKusick 2001, 2289).
Additionally, McKusick often spoke of “dissecting the human genome”, further
playing up a neo-Vesalian interpretation of the human genome and what researchers
could physically do to it (McKusick, 1980, 1981, 1982 1997b).12
In his 1982 paper, “Window Panes of Eternity. Health, Disease, and Inherited
Risk”, Scriver similarly pointed to this way of thinking about the human genome noting,
once again in reference to Vesalius’ 1543 anatomy text, “Another revolution in anatomy
is occurring; it is chromosomal and genetic cartography achieved by mapping of genes to
specific chromosomes and bands on chromosomes and the delineation of nucleotide
sequences in specific genes, respectively. We are beginning to possess chromosomal
12

McKusick sought more than just a morbid anatomy of the human genome, however.
He also called for a comparative evolutionary anatomy, a functional anatomy, and a
developmental anatomy (McKusick, 1981, 79). These terms closely resemble various
sub-disciplines of classical biological study. The human genome’s evolutionary anatomy
would allow it to be compared to the genomes of various other organisms, its functional
anatomy would describe the way its genes, and interactions among them, led to particular
clinical outcomes, and its developmental anatomy would reveal various ways in which
the arrangement of particular genes affected their functionality (McKusick, 1981).
Indeed, McKusick seems to have hoped to re-appropriate the human genome as
an important feature in both biological and medical research. As previous scholars have
demonstrated, much of genetics research since the 1930s had been biochemical in nature,
and often was not specifically oriented toward human characteristics (Abir-Am, 1982;
Kay, 1993, 2000; Keller, 2000; Rheinberger, 2008). The ability to visualize and compare
human chromosomes made possible by the introduction of banding in the 1970s however,
made these anatomical entities newly useful for more classical medical and biological
research.
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addresses for Mendelian disease” (Scriver 1982, 496). Scriver now refers to gene
mapping during the 1970s and early-1980s as “the genome project of the day”. As a
member of the HHMI medical advisory board during the 1980s, he was a major
proponent of funding this ongoing research. Scriver has described his interest in gene
mapping at the time to me in this way, “There was lots of initial episodic work, where a
certain gene might be mapped to a certain particular region of a chromosome, and so a
mosaic was being built up. I was interested in seeing the whole picture being completed”
(Interview with Charles Scriver, May 30, 2012). During the 1970s and 1980s, it was
McKusick who laid out the conceptual and visual framework for doing just this.
Starting with his 1982 paper, “The Human Genome Through the Eyes of a
Clinical Geneticist”, McKusick began publishing what he called “The Morbid Anatomy
of the Human Genome”. To illustrate this ‘morbid anatomy’, McKusick began with the
24 human chromosomal ideograms (1-22, X, Y), which were shown with banding
patterns based on the 1981 Paris Conference, and arranged them into an idealized
karyotype. Along each chromosome, genetic diseases, which had been mapped to certain
genomic locations, were identified. Some disorders were known only to be linked to a
specific chromosome, while others were associated with a particular chromosomal region
or band (McKusick 1982).
Reed Pyeritz, a medical geneticist, and former student of McKusick’s, has
described the impetus for maps depicting the morbid anatomy of the human genome to
me in this way,
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When people started laying out the 23 sets of chromosomes, the
ideograms, and then had next to [each] where a gene had been identified,
[McKusick] said, ‘that’s all well and good, but you can often map a
phenotype [like Marfan syndrome] to a specific site on a chromosome
before you know what the cause is’ (Interview with Reed Pyeritz, April
18, 2012).

In effect, the morbid anatomy diagrams acted to breakdown the visual divide between
laboratory and clinical knowledge: the anatomical markers of clinical disorders could
also be located and observed within the human genome, at the visual level of
chromosomes. As McKusick saw it, “this is what a geneticist does” (Interview with Reed
Pyeritz, April 18, 2012). Just as Morgagni had associated clinical disorders with the
anatomy of particular organs during the 18th century, McKusick felt that a major goal of
20th century geneticists should be to give human diseases a neo-Vesalian basis by
locating them in discrete, visible regions within the genome.
Updated versions of the morbid anatomy of the human genome appeared
frequently in print. For instance, morbid anatomy maps were included in the 1983 and
1986 editions of MIM (McKusick 1983; 1986c). New editions of the morbid anatomy of
the human genome were also included in various medical genetics texts during the 1980s
including, The Metabolic Basis of Inherited Disease (Scriver et al, 1989) and Genetics in
Medicine (Thompson and Thompson, 1986). In addition, the morbid anatomy was
published along with an interview of McKusick in a 1984 issue of the Journal of the
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American Medical Association, and in a four part series appearing in the journal Medicine
between 1986 and 1988 (McKusick 1984; 1986a; 1987a; 1987b; 1988). Indeed, during
the mid-1980s, this “neo-Vesalian” depiction of the human genome had made its way
more widely into the biomedical literature. With each new map, McKusick captured the
ongoing “dissection” of the human genome, while presenting a particular way of seeing
and thinking about the genome to his fellow geneticists and clinicians, who, by the midto-late-1980s, appear to have widely adopted it in their own texts (McKusick 1982, 88).
Like the anatomical prints in Vesalius’ Fabrica, McKusick’s human gene map
and ‘morbid anatomy’ of the human genome map were artistic depictions of the
genome’s anatomy. These maps were based upon idealized representations of each
chromosome, as captured by chromosomal ideograms. In addition, the gene locations
presented by them were quite crude, with little or no indication of the distances between
individual genes. More than anything, the genome map was meant as a database for
collecting and depicting existing information, which would be used as a basis for future
research. As McKusick put it in his 1986 report on “The Morbid Anatomy of the Human
Genome” published in Medicine, “Just as [Vesalius’] de corporis humani Fabrica (1543)
was the basis for the physiology of Harvey (1628) and the pathology of Morgagni (1761),
the chromosome information is the foundation for our understanding and management of
genetic disease in man” (McKusick, 1986a, 2).
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The Human Genome Goes Full Circle
In this chapter, I have demonstrated how standardized depictions of the human
chromosome set evolved during the 1970s and 1980s, just as conceptions of the human
genome were also shifting among medical professionals. Between 1971 and 1981,
chromosomal ideograms became increasingly linearized and densely packed with over
800 distinct bands, providing a standardized visual language for dividing up and
identifying discrete locations on each human chromosome. At the same time, beginning
around 1980, various clinically oriented geneticists, such as McKusick and Scriver, began
talking about and depicting the anatomical aspects of the genome. This way of thinking
about the human genome, as both observable and embodied, led to a noticeable shift in
how the genome was discussed in medical texts between the 1970s and the 1980s. The
genome was no longer referred to abstractly as ‘all of the human genes’. Rather,
definitions and representations of the genome became increasingly embedded in and
bounded by visual depictions of the human chromosome set.
In the 1987 edition of Harrison’s Principles of Internal Medicine, a new figure
was added to the text, which perfectly captures the simultaneous evolution of
standardized chromosomal ideograms and embodied conceptions of the human genome.
This image combines selected elements of McKusick’s human gene map and ‘morbid
anatomy’ of the human genome, but in a new way. Previously, the chromosomal
ideograms in these figures had been organized like a karyotype: with chromosomes lined
up side by side, often in order by size. In this figure however, the chromosomal
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ideograms were lined up end-to-end in a circle, from chromosome 1 to 22, followed by Y
and X, with “THE HUMAN GENOME” printed in the middle (Brauwald et al, 318).
This way of depicting the human genome is interesting for a number of reasons.
First, and most importantly, it takes the ongoing process of linearizing the chromosomal
ideograms to make them more ‘genomic’ one step further: the human genome was now
depicted as a continuous linear arrangement of all 24 human chromosomes, placed endto-end. While each chromosome remains physically distinct, this image offers a
particular view of the genome that allows it to be seen and mapped as a continuous
whole, instead of in 24 distinct parts. Another fascinating result of this way of
illustrating the human genome is how similarly it is in setup to the standard depiction of
bacterial and viral genomes. Instead of being broken down into chromosomes, these
genomes are comprised of one undivided loop of genetic material. Hence, such genomes
can be sequenced or mapped continuously, beginning and ending at any point. Depicting
the human genome, which is anatomically divided into 24 pieces, in this way, suggests a
similar (conceptual) continuity. The human genome becomes a single, bounded entity
that can be broken down visually into a continuous series of chromosomal bands, instead
of into 24 individual chromosomes, each having their own unique banding pattern.
Indeed, “THE HUMAN GENOME” captures in one image, the various
conceptual shifts that I trace in this chapter. In being physically comprised by the human
chromosome set, the genome was presented as a component of the human anatomy. As
part of becoming embedded in the chromosomes however, the human genome’s
presumed linearity clearly was not lost. Rather, as I have described, presumptions of
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linearity literally reshaped how standardized chromosomal ideograms were drawn. The
arrangement of these chromosomal ideograms from end-to-end into a closed circle
demonstrates dual understandings: the human genome is at once physically embodied by
discrete entities, and yet conceptually continuous and linear. In this image therefore, we
see the human genome presented as a discrete scientific object: one that could be
understood, described, and visually observed as a physically bounded whole.

Conclusion
Throughout this chapter, I have argued that, during the 1970s and 1980s, the
human genome became increasingly embedded – conceptually, physically, and visually –
within standardized depictions of the human chromosome set. After decades of being
regarded and referred to in abstract terms, such as ‘all of the human genetic material or
genes’ the genome began to be understood and analyzed in ways that made it increasingly
tangible and anatomical, and thereby more relevant to the interests and daily practices of
clinical researchers and medical geneticists. In addition to providing an anatomical basis
for conceptions of the human genome, its association of with human chromosomal
nomenclature has also helped to establish the genome as a scientific object. Indeed, the
standardized visual nomenclature of the human chromosome set provides a universal
language not only for identifying and communicating about chromosomal attributes, but
genomic locations as well.
The establishment of the human genome as a scientific object was an iterative
process: one which involved shifting definitions of the term ‘genome’, along with
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evolving standardized depictions of human chromosomes. Additionally, the development
of the genome as a scientific object involved new ways of thinking about, and visually
representing, how human disease can be identified, observed, mapped, and potentially
understood at the chromosomal level. While the human genome has frequently been
situated primarily within the informationally oriented domain of molecular and computerbased biology, this study demonstrates that, during the 1970s and 1980s, the genome was
conceptually re-appropriated as a tangible and valuable object of study among the more
visually oriented practitioners of human and medical genetics. Just as Scriver has put it,
the human genome could be seen as “a mosaic” in the 1980s, that was growing ever more
densely filled in as the process of gene and disease mapping continued (Interview with
Charles Scriver, May 30, 2012).13
Indeed, McKusick’s ‘morbid anatomy’ diagrams helped to establish the human
genome as an object amenable for broad-based biomedical research, by taking an
idealized representation of the biologically ‘normal’ human chromosome set, and using it
to map the genomic location of clinically-defined ‘pathological’ disorders. This seamless
alignment of the normal and the pathological – the known biological and medical
characteristics of the human genome – forms an important basis of contemporary
biomedical research.14 Therefore, along with molecular biology and its informational
13

This statement is reminiscent of Daston (2008, 110) on scientific observation, “Science
depends crucially on its own ontologies, so very different from commonsense ontologies,
painstakingly assembled from diverse shards of evidence as a mosaic is assembled from
tiny stones of diverse color and shape. It is observation, grounded in trained, collective,
cultivated habit, that fuses these bits and pieces into a picture– often a literal picture
crafted by the techniques of scientific visualization.”
14
This concept I draw from: Keating and Cambrosio (2003,72).
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approaches, the observational analysis of chromosomes is deeply embedded in
biomedicine’s postwar development. With this in mind, continued recognition and
analysis of observational approaches in postwar human genetics is likely to facilitate at
once a broader and more nuanced understanding of the mid-to-late-20th century birth of
biomedicine.
In upcoming chapters, I continue to trace the development and use of banded
chromosomal analysis for improving the delineation, diagnosis, and understanding of
genetic disorders. Throughout the 1970s and 1980s, the visual scanning of banded
chromosomes provided new ways of seeing and identifying clinically characterized
genetic disorders. Throughout this era, human and medical geneticists attempted to apply
chromosomal analysis to identifying new, more exact techniques of delineating disorders.
These novel methods were based in the association of clinical outcomes with particular
genomic locations and visual genetic aberrations, rather than the more variable and
confusing presentation of disease in human bodies.
As I explore, chromosomal methods for delineating human disease were at times
quite successful, while, in other instances, they produced confusing and frustrating
results. In working through these complications however, human and medical geneticists
increasingly came to conceptualize the human genome in ways directly shaped by the
visual analysis of chromosomes. As I argue, in the decades before the Human Genome
Project began in earnest, chromosomal analysis provided an unexpectedly valuable
experimental system for both the clinical delineation and mechanistic understanding of
genetic disorders. In the course of this, chromosomal analysis also facilitated the
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development of new, increasingly complex understandings of the structure and function
of the human genome more broadly.
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CHAPTER 2
Interpreting an ‘In Vitro’ Phenomenon: The Delineation, Diagnosis, Prevention, and
Treatment of Fragile X syndrome
In this chapter, I look at the role of chromosomal analysis in the history of a
particular form of inherited intellectual disability, now known as Fragile X syndrome.
Fragile X syndrome is believed to be the second most common cause of inborn
intellectual disability (Smith and Berry, 1983; Sutherland and Hecht, 1985; Nussbaum
and Ledbetter, 1986; McKusick, 1987; Kaufmann et al, 2002). Aside from intellectual
disability however, patients affected by Fragile X syndrome have been regarded as being
quite ‘normal’ in clinical appearance (Turner, 1983). Fragile X syndrome is one among
many forms of ‘non-specific’ X-linked intellectual disability, referring to its lack of other
highly relevant clinical features (Gerald, 1981). The delineation of Fragile X syndrome
was facilitated by the identification of two associated visual markers in the 1970s, one of
which – the fragile X site – became the disease’s namesake during the next decade.
The fragile X site is one of more than 100 ‘fragile’ sites that have been identified
in the human genome, based on observational, chromosomal analysis. Fragile sites are
believed to reflect specific structural characteristics of the human genome. Because of
their wide distribution throughout the genome, they have also proven to be valuable
visual markers for mapping various locations. The fragile X site discussed in this chapter
is unique among these genomic features in that it is associated with a clinical disorder
(Hecht, 1988). As I describe here, the correlation between the fragile X site and Fragile
X syndrome was, for decades, both highly confusing for, and of significant interest to,
clinicians and genetics researchers. Indeed, while it proved to be a valuable
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chromosomal marker of Fragile X syndrome when visible, the inheritance pattern of the
fragile X site, and its associated form of intellectual disability, did not fit neatly with
existing assumptions about Mendelian traits and genomic stability.
The laboratory history of the fragile X site parallels the broader history of
chromosomal analysis between the late-1960s and early-1990s in revealing ways.
Indeed, this marker was identified before chromosomal banding was developed (see
previous chapter) and was integrated into the new ‘genomic’ understanding of the human
chromosome set during the 1970s and 1980s. Likewise, the clinical history of Fragile X
syndrome offers a window into thinking about intellectual disability, more broadly,
during the postwar period. By the late-1970s, it was widely accepted that Fragile X
syndrome was ‘X-linked’ in two related ways. Because the disorder only seemed to
cause significant intellectual disability in males, it was assumed to be caused by a
recessive trait inherited on the X chromosome, of which females possess two copies,
while males have just one. In addition to this pattern of clinical expression, Fragile X
syndrome is also ‘linked’ to a microscopically visible “lesion” on the X chromosome
(Pembrey et al, 1985, 713).
During the postwar period, clinicians and genetics researchers looked for the
visible markers of disease both within the clinically visible body and the chromosomally
visible human genome. Fragile X syndrome offers an exemplary historical case study of
a genetic disorder that was delineated, diagnosed, and understood based on visible
markers from both the laboratory and the clinic. Since the late-1950s, the human
chromosome set has increasingly been understood as a part of the human anatomy, where
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the visible markers and mechanistic causes of genetic disease intermingle. This has had
implications for how clinicians and researchers think about and study the etiological
causes of, and potential treatments for, Fragile X syndrome and other genetic disorders.
In this chapter, and throughout this dissertation, I explore the impact that evolving
understandings of the relationship between the human chromosome set and genome have
had on the thinking and practices of postwar human and medical genetics.

Mid-20th Century Perspectives on X-linked Intellectual Disability
In 1943, British physician James Purdon Martin and human geneticist Julia Bell,
both at the National Hospital in London, published a report on a family showing an
inherited form of what appeared to be X-linked intellectual disability. X-linked disorders
often only affect males, because the causative genetic trait is located on the X
chromosome, of which females have two copies, and males have only one. If a female
inherits one aberrant X-linked genetic trait, its negative effects may be overridden by a
normal copy of that genetic entity on her other X chromosome. However, since males
have only one copy of the X chromosome, if they inherit a mutant genetic trait on it, they
generally are affected by it clinically, because they have no normal copy to potentially
override or mitigate these effects.
Among two generations of the family described by Martin and Bell (1943), eleven
males were affected by intellectual disability, along with two females, though their
symptoms were much milder. Unlike other forms of intellectual disability, such as Down
syndrome and phenylkeoluria (PKU), no additional clinical manifestations were noted as
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part of this inherited form of intellectual disability, which was described as involving an
extremely limited vocabulary and not progressing past the mental capacity of a young
child (Martin and Bell, 1943). At the time, these researchers regarded the family
pedigree they described as being an isolated case of X-linked intellectual disability.
Referring to the Colchester Study report (Penrose, 1938), the authors noted that, among
1280 cases of intellectual disability studied, British geneticist Lionel Penrose, “found
insufficient evidence to support the view that sex-linked genes played a significant part in
the etiology of mental defect – a testimony to the rarity of such a history as the one now
described” (Martin and Bell, 1943, 157). Though the Colchester Study demonstrated that
there was a higher incidence of intellectual disability among males, Penrose concluded
that this did not have a simple genetic basis, but was the result of several factors (Kevles,
1985, 162). With this in mind, and given the lack of other similar pedigrees in the
published literature, Martin and Bell concluded that the family they described was a rare
case, instead of a more widely representative one.
Over the next thirty years, several additional reports of other families affected by
similarly ‘non-specific’ forms of X-linked intellectual disability were published (Allan at
al, 1944; Renpenning et al, 1962; Dunn et al, 1963; Roboz and Pitt, 1969). In 1965,
physician John M. Opitz and colleagues reported on an extended family with 20
intellectually disabled males. This family became the basis of a Ph.D. thesis done by
Robert Lehrke in the years thereafter on the genetic basis intellectual disability. Lehrke
concluded that there existed one or more X-linked genes that were the cause of the higher
incidence of intellectual disability in males (Lehrke, 1972). This was a controversial
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conclusion at the time, both among Lehrke’s doctoral examiners, and other human
geneticists (Turner and Opitz, 1980; Turner, 1983). After all, as Lionel Penrose (1963)
suggested, given that humans have 22 other chromosomes, why should the X
chromosome in particular play an important role in intellectual disability?
Lehrke however, was not alone in arguing for the significant impact X-linked
genes on intellectual disability. During the early-1970s, an English study with similar
results was published (Davison, 1973), as were reports from Australian researchers
Gillian and Brian Turner (Turner et al, 1970; Turner et al, 1971; Turner et al, 1972).
Gillian Turner was working at this time, in a clinic for the intellectually handicapped, and
therefore was exposed to a large and diverse number of cases, the genetic basis of which
intrigued her. One day, Turner began going through a number of photographs of
intellectually disabled males, to look for common physical traits, and noticed to her
surprise, that many were quite ‘normal’ looking. As Turner later put it, “We gradually
woke up to the fact that to be ‘normal looking’ in a moderately mentally retarded
population was relatively abnormal” (Turner, 1983, 10). In these cases, the absence of
any additional clinical effects beyond intellectual disability was regarded as so unusual as
to be a visual marker of a unique disorder.
Turner noticed that the majority of ‘normal’ looking males with intellectual
disability had other males in their family that were similarly affected. This was not the
case for most intellectually disabled males that had more distinctive clinical features
(Turner, 1983). Multiple reports were published based on this finding (Turner et al,
1970; Turner et al, 1971), in which it was suggested that these normal looking males had
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a previously described X-linked disorder, ‘Renpenning Syndrome’ (Renpenning et al,
1962). Turner and her colleagues published an even larger study the next year, with
similar results (Turner et al, 1972). As she continued to examine sets of brothers with
non-specific intellectual disabilities in the Australian state of New South Wales, Turner
eventually came across an interesting clinical finding: in some cases the affected brothers
possessed unusually large testicles (also known as macro-orchidism) (Turner, 1983).
Testicle size is a feature that may be easily overlooked in the clinic; and, even
when noticed, is difficult to accurately measure. In 1966, Andrea Prader (one of the
physicians who first identified Prader-Willi syndrome, the topic of chapter 3) developed
an ‘orchidometer’ for the measurement of testicles, which was comprised of a series of
egg-shaped standards of known volume to be used for comparison (Prader, 1966). What
could be considered a ‘normal’ testicle size was not yet well established in the early1970s, as volume varied greatly by age and, some hypothesized, among different races
(Turner, 1983). Turner et al (1975) reported on two families in which all of the males
affected by an X-linked form of intellectual disability were also found to have testicles
that were approximately twice the normal volume, as established by Zachmann et al
(1974). In this paper, Turner and colleagues also noted a previous study that had
mentioned the presence of enlarged male genitals in a family affected by X-linked
intellectual disability, which was published earlier in the decade by a Ph.D. candidate in
Sao Paulo, Brazil (Escalante, 1971). Multiple follow-up studies reported similar findings
over the next few years, and established that the macro-orchidism in these cases did not
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result from an independent hormonal abnormality (Cantu et al, 1976; Biederman et al,
1977; Ruvalcaba et al, 1977).
Was this clinical feature part of the disorder that caused X-linked intellectual
disability? A patient with macro-orchidism who was not intellectually disabled was
knonwn in the medical literature (Nisula et al, 1974), demonstrating that the two features
did not always occur together. However, as Bowen et al (1978) pointed out, the
consistent occurrence of macro-orchidism in families with otherwise non-specific Xlinked intellectual disability was strong evidence that these two clinical outcomes were
related. What clinicians and researchers needed in the mid-1970s was a third marker,
common to this population, that could dispel doubts that the group was clinically distinct.
As it happened, another researcher had already identified such a marker based on
observational, chromosomal analysis in the late-1960s. However, as I describe in the
next section, various technical complications delayed the demonstration of its clinical
significance.

A Chromosomal Marker for X-linked Intellectual Disability
In 1969, Yale University School of Medicine physician Herbert Lubs reported on
the discovery of a new type of chromosomal abnormality. He described it as “an unusual
secondary constriction . . . seen at the ends of the long arm of a group C chromosome
[referring to chromosomes 6-12 and X]”. The aberration “gave the appearance of large
satellites”, greater in size than any of the satellites that normally appeared on certain
other chromosomes (Lubs, 1969, 234). Lubs had discovered this ‘secondary constriction’
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while studying the chromosomes of a boy affected by a severe form of intellectual
disability. Often times, when chromosomal aberrations are identified in patients with
clinical abnormalities, the chromosomes of one or both of their parents are also analyzed,
so as to determine whether or not the abnormality is inherited. If the same aberration is
found in a parent who is not similarly affected clinically, it is generally assumed that it
represents a benign form of ‘normal’ genetic variation.
In this case, after finding the secondary constriction in the intellectually disabled
boy, Lubs analyzed the chromosomes of the boy’s intellectually normal mother and his
similarly affected brother. These two family members also showed the exact same
chromosomal aberration. In response to this finding, Lubs noted, “Initially, it appeared
that the secondary constriction was not clinically significant since it was present both in a
normal mother and her abnormal son” (Lubs, 1969, 241). Upon further analysis
however, the same secondary constriction was also found in multiple individuals in the
patient’s extended family, some of who showed a similar form of intellectual disability.
It was noticed, in fact, that only males who possessed this secondary constriction were
affected by intellectual disability. Females with the marker were reported as showing no
clinical effects (Lubs, 1969).
Touting the importance of this new chromosomal marker to the future of clinical
cytogenetics, Lubs suggested that such secondary constrictions might “prove to be the
most important group of cytogenetic abnormalities both because they are common and
because they may permit prevention of clinical disease” (Lubs, 1969, 231). Unlike other
chromosomal abnormalities that had been identified in the previous decade, such as
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trisomy 21 in Down syndrome patients, Lubs’ marker was heritable, and thereby could be
tracked in families. With this in mind, Lubs suggested that, “descriptive human
cytogenetics is entering a new and important phase.” Indeed, identifying smaller,
heritable chromosomal anomalies, such as this one, was significant because, “they may
permit prevention of clinical disease by identifying high-risk marriages and allowing
subsequent amniocentesis and abortion of abnormal fetuses if requested by the family”
(Lubs, 1969, 231).
Lubs could see that this secondary constriction occurred on a ‘C group’
chromosome, a classificatory unit that is comprised of chromosomes 6-12 and X. As I
described in the previous chapter, it was very difficult to visually discriminate each C
group chromosome at this time, as they are all similar in size and shape. The specific
chromosome upon which the secondary constriction occurred therefore, could not be
easily determined visually. However, since the marker was associated with intellectual
disability only when present in males, and never when seen in female family members,
Lubs inferred that it was likely an X-linked trait. Indeed, while Lubs used other
laboratory methods to aid in demonstrating that the secondary construction occurred on
the X chromosome,15 it was the inheritance pattern of the related clinical disorder that
first suggested that this would be the case. It was not yet clear how the secondary
constriction caused intellectual disability, but since this clinical outcome was only seen in
males, the genetic trait itself seemed to be located on the X chromosome (Lubs, 1969).
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This included a more exacting measurement of the chromosome’s length and width, as
well as an analysis of when during the cell reproductive process it was replicated (Lubs,
1969).
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Lubs’ ‘Marker X’ chromosome was one of three secondary constrictions that
were independently reported by various cytogeneticists between 1968 and 1970. A year
earlier, Jerome Lejeune in France had identified a similar heritable marker on
chromosome 2 (Lejeune et al, 1968). And, in 1970, another was reported on
chromosome 16 by American cytogeneticists Ellen Magenis and Frederick Hecht
(Magenis et al, 1970). Unlike the Marker X however, neither of these visible
chromosomal anomalies were associated with abnormal clinical outcomes. In their 1970
report, Magenis and Hecht referred to the chromosomal abnormality they had identified
as a ‘fragile site’, a term that was widely adopted by geneticists thereafter.16
As it turned out, the immediate impact of Lubs’ fragile site, in both in the
laboratory and clinic, was minimal. No other researchers reported a similar X
chromosome fragile site again for seven years (Giraud et al, 1976; Harvey et al, 1977).
In fact, discussion of fragile sites largely disappeared from the scientific and medical
literature during the first half of the 1970s. This delay had not occurred because Lubs’
paper had gone unnoticed: it was published in the American Journal of Human Genetics,
and cited when the fragile X site was once again identified in the mid-1970s. Indeed, as
Gillian Turner later noted, she, and likely others, had been in pursuit of finding the
Marker X chromosome in patients ever since Lubs’ report (Turner, 1983, 12). Rather,
researchers stopped reporting on fragile sites in the early-1970s quite literally because
they stopped seeing them under their microscopes.
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Lubs however, continued to prefer the use of “Marker X chromosome” (Lubs, et al,
1984).
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The disappearance of fragile sites did not occur because of an existing need for
some technological advance to improve visibility: in fact, quite the opposite was the case.
While fragile sites were understood to be visual representations of certain heritable
structural characteristics of the human genome, it was ultimately determined that they
could only be seen in the laboratory under certain chemical conditions. Australian
geneticist Grant Sutherland eventually explained the disappearance of fragile sites from
chromosomes in 1977, by demonstrating that a change in cell culture media by many
cytogenetics laboratories around 1970 had inadvertently masked the sites (Sutherland,
1977; Gerald, 1981).
Following further experimentation, Sutherland determined that it was the presence
of higher concentrations of folic acid in the new media that had led to the absence of
visible fragile sites in the early-1970s.17 After this was widely reported, folic acid
deficient media was once again adopted for studying fragile sites, along with the new
protocols recommended by Sutherland (1979) (Interview with Loris McGavran, August
20, 2012).18 At this point, research on fragile sites, as well as their clinical associations,
began anew (Sutherland, 1979; Sutherland and Hecht, 1985). Indeed, as it turned out, a
technical change that was intended to improve chromosomal analysis (by enhancing the
ability to cells to reproduce in culture) inadvertently disrupted the study of the fragile X
site, at a key moment in the investigation of its associated genetic disease. As I describe
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Other cell culture factors such as pH also played an important role (Sutherland, 1979).
Loris McGavran is a Ph.D. cytogeneticist who played an important role in bringing
Fragile X testing to the University of Colorado Children’s Hospital in Denver during the
early-1980s.
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next, by the time that fragile sites began to appear again, the practices of cytogenetics had
been evolved significantly.

The Fragile X Marker in a New Era of Cytogenetics
Much had changed between the Lubs’ report in the late-1960s and Sutherland’s in
the late-1970s. Cytogenetics had emerged from its “doldrums” into the revolutionary era
of chromosomal banding (McKusick, 1997, 8) (For more on this, see the previous
chapter). Each human chromosome could now be visually differentiated based on its
unique banding pattern. As a result, standardized depictions of the human chromosome
set also had changed quite significantly. Additionally, chromosomal banding provided a
visual set of physical landmarks throughout the human genome, which could be used for
the purposes of mapping. Genomic locations were now identified based upon a
standardized visual nomenclature, built around the bands on each chromosome, which
had been developed in 1971 (Paris Conference (1971), 1972).
Based on this visual nomenclature, various genetic elements were now being
associated with particular genomic “addresses”. For instance, a number of human genes
and disease etiologies that had been visibly located in the human genome based on
chromosomal analysis, among other techniques, were identified based on the
chromosomal band in which they had been found (Scriver, 1982; McKusick, 1983).
Lubs’ X-linked fragile site, along with the twelve others known by 1982, was also
associated with distinct a genomic location. In many cases, these fragile sites were
named after the chromosomal band at which they appeared. For instance, the fragile site
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on chromosome two, initially identified by Lejeune was named after the band 2q11 and
the fragile X site was referred to as Xq27-8 (Sutherland, 1979; Hecht, 1982).19
With the rediscovery of the fragile X site, and its association with the genomic
location Xq27-8, Gillian Turner and her colleagues began reexamining patients affected
by X-linked intellectual disability and macro-orchidism cytogenetically. Among 16
families initially examined, Turner et al (1978) reported six families in which affected
males showed both macro-orchidism and the fragile X site, and ten families in which
intellectually disabled boys expressed neither. In four of the six families, female carriers
of the fragile X site were also visibly identified under the microscope, suggesting the
potential for offering prenatal diagnosis (Turner et al, 1978). In a number of families
then, cases of ‘non-specific’ X-linked intellectual disability had now been associated with
two visible markers, one clinical and the other chromosomal.
Around this time, discussions began concerning the appropriate name for this
newly delineated disorder. Previously, eponyms such as Renpenning and Martin-Bell
syndrome had been applied based on early reports of families with non-specific X-linked
intellectual disability (Richards, 1970; Turner et al, 1970). Since, researchers had
returned to the original family studied by Renpenning et al (1962), and found that males
showed neither macro-orchidism nor the fragile X site, suggesting that this was a distinct
form of intellectual disability (Fox et al, 1980). Turner and Opitz (1980) suggested a new
designation, describing the distinguishing features of intellectual disability associated
with the fragile X site and calling the disorder ‘Macro-orchidism Marker X syndrome’
19

The fragile X site was seen as being right at the border between bands Xq27 and Xq28
(Turner et al, 1978). For more on this cytogenetic naming system see: chapter 2.
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(MOMX). They noted that it was unknown whether the family initially described by
Martin and Bell (1943) possessed either of these delineating markers, making this
eponym inappropriate. Other clinicians however, opposed the designation MOMX,
because it made no reference to the most important feature in affected patients,
intellectual disability (Kaiser-McCaw et al, 1980; Richards, 1981).
In 1980, Randi Hagerman, a pediatrician at the University of Colorado, Denver
who had read Gillian Turner’s 1980 paper associating intellectual disability with macroorchidism and the Xq27-8 fragile site, became aware of a male patient being cared for
locally, who had intellectual disability and abnormally large testicles. At the time,
chromosomal analysis for the fragile X site was not available in Denver. Hagerman
worked with University of Colorado cytogeneticist Loris McGavran to make Fragile X
cytogenetic testing available for this and other patients in the area. The first test
eventually came back positive for the fragile site. As McGavran recounted to me, “It was
pretty thrilling to get our first positive and start down that road” (Interview with Loris
McGavran, August 20, 2012). And indeed, over the next 18 months, Hagerman and
McGavran identified about 25 additional similarly affected patients and diagnosed them
both clinically and cytogeneticially with Fragile X syndrome (Interview with Randi
Hagerman, March 2, 2012).20
Noting that there was very little US literature at the time on this disorder,
Hagerman and her colleagues decided to collectively write a book on the topic. The book
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Randi Hagerman is a physician who specializes in child development and behavior.
She began her career at the University of Colorado, Denver and is now at the University
of California, Davis, where she is part of the MIND institute.
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was ultimately published in 1983 under the title The Fragile X Syndrome: Diagnosis,
Biochemistry, Intervention (Hagerman and McBogg, 1983). This term ‘Fragile X
syndrome’ had already appeared in the published literature occasionally in the early1980s (Fox, 1980; Gerald, 1980; Jacobs, 1980). Hagerman and her colleagues however,
seem to be the first researchers to have fully embraced ‘Fragile X syndrome’ as the name
for this disorder. As Hagerman put it,

“We decided to use the name Fragile X syndrome, because Marker X
wasn’t interesting . . . and we were very struck with the fragile site. So we
said, ‘let’s call it Fragile X syndrome’ . . . There was a lot of confusion
about what its name was, and we decided to use Fragile X syndrome
consistently” (Interview with Randi Hagerman, March 2, 2012).

A few years before this, Richards et al (1981) had demonstrated cytogenetically
that family members from the Martin and Bell (1943) study did indeed possess the Xq2728 fragile site. With this in mind, some clinicians maintained the use of ‘Martin-Bell
syndrome’ during the mid-1980s (Opitz and Sutherland, 1984). The name ‘Escalante
syndrome’ was also suggested (Vianna-Morgante, 1982) during this time, but was
opposed by some, who noted that Esclanate did not mention macro-orchidism in his
original 1969 description of the disorder (and thereby did not have precedence over
Lubs). As a result, the term Escalante syndrome has not been widely adopted outside of
Brazil (Turner, 1983; Opitz and Sutherland, 1984). Indeed, while there were many
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claims on the name of this disorder throughout the early-1980s, by the middle of the
decade, the term Fragile X syndrome seems to have won out.
Despite its importance in the clinical delineation and naming of Fragile X
syndrome however, the association between the fragile X site and intellectual disability
remained unclear in the mid-1980s. Indeed, of the 17 fragile sites known at this time,
only the one Lubs had identified on the X chromosome was associated with a genetic
disease (Sutherland and Hecht, 1985). Clinicians and researchers continued to ponder
over whether these fragile sites were a form of ‘normal’ genetic variation, or if they
might be associated with some sort of ‘pathological’ mechanism. Whether the fragile X
site itself somehow caused this clinical syndrome, or was just closely linked to a
causative gene remained unclear (Hecht, 1982). Indeed, while much about the
mechanistic role of the fragile site in Fragile X syndrome remained unknown, clinicians
and researchers were not hesitant to use their existing knowledge of the fragile site in
attempting to better understand, and even treat this disorder. In the next section, I explore
how conceptions of the fragile X site based on observational, laboratory examination
were applied in the course of searching for potential clinical treatments.

The Fragile X Site as an In Vitro and In Vivo Phenomenon
Chromosomal analysis, unlike other methods used for identifying the visual
markers of human disease, takes place apart from the body (Landecker, 2007). Cells are
cultured from the skin, blood, or other patient tissue, and manipulated both chemically
and physically in a variety of ways, so as to make chromosomes visible and analyzable
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(Rapp, 2000, de Chadarevian, 2010). When the human chromosomes are seen under
laboratory conditions, it is anticipated that they look and act in much the same way as
they do in the bodies of patients. Indeed, to a significant degree, the veracity of clinical
cytogenetics is based on the assumption that chromosomes can pass from the body into
the laboratory without the loss, or significant alteration, of their physical characteristics.
This said, clinicians are well aware of the fact that, inside the body and out, chromosomes
are fluid entities that exist physically only for brief moments in the life of a cell, during
its reproductive cycle, and that they are continuously moving through varying stages of
condensation, organization, and genetic activity.
Even with all this in mind however, fragile sites are particularly vexing. As
Sutherland (1979) demonstrated, most fragile sites only can be seen in cell media that
lacks folic acid, meaning that specialized laboratory conditions are necessary to make
certain chromosomes appear ‘fragile’. The fragile X site has thus been referred to as, “an
in vitro phenomenon”: one that is only made visible by laboratory manipulations
(McGavran and Maxwell, 1983, 57). Is the fragile X site actually ‘fragile’ when it is in
the body? Researchers do not have a good answer to this question, because they cannot
see the X chromosome under normal bodily conditions. However, as Loris McGavran, a
cytogeneticist at the University of Colorado, Denver, put it,

I don’t think that we ever had this concept that it [the fragile X site] would
be manifest in vivo the same way, because then you would be wandering
around with a lot of chromosome X deletions . . . we really thought that it
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was an in vitro phenomenon (Interview with Loris McGavran, August 20,
2012).

Indeed, it was assumed that if the X chromosome acted in the same way in vivo as it
appeared to in vitro, more severe clinical problems would have resulted. Adding to this,
it was shown that the cells of Fragile X patients were not themselves deficient in folic
acid (Popovich et al, 1983).
What implications did this have for the role of the fragile X site, as it exists in
vivo, in causing intellectual disability? While this remained unclear in the 1980s, some
clinicians attempted to apply the laboratory understandings of the fragile X site to their
thinking and trials aimed at finding a clinical treatment for Fragile X syndrome. If folic
acid in cell culture prevents the visible expression of the fragile X chromosomal “lesion”
(Pembrey et al, 1985, 713), which is associated with intellectual disability, does this
mean that treating patients with additional folic acid could in fact reverse the clinical
effects of the Fragile X syndrome in the body?
French physician Jerome Lejeune posed this very hypothesis in a 1982 letter to
the Lancet (Lejeune, 1982). Lejeune is famous for being the clinician who first identified
the correlation between trisomy 21 and Down syndrome. By the late-1970s,
identification of trisomy 21 had become the primary indication for prenatal testing, and
offered the opportunity for these pregnancies to be terminated if Down syndrome was
diagnosed. Lejeune however, being a devout Catholic, was publically very unhappy
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about this application of his 1959 discovery (Cowan, 2008; Interview with Kurt
Hirschhorn, January 26, 2012).
In his 1982 letter to the Lancet, Lejeune lamented the fact that cytogenetic
findings were being used for terminating pregnancies instead of finding cures, saying,
“Interest in the in utero detection of the fragile X chromosome for the purpose of aborting
affected fetuses seems to have blurred the real prospect open to research” (Lejeune, 1982,
273). Based on the existing cytogenetic knowledge about Fragile X syndrome, Lejeune
saw hope for a cure. He reported on a trial that he had conducted in which eight children
clinically diagnosed with Fragile X syndrome were treated with high doses of folic acid.
The results of this uncontrolled trial were very encouraging, with noticeable clinical
improvement in seven of these children within the course of just a few weeks. Lejeune
also suggested that high doses of folic acid, when given to a pregnant female carrier,
might prevent the disease from developing in utero (Lejeune, 1982).
Multiple trials involving the treatment of Fragile X-affected individuals with high
doses of folic acid were conducted soon thereafter, at first with some positive results
being seen (Carpenter et al, 1983; Brown et al, 1984; Gustavason et al, 1985).
Ultimately however, it was determined that folic acid was not a cure for Fragile X
syndrome. The fragile X site was seen less often in the cells of patients that had been
treated with high doses of folic acid. However, when a known fragile site inducing agent
called 5-fluorodeoxyuridine was added to cell culture, the fragile X site appeared just as
prominently as it had been before folic acid treatment (Brown et al, 1986; Fisch et al,
1988; Neri et al, 1988).
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Additionally, since folic acid is water soluble, meaning that much of every dose is
immediately excreted, it would have been impossible for large enough amounts of folic
acid to build up in the body, and especially the brain, to have clinical effects within a few
weeks, as the Lejeune (1982) trial suggested (Opitz and Sutherland, 1984, 55). While
folic acid did not prove to be a preventative treatment or cure for Fragile X syndrome
however, debate continues among clinicians over whether folic acid treatment for
affected patients does at least improve attention span, hyperactivity, and behavior (BerryKravis and Potanos, 2004; Interview with Randi Hagerman, March 2, 2012). Indeedn,
attempts to treat Fragile X syndrome with folic acid offer valuable insight into how
clinicians and researchers interpreted the potential clinical implications of the laboratory
finding that fragile sites are only visible in folic acid deficient media. The fragile X site
represented, for clinicians, a physical “lesion” (Pembrey et al, 1985, 713) in the
chromosomes (and thereby in the human body and the genome, see chapter 1) of their
patients. As McGavran explained to me, “We’re used to thinking about chromosome
mutations as themselves sort of a phenotypic marker” (Interview with Loris McGavran,
August 20, 2012). Indeed, to think of the fragile site like other visible bodily lesions fit
with existing conceptions of the human genome, as at once anatomical and genetic.
By chance, clinicians knew of a way to make the fragile X site disappear, at least
in cell culture. Based on this, they seemingly hoped that ‘fixing’ the fragile X site would
somehow correct the genomic defect that they assumed caused Fragile X syndrome. This
came, despite the fact that clinicians had little knowledge about the etiological
mechanism that they were trying to repair. In the next section of this chapter, I further
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explore attempts to use the fragile X site as a chromosomal marker for tracking Fragile X
syndrome through a family. During the 1980s, the fragile site continued to pose
challenges to clinicians and researchers. While frustrating, the variable expression of the
fragile site did suggest new ways of thinking about this disorder.

Expression of the Fragile X Site in Affected Families
Despite its widespread association with a particular form of intellectual disability,
some clinicians expressed doubts about the reliability of the fragile X site as a
chromosomal marker for Fragile X syndrome. Daker (1981), for instance, had identified
two brothers who expressed the fragile X site, but did not have either macro-orchidism or
intellectual disability. Another paper published the same year raised doubts over whether
the fragile X site was exclusive to just one distinct form of intellectual disability (Proops
and Webb, 1981). Additional studies performed in the early-1980s also found patients
that had X-linked intellectual disability and macro-orchidism, but showed no sign of the
fragile X site (Jennings et al, 1980; Herbst et al, 1981; Fishburn et al, 1983). Indeed, the
fragile X site did not prove to be as distinctive and reliable of a chromosomal marker as,
for instance, trisomy 21 had for Down syndrome.21
Another major complication inherent to the fragile X site, going back to Lubs’
initial identification of it in 1969, was that it rarely appeared in more than one-third of
examined cells (usually out of 100-200 counted), even in severely-affected patients. This
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Though some complications also arose with the identification of trisomy 21 in some
patients clinically diagnosed with Down syndrome as well (Gaudilliere, 2001;
Santesmases, 2010).
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variable expression of the fragile site occurred independently of the need for a folic aciddeficient medium worked out by Sutherland (1979). While the fragile X site was almost
always visible, to some extent, in clinically affected males, in carrier females it was
usually present in less than 10% of cells, and often not seen at all (Turner, 1983).22 The
inconsistent expression of the fragile X site greatly complicated attempts to determine the
carrier status of clinically normal females within Fragile X families, who were potentially
at risk for having affected children (Fryns, 1986; Hogan, 2012).
Going back to the first clinical description of (what was later determined to be)
Fragile X syndrome (Richards et al, 1981), Martin and Bell (1943) recognized that this
form of intellectual disability did not exactly follow the normal inheritance pattern of an
X-linked recessive trait. Indeed, some female family members were affected by
intellectual disability as well, though more mildly than their male relatives. One possible
explanation for this was that the genetic trait causing intellectual disability was in fact
‘dominant’: meaning that a normal copy of this genetic entity could not fully overcome
an aberrant copy, and prevent any sort of clinical expression.
Another hypothesis for why females are sometimes mildly affected by X-linked
intellectual disability involves the process known as X-inactivation or ‘Lyonization’,
named after English geneticist Mary Lyon. While females possess two copies of the X
chromosome, only one of them is actively expressed in each of the body’s cells (Lyon,
1962). Which of the two X-chromosomes is expressed in each cell is usually the result of
random chance, meaning that on average about half of the body’s cells express one X
22

Clinicians and researchers expected, for instance, to see the fragile X site in mothers,
‘obligate carriers’ who had sons affected by Fragile X syndrome.
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chromosome, while in the rest the other is active. However, sometimes due to chance or
genetic effects, one of the two X chromosomes is expressed more often in the body’s
cells than the other. In these cases, if an X chromosome with a certain mutation is more
often expressed, its clinical effects may be seen in that patient (Puck and Willard, 1998).
Some females then, will show clinical effects of an X-linked disorder that generally only
affects males, because it is an X-linked recessive trait.23
The mild expression of Fragile X syndrome in female heterozygotes (those who
have one X chromosome with the fragile X site and one that appears normal) was studied
cytogenetically throughout the 1980s. It was estimated at this time that anywhere from
one-third to one-half of all females who possessed the fragile X site on one of their two X
chromosomes were affected by mild intellectual disability (Turner et al, 1980; Fishburn
et al, 1983). Such figures however, were complicated by the fact that the fragile X
marker was not visible in all of the females who assumedly possessed it. Therefore, it
was often females who already had sons clinically affected by Fragile X syndrome
(making them ‘obligate’ carriers) who were analyzed in order to determine the clinical
presentation of fragile X heterozygotes (Fishburn et al, 1983).
Multiple studies found that the clinical impact of Fragile X syndrome on female
heterozygotes was correlated with the percentage of their cells that expressed the fragile
X site (Jacobs et al, 1980; Fishburn et al, 1983; Fryns et al, 1986). As one set of
researchers noted, “We found the proportion of cells with the fragile X to be strongly
correlated with the mental status and to be inversely correlated to with age in
23

An example of this has been described in the case of Duchenne muscular dystrophy,
which is an X-linked recessive disorder normally only seen in males (Pena et al, 1987).
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heterozygous females” (Jacobs et al, 1980, 487). In males, similar trends were identified.
Parents with two sons affected by Fragile X syndrome were asked to identify which one
seemed to be ‘brighter’. These qualitative results were then compared to the percentage
of cells in each boy expressing the fragile X site. It was found that the more intellectually
capable brother of the two siblings often showed comparatively lower fragile X
expression (Turner and Partington, 1988).
The presence or absence of the fragile site in Fragile X syndrome was not a blackand-white marker of disease, as would have been clinically desired. While correlations
seemed to exist between the degree of fragile X expression and clinical outcomes, these
studies did not offer clinicians and researchers with a reliable option for carrier
identification or prenatal diagnosis. Though frustrating from one perspective, these
findings continued to offer clues about the link between the chromosomal expression of
the fragile site, and the clinical manifestation of this disorder. During the 1980s,
observational, chromosomal analysis gave clinicians and researchers an increasingly
nuanced understanding of Fragile X syndrome, particularly in terms of the range of
intellectual disability it caused in both males and females. Additional chromosome level
studies would eventually help researchers to better understand how the visible fragile X
site was associated with the genomic cause of Fragile X syndrome.

Tracing the Fragile X site Through Family Pedigrees
To this point, I have primarily focused on the fragile X site as a diagnostically
useful chromosomal marker for Fragile X syndrome in the clinical setting. The fragile
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site however, is also a genetic entity: one that moves through families, passing from one
generation to the next. When a relatively rare visible genetic abnormality, such as the
fragile X site, is identified in multiple cousins within an extended family, clinicians and
researchers generally assume that these individuals must have inherited the marker from a
common ancestor. This suggests that the abnormality should be visible in that person’s
chromosomes as well. In addition, when an inherited chromosomal aberration is
associated with a particular set of clinical outcomes in a younger generation, clinicians
expect to see the same symptoms in previous generations. The fragile X site and Fragile
X syndrome however, often did not meet these expectations, which left clinicians and
geneticists perplexed about how this genetic trait moved through families.
Many genetic disorders are caused by de novo mutations, which occur randomly
during the reproductive process, rather than being inherited from a parent. Patients
clinically affected with Fragile X syndrome however, almost never have a de novo
mutation (Brown et al, 1986). Instead the disorder occurs in families over multiple
generations. For instance, cousins in multiple branches of the family that Martin and Bell
first described in 1943 were affected by Fragile X syndrome, clearly suggesting that the
causative trait had been passed down through a common relative. As it turned out
however, neither clinical symptoms of Fragile X syndrome, nor the fragile site itself
could be traced back through the generations (Pembrey et al, 1985).
Throughout the 1980s, similarly perplexing Fragile X pedigrees were reported
(Fryns and Van den Berghe, 1982; Gardener et al, 1983; Froster-Iskenius et al, 1984). In
each of these cases, Fragile X syndrome suddenly appeared in multiple branches of a
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family, having never been seen previously (Sherman et al, 1985). Brown et al (1986)
analyzed two pedigrees of Fragile X-affected families, in which both the parents and
grandparents of the affected patients showed neither the clinical symptoms of Fragile X
syndrome, or the fragile X site. In each case, the syndrome had appeared in
grandchildren across multiple branches of the family, who did suffer from intellectual
disability and showed the fragile site. However, those who had clearly passed the trait
down showed no clinical or chromosomal signs of it (Brown, 1986).
The fragile X site, and its associated clinical effects, did not appear to be
following the expected patterns of Mendelian inheritance. In Fragile X families,
clinicians were finding a tight correlation between seeing this chromosomal marker and
intellectual disability in younger generations, but when they traced backwards in the
family tree, both the fragile site and intellectual disability disappeared from view.
(Froster-Iskenius, 1984; Sherman et al, 1985; Brown et al, 1986; Nussbaum and
Ledbetter, 1986). Indeed, the causative genetic factor for Fragile X syndrome seemed to
always pass through multiple generations of a family before it was clinically expressed.
As a result, this genetic trait was distributed throughout an extended family without any
warning for decades before its clinical effects became apparent (Figure 5).
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Figure 5 Pedigree from a family impacted by Fragile X syndrome. Note that only
individuals in younger generations are affected by intellectual disability (Brown, 1986).
Reprinted with permission from John Wiley & Sons, Inc.

Various mechanistic theories for the unusual inheritance pattern of Fragile X
syndrome were proposed in the mid-1980s. Some researchers suggested that the
insertion of a transposable element might somehow be involved in the sudden occurrence
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of Fragile X syndrome (Friedman et al, 1986; Hoegerman et al, 1986). Others proposed
that the maternal uterine environment could play a role in the usual inheritance pattern of
the disorder (Van Dyke et al, 1986). Another set of theories was derived from an idea
developed earlier in the decade by John M. Opitz. He had previously proposed that a
‘pre-mutation’ might be responsible for the inheritance pattern of another genetic
disorder: achondroplasia, which also had been seen to appear suddenly in distant relatives
(Opitz, 1981, 1984). A pre-mutation is a genetic abnormality, which is benign in the
patients who carry it, but may develop in future generations into a mutation with
significant clinical implications.
Pembrey et al (1985) applied Opitz’s theory to Fragile X syndrome, hypothesizing
that a pre-mutation might be responsible for its unusual inheritance pattern. As they put
it, the idea that Fragile X syndrome “is inherited in a regular X-linked fashion is
becoming untenable with the increasing number of reports of transmission through
phenotypically normal males.” Instead, these clinical researchers proposed, “an inherited
sub-microscopic chromosome rearrangement involving the Xq27/8 region that causes no
ill effect per se, but generates a significant genetic imbalance when involved in a
recombination event with the other X chromosome” (Pembrey et al, 1985, 709).
This hypothesis was meant to address multiple unique aspects of Fragile X
syndrome transmission as observed in family pedigrees. How was the causative genetic
factor passed through family members in earlier generations with no visible clinical
effects? And why did the symptoms of Fragile X syndrome only appear when the genetic
trait was passed from mother to child? Pembrey and colleagues envisioned a sub104

microscopic chromosomal event responsible for turning a pre-mutation into a causative
mutation. Their assumption was that the visible fragile X site, and its subsequent clinical
effects in men and women, must come about due to an uneven recombination event
between two X chromosomes, which must happen during the production of eggs in
females with a pre-mutation. Since males possess only one copy of the X chromosome,
such a recombination event cannot occur during the production of sperm, thereby
explaining why a pre-mutation can only be transformed into a causative mutation when
this X-linked genetic abnormality passes from mother to child (Pembrey et al, 1985).
The model proposed by Pembrey and colleagues however, was purely theoretical.
It was based on an analysis of family pedigrees, instead of laboratory experimentation.
During the latter half of the 1980s, researchers were increasingly focused on attempting
to characterize the fragile X site molecularly (Brown et al, 1988). Indeed, it was widely
assumed that only molecular level analysis of this genomic region could uncover the
mechanism that explained the unusual inheritance pattern of Fragile X syndrome (Turner
et al, 1986, 53-54). This proved to be a multi-year challenge however, for various
technical reasons (Interview with Robert Nicholls, April 5, 2012). In this interim
however, chromosomal analysis continued to provide valuable, and even experimental,
insights about the fragile X site, which helped clinicians and researchers to better
understand its genomic nature, and role in causing Fragile X syndrome.
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Is X Chromosome Fragility Normal?
One point of debate and uncertainty throughout the 1980s was over the threshold
of fragile X expression sufficient to diagnose a carrier or affected individual. Patricia
Jacobs and colleagues suggested in a 1980 paper that expression of the fragile X site in at
least 4% of cells was necessary for a positive diagnosis. In a second paper published two
years later, Jacobs suggested that 3% visibility was probably sufficient for the diagnosis
of a female carrier (Jacobs et al, 1980; Rhoads et al, 1982). Another group suggested that
fragile site expression in 1% or more of examined cells was sufficient to diagnose carrier
status (Herbst et al, 1981). According to McGavran, the normal threshold for diagnosis
in her laboratory was 5% fragile X site expression (Interview with Loris McGavran,
August 20, 2012).
Edmund Jenkins, who was the first cytogeneticist to successfully diagnose Fragile
X syndrome in a prenatal sample, has suggested to me that his laboratory was more
conservative, at least when it came to identifying an affected fetus. He preferred to see
10% fragile X cells before offering a positive diagnosis (Jenkins et al, 1981; Interview
with Edmund Jenkins, May 26, 2011). While Jenkins believed in the clinical value of the
fragile X site, he felt that relatively high expression levels were necessary for accurate
diagnosis of carriers and affected individuals, since the expression level of fragile X sites
in the wider population of clinically normal individuals was not well established.
Based on this own laboratory experience, Jenkins told me, “We found some
morphologically similar lesions, that looked like fragile sites, in control people at very
low frequencies.” Whether or not clinically normal individuals (aside from carriers)
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could show any fragile X site expression was a matter of debate at the time. Jenkins
recounted one instance to me from a conference where he was presenting on his
laboratory experience with the fragile X site, “someone from the audience [another
prominent cytogeneticist] said, ‘if you see one fragile site, that’s all you need’ and I said,
‘well what about baseline and controls?’ and they said, ‘that’s just the way it is’”
(Interview with Edmund Jenkins, May 26, 2011).24
If one fragile X site was seen among 100 examined cells in a fetus or a potential
carrier, was this sufficient evidence to make a positive diagnosis? Researchers and
clinicians clearly were adamant about developing the most sensitive test possible, so long
as it was still reliable. As McGavran put it to me, “Reproducibility was one of our big
deals” (Interview with Loris McGavran, August 20, 2012). While getting accurate results
was the number of goal of cytogeneticists, a 1984 review article pointed out, under the
section heading “A doctor’s dilemma”, “The early 1980s are witnessing a rush to entice
the fragile X to express itself reliably in lymphocytes, fibroblasts, amniocytes, and fetal
cells” (de Arce and Kearns, 1984, 88). In some cases, folic acid deficiency was not
enough to induce sufficient fragile X visibility, so researchers supplemented the cell
cultures with chemicals known to enhance fragile site expression. Like McGavran and
Jenkins, the authors of this article encouraged diagnostic caution, noting that the
correlation between the amount of fragile X site expression and the long-term clinical
severity of Fragile X syndrome remained unclear (de Arce and Kearns, 1984).

24

Edmund Jenkins is a Ph.D. cytogeneticist who has worked for over 30 years at the New
York State Institute for Basic Research in Developmental Disabilities, in New York City.
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Amongst all this, medical geneticists David Ledbetter of the Baylor college of
Medicine, and Robert Nussbaum, at the University of Pennsylvania, began to wonder if it
would be possible to chemically induce fragile X site expression in clinically normal
individuals. They hypothesized that folic acid deficiency alone would probably not be
sufficient. Chemicals such as flouorodeoxyuridine (FUdR) had previously been adopted
to enhance fragile site expression, particularly for purposes of prenatal diagnosis
(Tommerup et al, 1981; Jenkins et al, 1984). Ledbetter and Nussbaum used FUdR to
increase fragile site visibility, but they also began adding caffeine into cell culture as
well. This had a significant impact on fragile site expression (Ledbetter et al, 1986;
Interview with David Ledbetter, March 21, 2012).25
As many geneticists have been known to do, Ledbetter and Nussbaum began
testing their own cells for fragile X site expression, assuming that they were not carriers
of the mutant trait.26 With the addition of caffeine to cell culture, these researchers were
able to detect very low-level expression of the fragile X site in their own cells and those
of a chimpanzee (Interview with David Ledbetter, March 21, 2012). Additionally,
Ledbetter and Nussbaum demonstrated that clinically normal ‘transmitting’ males from
fragile X families showed an intermediate level of fragile site expression, which fell in
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David Ledbetter is a Ph.D. geneticist, who spent much of his career at the director of
the Cytogenetics Laboratory at Baylor College of Medicine in Houston. He has also
directed the Division of Medical Genetics at the Emory University School of Medicine in
Atlanta, and is now Chief Scientific Officer for the Geisinger Health System in Danville,
Pennsylvania.
26
One example of this, involving Roger Donahue who karyotyped his own chromosomes
during his training (as many geneticists do), is discussed in the previous chapter. Another
well-known example is Craig Venter’s use of his own DNA for sequencing the human
genome.
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between that of clinically affected individuals and their own normal cells. With caffeine
induction, affected males showed fragile X site expression in 30-40% of their cells,
normal transmitting males had 12% expression, and the two researcher’s cells showed 45% fragile X site expression (Ledbetter et al, 1986).27
As the observational cytogenetic analysis of Ledbetter and Nussbaum
demonstrated, fragile site expression was not all-or-nothing, but always a matter of
degrees: levels of fragile X expression could be seen to progressively increase from
normal individuals, to clinically unaffected transmitting males, to affected patients
(Ledbetter et al, 1986; Nussbaum and Ledbetter, 1986). Everyone’s X chromosome is (at
least) a little bit fragile. This finding implied a dynamic continuum that had mechanistic
implications for how the fragile site variably appeared in families and caused Fragile X
syndrome.
Indeed, Ledbetter and Nussbaum’s findings were the first experimental
demonstration of the existing ‘pre-mutation’ theoretical model based on pedigree
analysis. The fragile X site was shown to progress from normal, to predisposed for
mutation, to pathological over the generations of certain families. The researchers
suggested, based on these results – and in line with Pembrey et al (1985) – that a series of
chromosomal recombinations involving the fragile X site region might initiate the
development of a predisposed ‘carrier’ male or female, and then (in a later generation)
the production of a causative mutation. Interpreting their cytogenetic results to propose a
DNA level theory, the researchers concluded, “Thus, our data suggest that a normal DNA
27

Fragile X site expression in chimpanzees was seen in 1.6% of cells, suggesting that this
fragile site has a long evolutionary history (Ledbetter et al, 1986).
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sequence at Xq27 [the fragile X site] may be altered to produce a continuous quantitative
variation in fragile site DNA resulting in varying degrees of cytogenetic expression and a
threshold for clinical manifestation of a mutation” (Ledbetter et al, 1986, 163).
This finding came at an important time for clinicians and researchers interested in
Fragile X syndrome. Ultimately, it would take five more years for the fragile X site to be
fully characterized molecularly. When this did finally occur, the findings of Ledbetter
and Nussbaum were largely verified. Molecular analysis allowed for a DNA level
explanation of the mechanism behind fragile X syndrome. However, Ledbetter and
Nussbaum’s chromosome level demonstration that the fragile site became increasingly
prominent between clinically normal transmitters of Fragile X syndrome and clinically
affected individuals offered significant insight into the complex relationship between this
cytogenetic marker and its associated clinical disorder. In addition, this observational
experiment provided a new perspective on the impact of visible variations in genomic
structure on human disease.

A Molecular Genetic Explanation of Fragile X Syndrome
Throughout the late-1980s and into the early-1990s, clinicians and researchers
attempted to locate, at the DNA sequence level, a gene, mutation, or abnormality that
could account for the fragile X site as well as the clinical expression of Fragile X
syndrome (Brown et al, 1988; Heilig et al, 1988; Nguyen et al, 1988; Dahl et al, 1989;
Oostra, 1990). In 1991, the exact location of the causative genetic trait for Fragile X
syndrome was identified, and found in close proximity to the fragile site. As Ledbetter
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and Nussbaum’s earlier experiment had suggested, the structure of this genomic region
seemed to change over the generations of a family.
The molecular explanation of Fragile X syndrome was an international
accomplishment (Interview with Randi Hagerman, March 2, 2012). In 1991, papers
from research teams in Australia, the Netherlands, France, and the United States were all
significant contributions to the molecular characterization of the fragile site and its role in
Fragile X syndrome. Vincent et al (1991) offered evidence that the Fragile X region is
abnormally methylated in affected individuals (more on this below). Yu et al (1991)
molecularly demonstrated the instability of the fragile X site, showing that it sometimes
grew significantly in size when passed down from mother to child. Verkeck et al (1991)
were able to sequence the DNA in this region, finding that it contained a gene, which
these researchers named FMR-1 (fragile X mental retardation-1), as well as a long string
of CGG trinucleotide repeats. Fu et al (1991) found that the number of consecutive CGG
repeats in the FMR-1 area was directly related with clinical outcome in Fragile X
families. Normal individuals appeared to have less than 52 CGG repeats in this region,
while those with a ‘pre-mutation’ had between 52 and 200. Pre-mutations were at risk
for expanding further when passed from mother to child, with Fragile X-affected children
having 200 or more CGG repeats, which became known as a ‘full mutation’.
Further analysis of Fragile X families suggested that there were no exact
boundaries among normal individuals, those with a pre-mutation, or the presence of a full
mutation. In general, if one has less than 55 CGG repeats in the FMR-1 region, it is
unlikely that there will be an expansion into a pre-mutation. What defines pre-mutations
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is instability: the likelihood of CGG expansion from one generation to the next, though
only when passed from mother to child. A full mutation begins at about 200 CGG
repeats, but is actually defined by its direct affect on FMR-1 gene activity. When 200 or
more CGG repeats are present, this region often becomes ‘methylated’. Methylation
involves the addition of a small molecule onto certain nucleotides in the region, which in
effect turns ‘off’ the FMR-1 gene. The lack of FMR-1 gene product, (or its reduced
activity, which occurs in females who possess a second, normal FMR-1 gene), is what
causes the Fragile X syndrome clinical outcome (Oberle et al, 1991; Nolin et al, 1996).
This sequence-level analysis of the FMR-1 gene region helped to resolve many of
the abnormal characteristics of Fragile X syndrome inheritance. The pre-mutation theory
turned out to be quite accurate, with molecular genetics providing an explanation for
what defined a pre-mutation, how it became a full mutation over the generations of a
family, and how a full mutation causes Fragile X syndrome. It was also demonstrated
that the prevalence of the visible fragile X site under the microscope is directly related to
the presence, and relative size (in term of CGG repeats) of a full mutation (de Vries et al,
1993). This means that the fragile site was a visible effect of Fragile X syndrome, rather
than its etiological cause. Such a finding did not come as much of a surprise given the
large number of other clinically benign fragile sites that had been identified by the late1980s (Hecht, 1988).
Once the molecular techniques now used for Fragile X diagnosis were clinically
proven in the mid-1990s, the era of using chromosomal analysis for the diagnosis of
Fragile X syndrome was declared over (Jenkins et al, 1995). Individuals possessing a
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Fragile X pre-mutation or full mutation are now diagnosed using molecular genetic
techniques. This has allowed for those women at risk for having a Fragile X syndromeaffected child to be much more accurately identified, and for more reliable prenatal
diagnosis of the disorder. Additionally, the ability to identify pre-mutation carriers of
Fragile X syndrome has led to the recognition that these individuals are themselves at risk
for certain clinical effects. Females with a Fragile X pre-mutation are at risk for premature ovarian failure (Allingham-Hawkins et al, 1999), and many pre-mutation males
experience Parkinsonian tremors and ataxia late in life (Hagerman and Hagerman, 2004;
Hogan, 2012). As a result, Fragile X pre-mutation status has also become an important
indicator of potential clinical outcomes.
The association of Fragile X syndrome with an expanded trinucleotide repeat also
led researchers to hypothesize that other clinical disorders that seemed to grow worse
over the generations of a family (a phenomenon also referred as genetic ‘anticipation’)
might have a similar cause (Sutherland et al, 1991; Harper et al, 1992; Friedman, 2011).
Over the next two years, both Huntington’s disease and Myotonic Dystrohy were
demonstrated molecularly to also involve the expansion of trinucleotide repeats
(MacDonald et al, 1993; Orr et al, 1993). Indeed, the multi-step mechanism of Fragile X
syndrome quickly became an important exemplar for thinking about how genomic
abnormalities might play a role in other, similarly inherited genetic diseases. While the
identification of the CGG trinucleotide repeat in 1991 was the lynchpin in demonstrating
this novel mechanism of disease development, the important contribution of
observational chromosomal analysis should not be overlooked. After all, it was the
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cytogenetic analysis of Ledbetter and Nussbaum that first demonstrated to researchers
that genomic abnormalities are not necessarily all-or-nothing, but rather that they may
also be observed and thought of as occurring over a dynamic continuum from normal to
pathological.

Conclusion
In his 1982 paper, “Window Panes of Eternity. Health, Disease, and Inherited
Risk”, geneticist Charles Scriver discussed heritable fragile sites in the human genome as,
“Another example [that] illustrates how neo-Vesalian anatomy can be put to use”
(Scriver, 1982, 498).28 Scriver highlighted the role that the Xq27-8 fragile site had in the
clinical delineation of a particular, and prominent, form of intellectual disability. He also
noted the potential uses of this chromosomal marker for carrier and prenatal screening.
Indeed, during the 1980s, the fragile X site came to be one exemplar of a novel way of
naming, diagnosing, and understanding human disease: based on the visible association
of a genetic disorder with a particular genomic location.
When Lubs first identified the Marker X chromosome in 1969, he recognized its
diagnostic, and preventative, value within families impacted by inherited intellectual
disability. As this chapter traces however, by the time the fragile X site was re-identified
in the late-1970s, its potential stretched beyond just clinical diagnosis. At this point, the
fragile X site became integrated into a newly developing conceptual framework, based on
the standardization of the human chromosome set and evolving conceptions of the human
28

For more on Scriver’s concept of genome mapping as a “neo-Vesalian” anatomy, see
the previous chapter.
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genome as an object of clinical research. This visual abnormality was now understood to
be the Xq27-8 fragile site, a unique genomic characteristic, which had potential
implications for understanding novel structural and functional characteristics of the
human genome, and their role in causing disease.29
As I suggest throughout this dissertation, the human chromosome set (and the
human genome) is as a place in the body where the visual markers and etiological causes
of disease are understood to intermingle. This way of thinking among human and
medical geneticists can be seen in various attempts to correlate the relative expression of
the fragile X site with the severity of its clinical impacts. It is also made particularly
apparent by various attempts to treat Fragile X syndrome in the clinic through the
application laboratory knowledge about how the fragile X chromosome “lesion” could be
fixed by adding folic acid to cell culture.
While the mechanistic correlations between the visible fragile X marker and
intellectual disability remained unexplained by clinicians and researchers during the
1980s, these individuals continued to assume that they could come to better understand
Fragile X syndrome, and identify potential treatments, with the help of knowledge
collected from sustained observational, chromosomal analysis. As Loris McGavran put it
to me,

29

Indeed, I have been told that Lubs has said in jest that the implications of the Marker X
chromosome have become so complex that sometimes he wishes he had never discovered
it (Phone Interview with Charles A. Williams, March 16, 2012).
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Not knowing the mechanism [of Fragile X syndrome], we were just so
fascinated by what it could be. And, living for almost 10 years not
knowing was pretty interesting. It allowed us to ask questions that
probably were not very smart, but still interesting (Interview with Loris
McGavran, August 20, 2012).

Indeed, the clinicians and researchers who examined Fragile X syndrome cytogenetically
did not always know what they were looking at (or for) under the microscope.
Nonetheless, observational analysis of the fragile X site produced new and interesting
research questions, and novel directions for improving the clinical understanding of
Fragile X syndrome, and simultaneously, the functional role of the human genome in
genetic disease more broadly.
This historical case study of Fragile X syndrome highlights the importance and
influence of chromosomal analysis in postwar biomedicine. While the desire to develop
molecular level understandings of disease certainly was prevalent among clinicians and
geneticists during this era, the central role and contributions of ‘observational’
cytogenetics should not be overlooked. Indeed, seeing the fragile X site under the
microscope was the original and definitive basis for delineating and naming Fragile X
syndrome. In addition, the localization of the fragile X site pointed geneticists toward a
particular genomic “address” for continued chromosomal and molecular research. As the
experimental cytogenetic work of Ledbetter and Nussbaum and the clinical trials of
Lejeune, among other examples, demonstrates researchers and clinicians were not sitting
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on the sideline waiting for a molecular characterization of this disease. Rather, they took
full advantage of existing knowledge and opportunities, based on chromosome level
analysis, to further examine the etiology and potential treatment options for Fragile X
syndrome.
While Fragile X syndrome may be thought of today as a molecular disease, the
history of its delineation and diagnosis during the 1970s and 1980s highlights the visual
culture of postwar biomedicine. Along with many other genetic disorders, Fragile X
syndrome was integrated into a larger visual framework of human disease during this
time, which highlighted the unique genomic location and nature of individual disorders.
Following its observational localization in the genome, Fragile X syndrome gained both
an anatomical “neo-Vesalian basis” and a likely genetic etiology. It, along with PraderWilli syndrome, which I discuss in the next chapter, was an exemplar of a new way of
locating diseases in the human body. Based on its genomic location at Xq27-8, Fragile X
syndrome could be further examined, leading to new mechanistic understandings of its
cause, and of the human genome’s functionality in disease more broadly.
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CHAPTER 3
Establishing and Reimagining a Genomic Exemplar: Prader-Willi Syndrome and its
Unanticipated Relationship with Angelman Syndrome
This chapter examines the history of two clinically distinct diseases: Prader-Willi
and Angelman syndromes. Unlike Fragile X syndrome, each of these disorders was
clinically delineated and diagnosed decades before being associated with a visible
chromosomal marker or genomic location. Indeed, until the late-1980s, there was no
reason to believe that the historical trajectories of these two syndromes would ever
intersect. This changed in 1987 however, when multiple clinical teams reported that the
same chromosomal aberration had been identified in patients clinically diagnosed with
each disorder. Suddenly, these two distinct diseases, with their independent histories,
social interest groups, and clinical identities became chromosomally, and genomically,
related. In this chapter, I explore the lead up to this finding, as well as its long-term
implications for biomedical conceptions of the human genome, and its structural, as well
as functional, role in disease.
As I described in Chapter 1, medical genetics introduced a new nosological
system to clinical diagnosis during the postwar period, based on the idea that many
human diseases could be associated with discrete locations in the human genome.
Cytogenetic analysis, and in particular the development of chromosomal banding in the
1970s, offered clinicians and researchers the opportunity to identify visible abnormalities
in the human chromosome set, and specify their standardized genomic location. This
system was further enhanced later in the decade by the development of high-resolution
chromosomal analysis. As Victor McKusick put it in a 1988 grant application to
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establish a center for genomic analysis at Johns Hopkins, “The refinement of high
resolution cytogenetics of extended chromosomes increased the precision of mapping and
revealed small deletions and other changes that were important initial clues to the
location of mendelian disorders . . .” (McKusick Papers, Box 2010-081-53, “Program
Project Grant-Mapping the Chromosomes of Man”, 1988 Grant Application Folder, 157).
Indeed, the human genome, seen at the microscopically visible level of chromosomes,
had become an entity that clinicians and researchers increasingly turned to in order to
‘locate’ new markers of disease.
During the early-1980s, Prader-Willi syndrome was a regularly cited example of
this ability to chromosomally identify genetic diseases in the human genome (McKusick,
1981, 79; McKusick, 1982, 17; Scriver, 1982, 498). As I describe presently, this came
about after the association of Prader-Willi syndrome with a small, but still
microscopically visible, deletion of genetic material on chromosome 15. Over time, it
became apparent that this deletion could not be seen in the genome of all individuals
clinically diagnosed with Prader-Willi syndrome, but it was present often enough to
suggest that the aberration played a role in the disorder’s etiology.
Similar to Fragile X syndrome, the association between Prader-Willi syndrome
and a visible chromosomal abnormality did not prove to be as straightforward or reliable
as the correlation between Down syndrome and trisomy 21. The deletion’s not infrequent
absence in clinically diagnosed Prader-Willi patients kept clinicians and geneticists
guessing about the nature of this chromosomal marker and its role in causing the disease.
However, it was not until the late-1980s, when this deletion was also identified in patients
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clinically diagnosed with Angelman syndrome, that clinicians and researchers began to
recognize that Prader-Willi syndrome’s relationship with the chromosome 15 deletion
was more complex than previously anticipated. This finding forced clinicians to rethink
the apparent ease with which, in the early-1980s, most cases of Prader-Willi syndrome
could be cytogenetically delineated and diagnosed.
As I describe in this chapter, medical geneticists never seriously discussed or
debated the possibility, during the late-1980s, that Prader-Willi and Angelman syndrome
were in fact two historically distinct forms of the same genetic disease. These two
disorders were simply too different in their clinical expression to possibly have the exact
same genetic cause. Indeed, at this time, most clinicians and researchers felt that there
was something still unseen in the human genome that could account for such different
clinical outcomes being caused by the same chromosomal deletion. As evidence
mounted that the chromosome 15 deletions in both Prader-Willi and Angelman patients
were the same, in terms of their genomic location and size, researchers began to consider
novel conceptions of human genome functionality that could account for what they saw
in the clinic.
This chapter offers another example of the dual role of chromosomal analysis as
both a diagnostic tool and experimental system in postwar biomedicine. As in the case of
Fragile X syndrome, the simple presence or absence of a visual cytogenetic marker alone
was not sufficient to reliably diagnose Prader-Willi syndrome. Ultimately however, the
complications incurred in course of chromosomally analyzing Prader-Willi, and later
Angelman, patients led to long-term improvements in diagnosis, as well as a better
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understanding of the human genome and its role in disease. This historical instance, I
argue, is representative of the important part that the human genome has played as a
conceptual space in the development of contemporary biomedicine (Hogan, 2013a). As I
describe, the chromosomally examined and depicted human genome became a location
where the conventions, questions, and interests of clinical and basic genetics continue to
intersect and intermingle.

The Clinical Delineation of Prader-Willi Syndrome
In 1956, Swiss clinicians Andrea Prader, Alexis Labhart, and Heinrich Willi
reported on nine children affected by obesity, short statue, abnormally small genitals
(cryptorchidism), intellectual disability, and muscle weakness during infancy (Prader et
al, 1956). In the five years following this initial report, other clinicians also described
children with similar attributes (Jenab et al, 1959; Dunn et al, 1961, Laurance, 1961).
Prader and Willi alone published a follow-up paper five years later, in which they
reported on five additional affected children (Prader and Willi, 1961). In a paper on
delineating different forms and causes of muscle weakness (hypotonia) early in life,
Zellweger et al (1962, 599) noted that, “‘Floppy’ or ‘limp’ infants and children are
encountered frequently”, in the clinical setting. Among those cases he and his colleagues
had seen, ten were similar to the syndrome that Prader, Labhart, and Willi had described
seven years earlier (Zellweger et al, 1962).
Prader-Willi syndrome was clinically differentiated from other forms of infant
hypotonia by the sudden onset of obesity in children around the age of three. Evans
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(1964, 207) described the early childhood progression of Prader-Willi syndrome in this
way, “They remain feeble and emaciated for a time; then the wasting gives way to
obesity.” Indeed, Prader-Willi syndrome was defined by this uniquely cruel twist, in
which very weak, poorly feeding infants, just as they seem to be getting better, suddenly
developed a voracious appetite. Without careful, and difficult dietary regulation, these
children quickly grew to be dangerously obese.
Some clinicians referred to Prader-Willi syndrome, and other conditions like it, as
“Pickwickian-like syndrome” in reference to the Charles Dickens character (Jenab et al,
1959, 23; Zellweger and Schneider, 1968, 597; Hawkey and Smithies, 1976, 155). It has
also been suggested that a short and overweight child depicted in Velazquez’s famous
painting Las Meninas was affected by Prader-Willi syndrome (Hawkey and Smithies,
1976, 152). Some reports of Prader-Willi syndrome during the 1960s identified
individuals who were likely affected, but not fully obese. These young male patients
however, were overweight and showed distinctly abnormal fat distribution, described as
resembling that of an older woman, with accumulation in the buttocks and thighs
(Forssman and Hagberg, 1964). Another report referred to the fat distribution in PraderWilli patients as being “feminine”, (Juul and Dupont, 1967, 19).
It was quickly recognized that Prader-Willi patients were at great risk for
developing debilitating adult-onset diabetes by their teenage years due to their obesity
(Evans, 1964). Unfortunately, these patients not only showed a ravenous appetite for
food, but also seemed to have a slower than normal metabolism. Evans (1964) recounted
a case in which a 500-calorie daily diet was necessary to help a 16 year-old male Prader122

Willi patient to lose weight and overcome diabetic symptoms (a normal daily diet for this
individual would be 2500 calories). In some early cases, such diets were quite successful
for treating patients. This however, did not change their voracious appetite, so
maintaining a healthy weight was a challenge (Evans, 1964).
Prader-Willi patients were also recognized as being intellectually disabled (Buhler
et al, 1963; Engel and Hogenhuis, 1965). Evans (1964) described eight Prader-Willi
patients who were developmentally delayed and had IQs between 41 and 87. Some of
these individuals seemed to improve intellectually as they grew older, though only one
patient was able to attend a normal school. Engel and Hogenhuis (1965) described three
additional affected individuals as having an IQ between 60 and 80, a level regarded as
below normal, but still ‘mild’ in terms of intellectual disability. In comparison, the
majority of males affected by Fragile X syndrome have ‘moderate’ intellectual disability,
with IQ scores between 35 and 49 (Hagerman et al, 1983, 41). Most children affected by
Prader-Willi syndrome required special education, but only a few were regarded as
‘ineducatable’ in the 1960s. Indeed, some showed improved IQ scores and acuity with
age (Evans, 1964; Laurance, 1967).
Discussions of what to call this distinct clinical syndrome began appearing in the
medical literature during the mid-1960s. Engel and Hogenhuis (1965) suggested “H2O
syndrome” referencing the disorder’s primary distinguishing features of hypotonia in
infancy, hypomentia (intellectual disability), and obesity beginning around age three.
Another set of researchers suggested that a third H should be added to the description to
account for the common presence of hypogonadism (small or hidden testicles), making it
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“HHHO syndrome” (Zellweger and Schneider, 1968). In 1968, a letter to the Lancet
described three additional cases of this disorder under the title “Prader-Willi syndrome”
(Spencer, 1968, 571). It is unclear why Labhart’s name was excluded from this
designation (perhaps it was because he had not been a co-author on the Prader and Willi
(1961) follow-up report). The eponym Prader-Willi syndrome has been widely used ever
since, though the disorder has also occasionally been referred to as Prader-Labhart-Willi
syndrome as well (Cassidy et al, 1984; Magenis et al, 1990).30
During the 1960s, the disorder that eventually became known as Prader-Willi
syndrome featured a rather unique clinical signature. What set the disorder apart from
others like it was its distinct two-stage natural history, from ‘floppy’ infants to
overweight young children. Seeing these two stages in progression within a single
patient made for an easier clinical diagnosis. However, when viewed in isolation, either
the weakness or obesity could easily be mistaken for another disorder. From a treatment
perspective, preventing obesity before it took hold was the most promising strategy.
Ideally, clinicians would be able to make the diagnosis of Prader-Willi syndrome before
the transition to overeating began. But, based on clinical presentation alone, this was
often difficult to do, especially in such physically weak and poor feeding infants. As I
discuss in the next sections, the identification of another visual sign of Prader-Willi
syndrome, this time a chromosomal marker, promised to improve both diagnosis and
treatment.
30

Some have suggested that Langdon Down, the British clinician best known for
identifying Down syndrome in the mid-19th century, was also the first person to describe
Prader-Willi syndrome, in 1887 (Kousseff and Douglass, 1982; Bonuccelli et al, 1982;
McKusick, 1987)
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Associating Prader-Willi Syndrome with a Chromosomal Marker
Clinicians and geneticists who examined early cases of Prader-Willi syndrome
frequently performed chromosomal analysis on their patients, with a few findings of
interest. While many patients appeared to have normal karyotypes (Laurence, 1961;
Dubowitz, 1967; Juul and Dupont, 1967; Cohen and Gorlin, 1969), Dunn et al (1961)
identified an extra G group (21, 22, Y) chromosome in one patient with Prader-Willi
features. Two years later, a translocation involving two D group (13, 14, 15)
chromosomes was seen in one individual who appeared clinically to have Prader-Willi
syndrome. Similar D group translocations had previously been seen in normal
individuals by other clinicians though, calling into question whether this aberration in
fact played a role in the patient’s disorder (Buhler et al, 1963). In 1969, a woman was
reported who also had a D group translocation, and appeared clinically normal, but had
experienced multiple miscarriages (Lucas, 1969). Ridler et al (1971) identified an extra
chromosome in a clinically diagnosed Prader-Willi patient, though it appeared smaller
than any of the normal human chromosomes. Based on its visible structure, the
chromosome was reported to be an extra, duplicated fragment from either the D or G
group.
As in the case of Fragile X syndrome, a major problem with these early reports of
abnormalities in Prader-Willi patients was that the exact identity of the chromosomal
aberrations was unknown. The extra chromosomes reported by Dunn et al (1961) and
Ridler et al (1971) may have represented the duplication of a G group chromosome (as
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happens in Down syndrome), or the presence of an extra small piece of another
chromosome. Likewise, the D group translocations reported by other clinicians might
have involved any of three different chromosomes (13, 14, 15). Once again, it was the
introduction of banding techniques in the early-1970s that helped to resolve these issues
of uncertainty. Cytogenetic banding offered clinicians a more definite knowledge of
which chromosomes were involved in the abnormalities they observed, and what
portions, if any, of these chromosomes were lost or duplicated.
In 1976, with the aid of chromosomal banding, an individual clinically diagnosed
with Prader-Willi syndrome was seen to have an unbalanced chromosomal translocation
involving the fusion of both copies of chromosome 15 (Figure 6). The researchers who
saw this translocation microscopically, inferred that at least the short arm, and perhaps a
small portion of the long arm of one copy of chromosome 15 had been deleted (Hawkey
and Smities, 1976). Such a specific description of this translocation would not have been
possible five years earlier, before the introduction of new chromosomal banding
techniques (Hirschhorn et al, 1973). In response to their finding, the authors stated, “it
would be tempting to speculate that the number 15 chromosome is involved in this
pathogenesis [Prader-Willi syndrome]. However, as the great majority of cases had
normal karyotypes it may be that the chromosomal abnormality in our patient was
unrelated to the clinical condition” (Hawkey and Smithies, 1976, 156).
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Figure 6 Karyotype from a Prader-Willi patient showing a translocation involving both
copies of chromosome 15. Reproduced from Journal of Medical Genetics, Hawkey and
Smithies, vol. 13, pp. 152-163, 1976, with permission from BMJ Publication Group Ltd.

A second report of an unbalanced translocation also involving chromosome 15 in
two Prader-Willi syndrome patients came a year later. Based on these findings, Fraccaro
et al (1977) suggested that all individuals clinically diagnosed with Prader-Willi
syndrome should be evaluated for anomalies of chromosome 15. This publication was
followed by multiple other reports over the next four years of Prader-Willi syndrome
patients showing chromosome 15 translocations (Zuffardi et al, 1978; Fleischnik et al,
1979, Wisniewski et al, 1980). In some instances, the researchers were able to more
specifically identify what portions of chromosome 15 had been affected by the
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translocation. For instance, Zuffardi et al (1978) noted that the visible chromosomal
region 15q11-15 had been lost in one of the translocations they observed in a PraderWilli patient. By the end of 1980, it was quite clear to clinicians that Prader-Willi
syndrome was in some way associated with a genetic abnormality on chromosome 15.
While this series of reports suggested that Prader-Willi syndrome had something
to do with chromosome 15, a translocation involving this chromosome could not be
considered as either a necessary or sufficient cause of the syndrome. Translocations were
only seen in a few affected patients, and family members of these patients sometimes
appeared to have the same translocation, but showed no clinical signs of Prader-Willi
syndrome (Smith and Noel, 1980). As one group of researchers put it, “Normal
karyotypes have been found in many cases of Prader-Willi syndrome. These could be
assumed to be due to a deletion of 15p undetectable by present cytogenetic techniques”
(Zuffardi et al, 1978).
It was thought that the chromosome 15 translocations, which clinicians were
seeing in certain patients affected by Prader-Willi syndrome, likely involved some loss of
genomic material. As I describe in the next section, the further improvement of
cytogenetic methods in the late-1970s helped to provide geneticists with the visual
resolution necessary to identify a common chromosomal deletion in many Prader-Willi
patients. Based on these techniques, Prader-Willi syndrome became associated with
particular chromosomal bands, and a specific genomic location, in the early-1980s. As a
result, the disorder came to be an exemplar of the promise of using cytogenetic analysis
in describing the ‘morbid anatomy’ of the human genome.
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The Application of High Resolution Chromosomal Analysis to Prader-Willi
Syndrome
Throughout the 1970s, human and medical geneticists were working on various
methods to improve the visual resolution of chromosomal analysis. Functionally,
chromosomes are a highly condensed form of DNA, the compaction of which varies
greatly during the process of cell reproduction. This makes chromosomes look different
under the microscope at each stage. During the late-1970s, the promise of ‘high-density’
cytogenetic analysis was recognized. This technique involves arresting cellular
reproduction at a stage when chromosomes are less condensed (and hence more stretched
out) than usual, meaning that smaller aberrations might be visible. In effect, staining
chromosomes when they are less condensed means that more bands are visible, thereby
improving the resolution of analysis (Yunis et al, 1978).31
In the late-1970s, Ph.D. student David Ledbetter, having read the Hawkey and
Smithies (1976) report of a chromosome 15 translocation in Prader-Willi syndrome,
began to wonder if high-resolution chromosomal banding might reveal a deleted
chromosomal region in affected patients. At the time, Ledbetter was a member of the
Baylor College of Medicine cytogenetics laboratory, run by clinical geneticist Vincent
Riccardi. Ledbetter was actually working in this laboratory part time as a technician, in
order to make money as he pursued his dissertation research on primate chromosomal
evolution in the nearby laboratory of T.C. Hsu (Interview with David Ledbetter, March
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For more on the impacts of ‘high-density’ chromosomal banding on standardized
depictions of the human chromosome set, see chapter 1.
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21, 2012).32 Riccardi’s laboratory was involved, at the time, in applying high-resolution
techniques to diagnose a form of kidney cancer, the Wilms’ tumor, based on a visible
deletion on chromosome 11 (Riccardi et al, 1978; Riccardi et al, 1980).
According to Ledbetter, a sample from a Prader-Willi patient came into the
Baylor cytogenetics laboratory one day, thus giving him the opportunity to see if highresolution chromosomal analysis would reveal a chromosome 15 aberration. Ledbetter
was already quite experienced in identifying small deletions in patients with Wilms
tumor, and so when he saw the karyotype of the Prader-Willi patient, he was able to see
that one copy of chromosome 15 looked smaller than the other, suggesting a small
deletion. To verify this finding, a new sample was acquired from the patient, and
Riccardi set up blinded analysis. Ledbetter was still able to pick out the deletion in this
one patient. Based on this, samples from five additional patients, also blinded, were
acquired from a Prader-Willi researcher in Boston, and Ledbetter was once again able to
identify the same chromosome 15 deletion in the affected patients. This suggested a
reliable, and potentially informative, visual correlation between the chromosome 15
aberration and Prader-Willi syndrome (Interview with David Ledbetter, March 21, 2012).
In a 1981 New England Journal of Medicine article, Ledbetter et al (1981)
reported that they were able to identify the same deletion on the long arm of chromosome
15 in the karyotypes of four out of five patients clinically diagnosed with Prader-Willi
syndrome. The specific genomic location of this deletion, based on visual chromosomal
nomenclature, was 15q11-13 (Figure 7). Ledbetter followed-up on his initial report with
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For more on Ledbetter, see chapter 2.
130

a larger cytogenetic study of PWS patients published the next year. He found the very
same 15q11-13 deletion in many more PWS patients, though only 19 of the 40 analyzed
(Ledbetter et al, 1982). The same year, another group of researchers published similar
results, 14 Prader-Willi syndrome patients had been cytogenetically analyzed, and seven
showed a 15q11-13 deletion (Butler et al, 1982).
Clearly this deletion was associated with Prader-Willi syndrome, but why was it
only visible in about half of all patients? Were there multiple causes of this disorder, or
was the deletion simply too small to be seen microscopically in many patients
(Bonnucelli et al, 1982)? With possible clinical implications in mind, Ledbetter et al
(1982) suggested that the two cytogenetic sub-populations of Prader-Willi syndrome
patients, those with and without a visible 15q11-13 deletion, should be examined for
variability in their clinical outcomes. Studies of larger cohorts of PWS patients in the
following years continued to find that almost half showed no 15q11-13 deletion. Very
little in the way of clinical variations were found however, among the deletion and nondeletion groups (Reed and Butler, 1984; Butler et al, 1986). Differences that were
identified included lighter skin tone and hair color, along with increased sun sensitivity,
in Prader-Willi patients with a visible 15q11-13 deletion. Individuals with this deletion
also showed greater homogeneity of fingerprint patterns (Butler et al, 1986).
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Figure 7 Chromosome 15 ideogram showing the location of the visible deletion in
Prader-Willi patients. Also, comparative images of chromosomes with and without the
deletion. Reproduced with permission from New Englad Journal of Medicine, Ledbetter
et al, vol. 304, pp. 325-329, 1981, Copyright Massachusetts Medical Society.

During the mid-1980s, clinicians widely agreed that Prader-Willi syndrome was
somehow associated with chromosome 15 anomalies. How these visually observed
cytogenetic abnormalities were involved in the clinical expression of Prader-Willi
syndrome however, remained unclear. In 1986, clinicial cytogeneticist Arabella Smith
noted, “While an association between chromosome 15 abnormality and the Prader-Willi
syndrome is clearly apparent and undisputed, there is debate as to whether this
relationship is causal” (Smith, 1986, 278). Indeed, while the visual correlation seemed
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undeniable, one team of researchers surmised that the chromosome 15 deletion seen in
many Prader-Willi patients might be a chromosomal effect of the disorder, rather than its
etiological cause (Kousseff and Douglass, 1982).
Uncertainty about the functional role of chromosome 15 aberrations in PraderWilli syndrome did not stop clinicians and researchers from touting the importance of
these visual markers in the clinic. McKusick noted in 1981 that the association of PraderWilli syndrome with chromosome 15 anomalies helped to distinguish it from other
conditions characterized as eating disorders, thus giving it a genetic basis. As McKusick
put it, “Like other problems lumped together as eating disorders, this has often been
viewed as a psychiatric state and the organic basis revealed by the chromosomal
aberration has been in my experience a relief to families of the afflicted. This finding
adds another stone to the foundations of an organic basis of morbid obesity” (McKusick,
1981, 80). Indeed, even if Prader-Willi syndrome’s visual association with chromosome
15 did not explain the exact nature of its etiology, it did offer families peace of mind,
knowing that the cause of obesity was genetic, rather than psychological.
The next year, Charles Scriver pointed to the value of being able to associate
clinical disorders with genomic locations, noting that even though not all patients with a
particular syndrome may show the associated chromosomal marker, knowledge of the
link could still be used to identify the genes and biochemical pathways etiologically
involved. In his paper, Scriver suggested, “Careful study of these and other syndromes
[Wilms’ tumor, retinoblastoma, and Prader-Willi] will determine whether enzyme
phenotypes can be used systematically to diagnose the chromosomal phenotype
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prospectively. This represents an interesting development in genetic counseling and a
novel application of gene mapping and cytogenetics” (Scriver, 1982, 498). While
uncertainty remained concerning the relationship between visible chromosome 15
aberrations and Prader-Willi syndrome, the marker could still be used in the laboratory
and the clinical in attempts to improve the treatment and understanding of the disorder.
Indeed, during the early-1980s, the microscopically visible 15q11-13 deletion
became an important exemplar of a new way of doing medical genetics. With the
example of cytogenetic analysis of Prader-Willi patients specifically in mind, Scriver
suggested that high-resolution chromosome banding was a “technology clearly capable of
further refining the morbid anatomy of human disease” (Scriver, 1982, 496). This
statement was followed by a full-page figure depicting McKusick’s ‘morbid anatomy’ of
the human genome diagram. New cytogenetic capabilities had been successfully used to
associate Prader-Willi syndrome with a unique, and visible, anatomical location in the
human genome. Just as the 15q11-13 deletion had helped to give Prader-Willi a genetic
basis, and distinguish it from Froelich syndrome and other clinical disorders, highresolution chromosomal seemed to promise improvements in the delineation and
diagnosis of other diseases. Later in the 1980s however, an unanticipated complication
arose: the same 15q11-13 deletion was identified in multiple patients diagnosed with a
very different clinical disorder. In the next section, I offer a clinical history of this
distinct disease.
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The Clinical Delineation of Angelman Syndrome
In 1965, British pediatrician Harry Angelman reported on three cases of what he
called ‘Puppet’ children. These children all suffered from inborn intellectual disability,
and showed similar physical abnormalities. Of their clinical attributes Angelman noted,
“Their flat heads, jerky movements, protruding tongues and bouts of laughter give them a
superficial resemblance to puppets, an unscientific name but one which may provide easy
identification” (Angelman, 1965, 681). These children were developmentally delayed,
severely disabled intellectually, and suffered from frequent epileptic seizures (Angelman,
1965). Angelman later recounted that what convinced him to publish on these three
patients, as being affected by a unique and distinct clinical syndrome, was coming across
the painting “Boy with a Puppet” by Giovanni Caroto while on vacation in Italy. He said
of this moment, “The boy’s laughing face and the fact that my patients exhibited jerky
movements gave me the idea of writing an article about the three children with a title of
Puppet Children. It was not a name that pleased all parents but it served as a means of
combining the three little patients into a single group” (Williams, 2011). The delineation
of this syndrome was entirely visible and impressionistic. Though Angelman’s name for
the syndrome was understandably offensive to affected families, it ultimately helped
other clinicians to see the disorder in their own patients.
Another group of clinicians reported on two additional similarly affected patients
in 1967, referring to this disorder as ‘Happy Puppet’ syndrome. These clinicians said of
Angelman’s initial account of this syndrome, “It was immediately apparent to us that two
patients whom we had studied for several years conformed to his description” (Bower
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and Jeavons, 1967, 298). Clearly, Angelman had succeeded in capturing the gestalt of
this syndrome through its name, thereby making it more likely that other clinicians would
see it. A third account of a patient with severe intellectual disability and similar clinical
characteristics appeared in the literature again five years later. The individual was
diagnosed as having “Angelman’s (‘Happy Puppet’) Syndrome” (Berg and Pakula,
1972). Many additional reports of the syndrome were published over the next decade, all
based on Angelman’s original clinical description and name (Mayo et al, 1973; Elian,
1975; Kuroki et al, 1980; Dooley et al, 1981).
In 1982, U.S. clinicians Charles Williams and Jamie Frias noted six additional
cases of the disorder, and suggested that this syndrome might be less rare than had been
assumed ten years earlier (Berg, 1972). At the end of their report, the clinicians put
forward a new potential name for the disorder remarking, “We feel that the term ‘Happy
Puppet’ is inappropriate as the patient’s family may feel the term is derisive and
derogatory. For this reason, and despite the limitation of eponymic designations, we
propose the name of this disorder should be Angelman syndrome” (Williams and Frias,
1982, 460). Another group of clinicians made a similar call at about the same time for a
new “less imaginative, eponymous designation” (Dooley et al, 1981, 624). As other
historical syndrome case studies in this dissertation also demonstrate, clinicians are often
hesitant to move away from an existing name for a syndrome when it plainly describes
the disorder’s symptoms. In this instance though, it was argued that despite its
descriptive accuracy, a name like ‘Happy Puppet’ syndrome was both offensive and not
in keeping with medical precedent (Dooley et al, 1981; Williams and Frias, 1982). No
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less, while Angelman syndrome was widely adopted in the mid-1980s, the ‘Happy
Puppet’ designation has not fully disappeared (Willems et al, 1987; Brown and
Consedine, 2004; Sarkar et al, 2011).
Many of the early studies on this syndrome included chromosomal analysis, but
none of them identified any microscopically visible abnormalities (Angelman, 1965;
Bower and Jeavons, 1967; Berg, 1972; Dooley et al, 1981). Williams and Frias (1982)
identified an inversion within chromosome 3 in an Angelman syndrome patient, but
suspected that it was benign, since no genomic material appeared to have been lost as a
result. As Charles Williams later noted to me, “We had no idea of what causation was. I
think if any anything we presumed it was possibly a single gene disorder, although we
didn’t know that either . . . there was some recurrence in families” (Interview with
Charles Williams, March 16, 2012).33
For the most part, Angelman syndrome was seen to occur sporadically, suggesting
that the causative mutation, if there was one, happened de novo. As Williams alluded to,
the disorder was occasionally identified in siblings (Kuroki et al, 1980; Pashayan et al,
1982; Willems et al, 1987); however, this was not seen frequently enough to infer that
Angelman syndrome was inherited (Willems et al, 1987). Indeed, well into the 1980s,
the disorder’s etiological basis and genetic characteristics (if any) remained unknown to
the clinical community. All of this would change in 1987 however, with two independent
reports of a small chromosome 15 deletion in multiple Angelman syndrome patients.
33

Charles Williams is a Pediatrician and Medical Geneticist at the University of Florida.
He has spent much of his career doing research pertaining to Angelman syndrome, and
played a central role in the founding of the Angelman Syndrome Foundation in the
United States.
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This event brought about a previously unanticipated chromosomal relationship with
Prader-Willi syndrome, and forced clinicians and researchers to reassess their
assumptions about the anatomical and etiological relationship between visible genomic
locations and abnormalities, and clinical disease.

Prader-Willi and Angelman Syndrome As Chromosomally Related
In 1987, Prader-Willi syndrome researchers became aware of a set of vexing
cytogenetic findings: in two clinical reports, the 15q11-13 chromosomal deletion was
seen in multiple patients, who by clinical analysis, were affected by a disorder that was
not Prader-Willi syndrome. Lawrence Kaplan and colleagues reported on three patients
with this chromosomal aberration, but heterogeneous clinical outcomes. One patient
showed what could be interpreted as a mild case of Prader-Willi syndrome, another was
diagnosed with Angelman syndrome, and a third patient was identified as having
Williams syndrome, which shares some similar attributes with Angelman syndrome,
including intellectual disability, abnormal facial features, and a happy demeanor (Kaplan
et al, 1987). Another publication that year by Ellen Magenis and colleagues identified
two additional, unrelated, patients with the 15q11-13 deletion, who were not affected by
Prader-Willi syndrome. Magenis had initially presented these cases at a 1987 national
Prader-Willi syndrome meeting in Houston, Texas, not knowing what clinical disorder
these patients had. A clinical geneticist in the audience named Charlotte Lafer,
recognized the patients as having Angelman syndrome (Interview with Charles Williams,
March 16, 2012; Magenis et al, 1987).
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As I outlined in previous sections, Prader-Willi and Angelman syndrome are two
very different disorders clinically. Therefore, it was quite confusing for clinicians and
researchers to hear that they had been associated with the same chromosomal aberration.
Some suggested that the cytogenetic analysis done of Prader-Willi and Angelman
patients was not yet high-resolution enough to identify the subtle differences in the
deletions that caused Prader-Willi and Angelman syndromes. Kaplan et al (1987, 45)
suggested in their paper, “It is proposed that different molecular abnormalities involving
specific points or segments along the long arm of chromosome 15 might account for the
clinical diversity seen among these and other patients”. This position was echoed by
Magenis et al (1987, 837), “Further resolution of these syndrome and their clinical
characteristics will likely be at the molecular level”.
These clinical researchers were suggesting that what could not be seen at the level
of chromosomes would be resolved at the level of molecular markers. In making this
argument, Magenis et al (1987) cited the work of Donlon et al (1986), who had been
working on developing molecular ‘probes’ for this region of chromosome 15. Such
probes were able to interact specifically with particular areas of a chromosome at the
DNA level, while still being visible under the microscope because of an attached
radioactive trace. It was assumed that the chromosomal deletions that cause Prader-Willi
and Angelman syndrome would be differentiated using this technique. In this case, it was
expected that one probe would not be able to attach to chromosome 15 in Prader-Willi
patients, and another probe would not be able to affix itself in Angelman patients. This
would indicate that adjacent, but distinct (though perhaps overlapping) regions were
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differentially deleted in these patients. Donlon (1988) however, found this not to be the
case. Even at the molecular level, the deletions in patients with Prader-Willi and
Angelman syndrome seemed to be the same.
At about the same time Robert Nicholls, a postdoctoral fellow at Harvard, was
also using molecular techniques to study the chromosome 15 deletion in Prader-Willi and
Angelman patients. He found similar results. According to Nicholls, “We found first
that the deletions, using the DNA probes that we had access to, were actually the same
size, and so that was kind of unexpected in the field” (Interview with Robert Nicholls,
April 5, 2012). Indeed, existing assumptions about the human genome, and its role in
disease, could not account for how two very distinct clinical disorders might be caused by
a deletion in the same genomic location. Williams described the confusing situation to
me in this way, “We had a good two to three years where people thought it must be the
same gene, which causes the two syndromes . . . it took a while to sort that out”
(Interview with Charles Williams, March 16, 2012).
When asked if these genomic findings suggested to clinicians and researchers that
Prader-Willi and Angelman syndrome were in fact historically distinct forms of the same
genetic syndrome, Williams remarked to me, “They were totally different . . . Back then
there wasn’t any sense that these are very similar disorders, they are quite different”
(Interview with Charles Williams, March 16, 2012). Indeed, it was assumed that some
functional distinction must exist, which would explain how one genomic aberration could
cause two clinical disorders. While this finding complicated the cytogenetic diagnosis of
Prader-Willi syndrome, it also opened the door to new ways of thinking about the human
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genome and its role in disease. As David Ledbetter put it to me, “There was a lot of
frustration and curiosity . . . it was pretty puzzling” (Interview with David Ledbetter,
March 21, 2012). In the late-1980s, various theories and experiments were proposed to
explain this unanticipated genomic link.
With his molecular findings in mind, Donlon (1988) offered one hypothesis for
the different clinical outcomes. He suggested that instead of being caused by ‘dominant’
chromosomal deletions, Prader-Willi and Angelman syndromes might instead each
represent, “ a compound recessive disorder . . . involving more than one gene” (Donlon,
1988, 326). Since the deletion associated with these two syndromes was so large, and
likely contained 10-30 genes (in Donlon’s estimation), various combinations of recessive
genes on the non-deleted chromosome 15 might lead to differing clinical outcomes.
When there is no deletion on the other copy of chromosome 15, these clinical outcomes
are prevented. However, with the 15q11-13 genetic material on one chromosome
missing, the remaining recessive genes are fully expressed, leading in some cases to
either Prader-Willi or Angelman syndrome. In additional, Donlon (1988) suggested that
other syndromes with overlapping clinical outcomes might also be associated with such
deletions and compound recessives.
In 1989, Robert Nicholls, then at Harvard University, made an important
observation: in patients with Prader-Willi syndrome, the 15q11-13 deletion, if present,
was always inherited on the copy of chromosome 15 inherited from their father, who did
not himself have the mutation (Nicholls et al, 1989). Humans possess two copies of each
of their chromosomes: one copy comes from their father and one from their mother.
141

Throughout the 1980s, clinicians were able to visually distinguish between different
copies of chromosome 15 based on subtle variations on its short arm (Wachtler and
Musil, 1980). Interestingly, the observation reported by Nicholls et al (1989) had already
been published on six years earlier by a different team of clinical researchers (Butler and
Palmer, 1983). However, Butler and Palmer (1983) had not inferred that this occurrence
was unique to Prader-Willi syndrome. Rather, they suggested that such de novo deletions
might occur more often on paternally inherited chromosomes.
At the time, Nicholls was a postdoctoral fellow in the laboratory of Samuel Latt,
who had died in August 1988. The team of researchers he had assembled however,
proved to be highly productive in the year after his passing. Also in 1989, cytogeneticist
Joan Knoll, a colleague of Nicholls’ in Latt’s laboratory, reported on multiple cases in
which patients with Angelman syndrome had inherited the 15q11-13 deletion on their
maternal copy of chromosome 15 (Knoll et al, 1989). This provided further evidence that
differential inheritance indeed did play a role in clinical outcome for these syndromes.
As Williams later put it, “Once there was recognition that the maternal deletion has a
different syndrome, then everything caught fire” (Interview with Charles Williams,
March 16, 2012).
Closely related to Knoll’s report, Nicholls’ 1989 paper had discussed an
interesting case of a patient affected by Prader-Willi syndrome who had no visible
15q11-13 deletion.34 This individual did however, possess a different variety of
chromosome 15 abnormality: he had inherited two maternal copies of chromosome 15,
34

Nicholls was second author on Knoll’s 1989 paper, and Knoll was second author on
Nicholls’.
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but no paternal copy, a condition referred to as ‘uniparental disomy’. This finding
provided even more evidence that there existed some difference between the maternally
and paternally inherited copy of chromosome 15, leading to either Prader-Willi or
Angelman syndrome in the clinic (Nicholls et al, 1989). The difference, researchers
knew, was most likely not in the DNA sequence itself, as chromosomes (aside from the
Y) are not themselves gendered: a chromosome inherited paternally in one generation
may have been passed down maternally in the previous generation.
Ultimately, these findings also provided an explanation for why the 15q11-13
deletion was not always visible in Prader-Willi syndrome patients. Prader-Willi was
caused by a paternally inherited deletion of 15q11-13, but the disease also occurred in
instances when an individual inherited two normal maternal copies of chromosome 15
and no paternal copy. Angelman syndrome was clinically seen in the opposite case,
when two paternal, but no maternal copy of chromosome 15 was inherited (Nicholls et al,
1989). These findings suggested a novel functionality of the human genome, called
‘imprinting’ that had only previously been described in mice. As Ledbetter has put it to
me, “When Rob Nicholls published his paper, we all kicked ourselves for not figuring it
out, because we should have been able to based on the mouse literature. If any of us had
paid attention to imprinting in the mouse, we should have been able to predict this”
(Interview with David Ledbetter, March 21, 2012). Genomic imprinting led to the
expression of certain genes on one parental copy of a chromosome, but not the other.
Indeed, the differential clinical outcomes in Prader-Willi and Angelman syndromes
demonstrated that in humans, just as in mice, certain portions of the genome are always
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‘turned off’ on one member of a chromosome pair (Knoll et al, 1989; Nicholls et al,
1989).

Further Analysis of Prader-Willi and Angelman Syndrome in the 1990s
During the early-1990s, clinicians worked to better resolve the genetic basis of
Prader-Willi and Angelman syndrome, and to further explain the previous decades’ often
confusing chromosomal observations. When abnormal clinical outcomes were initially
noted in patients with a 15q11-13 deletion in 1987, it was suggested that those with nonPrader-Willi phenotypes, eventually determined to be Angelman syndrome, might have a
larger deletion than classic Prader-Willi patients (Greenberg et al, 1987). By the early1990s however, it had become widely accepted, following the 1989 papers from Samuel
Latt’s laboratory by Robert Nicholls, Joan Knoll, and their colleagues, showing that
differential parental inheritance led to the vastly different clinical outcomes. Based on
the clinical and cytogenetic analysis of 17 Prader-Willi and Angelman patients, Ellen
Magenis and colleagues noted that, on average, the chromsome 15 deletion in Angelman
patients appeared under the microscope to be larger than in those with Prader-Willi
syndrome (Figure 8). Among the patients with either Prader-Willi or Angelman
syndrome however, the visual size of the deletion did not seem to correlate with the
severity of clinical effects. Magenis and colleagues also suggested the possible role of
uniparental disomy in these two disorders, citing the work of clinical researcher Judith
Hall (Magenis et al, 1990).
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Figure 8 Chromosome 15 ideogram depicting the relative cytogenetic size of 15q11-13
deletions seen in Prader-Willi (left) and Angelman syndrome (right) patients (Magenis et
al, 1990). Reprinted with permission from John Wiley & Sons, Inc.

In the early-1990s, clinicians and researchers continued to ponder how many of
the cases of Prader-Willi and Angelman syndrome having no visible cytogenetic deletion
were caused by uniparental disomy, versus a deletion that was too small to see
microscopically. Among 30 patients who were clinically diagnosed with Prader-Willi
syndrome, but did not have a microscopically visible 15q11-13 deletion, Mascari et al
(1992) found 18 had uniparental disomy of the maternal copy of chromosome 15, and
another eight patients who had a deletion that was only detectable using molecular
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techniques. Four individuals showed no sign of a deletion or uniparental disomy, but
each of these patients had clinically abnormal forms of Prader-Willi syndrome. From
this, it was inferred that about 20% of all cases of Prader-Willi syndrome was caused by
uniparental disomy (Mascari et al, 1992).
Uniparental disomy proved to be much less common in Angelman syndrome,
only occurring 2-5% of the time. Researchers believed that this was related to the
relative prevalence of non-disjunction in female reproductive cells (when an ovum ends
up with two copies of a certain chromosome instead of just one), which is the cause of
other chromosomal disorders, such as Down syndrome. It is suspected that the rapid
increase in Down syndrome cases in women over age 35 is an effect of the increase in
non-disjunction with maternal age. A similar effect was demonstrated with Prader-Willi
syndrome (Robinson et al, 1991). It was further surmised that uniparental disomy often
results from what is called a ‘trisomic rescue’: when a fertilized egg begins with three
copies of chromosome 15, but then loses one early on in the development process. If the
embryo has received two maternal copies of chromosome 15 and one paternal, and the
paternal copy is lost in this ‘rescue’, the embryo will develop with uniparental disomy.
This is more commonly the case in Prader-Willi than Angelman syndrome simply
because non-disjunction (and hence the presence of two maternal copies of chromosome
15) is more prevalent in women. Therefore, maternal uniparental disomy, leading to
Prader-Willi syndrome, occurs much more frequently than Angelman syndrome due to
paternal uniparental disomy (Nicholls, 1993).
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Very much like in the case of Fragile X syndrome, it was suggested in the early1990s that DNA methylation might also play a role in the differential expression of
Prader-Willi and Angelman syndrome. As I have already described, methylation
involves the addition of a small molecule to certain DNA nucleotides in particular genetic
regions, in effect turning them off.35 In Fragile X syndrome, methylation was determined
to be the result of a causative genetic aberration (more than 200 CGG trinucleotide
repeats) (Yu et al, 1992). Prader-Willi and Angelman syndrome, on the other hand,
appeared to be associated with the normal pattern of methylation (due to ‘imprinting’) on
chromosomes. Driscoll et al (1992) demonstrated that the 15q11-13 chromosomal region
is differentially methylated based on its maternal or paternal origin, and that this
methylation pattern can be used as a diagnostic test for Prader-Willi and Angelman
syndrome. These clinicians identified a gene, DN34, that was differentially methylated
in the 15q11-13 region based on parental origin, thereby suggesting that it might be
involved in the clinical expression of one or both of these disorders (Driscoll et al, 1992).
Over time, additional candidate genes for causing Prader-Willi and Angelman
syndromes have been identified. Ozcelik et al (1992) identified the SNRPN gene, which
is located within the smallest deleted genomic region known in Prader-Willi patients.
SNRPN was shown to be maternally methylated in mice, so clinicians assumed that it
probably would be in humans as well. Additionally, it was found that the SNRPN gene
was specifically disrupted by chromosomal translocations in multiple Prader-Willi
patients (Nicholls and Knepper, 2001). Angelman syndrome is now thought to be cause

35

For more on this, see chapter 2.
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by a specific gene, UBE3A. This result is based on the finding that Angelman syndrome
can be caused by a mutation in this gene alone (Matsuura et al, 1997; Kishino et al,
1997). This is not believed to be the case in Prader-Willi syndrome, which has never
been associated with a specific mutation in any one gene alone, suggesting that it is likely
caused by multiple maternally imprinted genes (Buiting, 2010).
Indeed, clinical and laboratory conceptions and understanding have evolved
significantly over the past 30 years. During the 1980s, Prader-Willi syndrome went from
being representative of the ability to visually and discretely ‘locate’ a disease in the
human genome using chromosomal analysis, to an exemplar (along with Angelman
syndrome) of an entirely new form of genomic functionality. As I discuss in the next
section, clinicians and researchers looked to this new phenomenon, genomic ‘imprinting’,
during the early-1990s as a possible explanation for a number of other complex genetic
diseases. It appears that experience with Prader-Willi and Angelman syndrome taught
human and medical geneticists to think differently about the human genome and how its
various dimensions of functionality impact clinical disease.

Examining a New Exemplar of Genomic Functionality
What was the relevance of genomic imprinting to human and medical genetics
more broadly? This question was addressed by clinical geneticist Judith Hall in a series
of papers published during the early-1990s. Hall targeted multiple audiences with these
reports, which appeared in the American Journal of Human Genetics, Development,
Archives of Disease in Childhood, Current Opinion in Genetics & Development, and The
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New England Journal of Medicine (Hall, 1990a, 1990b, 1990c, 1991, 1992). At about the
time that Robert Nicholls’ 1989 report on imprinting in Prader-Willi and Angelman
syndromes first appeared, Hall was just returning from a Sabbatical year in the UK,
where she had been working with mouse geneticists studying imprinting in mammals.
Based on this experience, Hall already recognized the potential importance of imprinting
in human and medical genetics (Interview with David Ledbetter, March 21, 2012). The
emerging Prader-Willi and Angelman story offered an excellent forum to present
imprinting to the broader biomedical community.
In her 1990 American Journal of Human Genetics paper, Hall noted the potential
value of genomic imprinting in explaining diseases that did follow normal inheritance
patterns,

One of the important challenges of contemporary genetics is to explain
those traits and conditions that do not mendelize [show Mendelian patterns
of inheriance]. It is in that regard that the concept of genomic ‘imprinting’
has assumed increasing importance, because it may provide an explanation
for a remarkably diverse set of observations on conditions whose genetic
transmission and expression does not conform to the predictions of singlegene inheritance (Hall, 1990a, 857).

Imprinting, suggested Hall, offered a new way of thinking about genomic functionality,
and one that could open up new avenues of biomedical thought and research, “Genomic
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imprinting appears to be a form of regulation, allowing another level of flexibility within
the control and expression of the mammalian genome, and may explain why mutations in
some parts of the mammalian genome function differently depending on whether they
come from the father of the mother” (Hall, 1990a, 857). It was no longer sufficient to
consider just what genes a person possessed, but also from whom they were inherited.
Within each of her papers on genomic imprinting, Hall discussed Prader-Willi and
Angelman syndromes as a prime example of how imprinting impacted the human
genome and its role in genetic expression. Based on what researchers had learned about
the impacts of uniparental disomy in Prader-Willi and Angelman patients, and what had
been observed in mice more generally, Hall suggested other human diseases in which
imprinting might play a role. Researchers had found that in mice uniparental disomy was
often associated with disorders that showed behavioral rather than structural
abnormalities. With this in mind, Hall pointed to other disorders, beyond Prader-Willi
and Angleman syndrome, that might be caused by uniparental disomy based on clinical
traits, “If one reflects on common human syndromes that are as yet unexplained, such as
Rubinstein-Taybi syndrome, Cornelia de Lange syndrome, Williams syndrome, RusselSilver syndrome, etc. the possibility that they represent uniparental disomy for other
chromosomes must be explored” (Hall, 1991, 144).
Targeting clinicians more broadly, Hall attempted in her 1992 New England
Journal of Medicine article to use the example of Prader-Willi and Angelman syndrome
to demonstrate why and how genomic imprinting could matter to them, “What do rare
conditions such as the Prader-Willi and Angelman syndromes have to do with the real
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world of the busy practitioner? They seem esoteric and exotic, and yet these rare
syndromes are windows into the world of a newly recognized phenomenon of inheritance
called genomic imprinting” (Hall, 1992, 827). Hall explained that imprinting was
particularly relevant in the context of prenatal testing, when there was little else to rely on
than the analysis of chromosomes, “There is urgent need to determine whether
uniparental disomy will be a problem in the case of each of the other chromosomes, since
there may be vary real consequences for prenatal diagnosis” (Hall, 1992, 828).
Indeed, the role of imprinting and uniparental disomy in Prader-Willi and
Angelman syndromes made it particularly clear that seemingly ‘normal’ karyotypes may
in fact be aberrant in clinically significant ways. Two cautionary reports were
independently published on this in 1992 (Cassidy et al, 1992; Purvis-Smith et al, 1992).
Each involved prenatal testing based on chorionic villus sampling (CVS), a technique
that samples from the placenta rather than the amniotic fluid as in amniocentesis (Hogan,
2013b). In both cases, CVS results suggested trisomy 15, though the fetus appeared to be
normal under ultrasound. Not infrequently, trisomies are confined to the placenta, but do
not affect the fetus due to the occurrence of a ‘trisomic rescue’ described in the previous
section. In each of these cases, amniocentesis later suggested that each fetus had a
normal karyotype, and the pregnancies were continued to term.
When born, each of the children showed muscle weakness, and eventually
progressed to reveal signs of Prader-Willi syndrome in early childhood. It turned out that
each individual had uniparental disomy of the maternal copy of chromosome 15, thus
causing Prader-Willi syndrome (Purvis-Smith et al, 1992; Cassidy et al, 1992). Hall
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(1992) highlighted the case uncovered by Cassidy and colleagues in making her argument
for why widespread awareness about genomic imprinting was so important for the
medical community. Referencing the new era of laboratory and clinical thinking that
Prader-Willi and Angelman syndrome had helped to bring about, Hall noted, “The
concept of genomic imprinting is a difficult one for many physicians and scientists who
were not trained to ask whether the sex of the transmitting parent makes a difference to
the outcome. But from now on we must ask this question about biological phenomena
and all disease processes that may have a genetic component” (Hall, 1992, 828-9).
Indeed, clinicians and researchers had to be on the look out, because even karyotypes that
appeared ‘normal’ at first glance might in fact possess significant chromosomal
abnormalities.
In the next section, I discuss another interesting and unexpected occurrence,
involving the at times confusing ‘look’ of Prader-Willi patients. While the disorder’s
association with chromosome 15 abnormalities improved its delineation and diagnosis
during the 1980s, clinicians sometimes continued to see Prader-Willi syndrome when,
genomically, it was not there. Whether the term ‘Prader-Willi’ should be used
exclusively to designate a specific genetic syndrome, or if it had value for describing a
broader clinical presentation, was a matter of debate in the 1990s. As I describe in the
next section, the names of genetic disorders sometimes move out beyond the boundaries
set by their discrete genomic localization.
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‘Prader-Willi-like’ as a Clinical Category
In 1981, McKusick suggested that the association of Prader-Willi syndrome with
chromosome 15 aberrations made it a genetic disease, thus distinguishing it from a
broader array of clinically diagnosed dietary problems (McKusick, 1981). Despite this
however, the ‘look’ of Prader-Willi, in one interesting case involving Fragile X
syndrome, has been identified as a clinical category, even in the absence of chromosome
15 abnormalities. The first instance of this was a report by J.P. Fryns and colleagues in
1987. Four patients clinically and cytogenetically diagnosed with Fragile X syndrome,
also appeared to have ‘Prader-Willi-like’ characteristics, most notably, showing short
stature and extreme obesity as young children (Fryns et al, 1987).
J.P. Fryns, Bert de Vries, and colleagues reported on additional five patients in
1993, clinically and cytogenetically diagnosed with Fragile X syndrome, but who once
again showed distinct ‘Prader-Willi-like’ features. Each of these individuals expressed
the fragile X site and showed no sign of the 15q11-13 deletion. Among family members
also affected by Fragile syndrome, most did not show similar Prader-Willi characteristics.
Unlike most Prader-Willi patients, these individuals did not show hypotonia as infants,
nor was their obesity caused by a sudden change in eating habits. Also, most patients
showed more severe intellectual disability than is common to Prader-Willi syndrome.
Many of these patients did however, have small testicles, a common feature of PraderWilli syndrome, rather than abnormally larger ones, as is frequently seen in Fragile X
syndrome (de Vries et al, 1993).
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One group of clinicians criticized the use of ‘Prader-Willi-like’ by de Vries et al
(1993), arguing that obesity and intellectual disability are common in many disorders,
and that their association with Prader-Willi syndrome would only confuse its clinical
diagnosis (Gillessen-Kaesbach and Horsthemke, 1994). De Vries and Niermeijer (1994)
however, responded to this criticism by noting that this special sub-category of patients
showed many features common to Prader-Willi syndrome, but not Fragile X patients, like
a round face and small testicles. Since two of their Fragile X patients had previously
been misdiagnosed with Prader-Willi syndrome, these clinicians felt broader clinical
knowledge of this sub-type of Fragile X syndrome would improve diagnosis, rather than
confuse it (de Vries and Niermeijer, 1994).
An additional report of a patient diagnosed with Fragile X syndrome, but
demonstrating Prader-Willi-like symptoms came, once again from the Fryns group, in
1994. The patient showed fragile X site expression, early onset childhood obesity, and
small genitals, but no 15q11-13 deletion. Hormonal studies on this patient did not
suggest any abnormalities that could explain his obesity (Schrander-Stumpel et al, 1994).
Another more recent report has also identified 13 additional cases of this Prader-Willi
phenotype of Fragile X Syndrome. Nowicki et al (2007) noted overeating, leading to
obesity, and more severe behavioral problems than what is seen in most Fragile X
patients. These researchers also pointed to a gene, CYFIP1, in the 15q11-13 region,
which appeared to interact with the FMR-1 protein, as a possible molecular explanation
for this overlapping clinical phenotype. Indeed, it has been found that patients with

154

‘Prader-Willi-like’ Fragile X syndrome often show lower than normal expression of
CYFIP1 (Nowicki, 2007; Hagerman et al, 2010).
While interesting to this dissertation in a coincidental sense, the Prader-Willi
phenotype of Fragile X syndrome also offers a valuable opportunity to reflect on how
researchers and clinicians name genetic diseases and clinical categories. The name
Fragile X syndrome comes from its chromosomal marker, whereas the term Prader-Willi
syndrome seems to evoke a particular clinical expression. Is classifying certain patients
with Fragile X syndrome as being ‘Prader-Willi-like’ clarifying or confusing for other
clinicians? Those who opposed the designation felt that it would mislead physicians, and
add to an existing over diagnosis problem (Gillessen-Kaesbach and Horsthemke, 1994).
On the other hand, the term reminded clinicians that individuals with Fragile X syndrome
could ‘look’ as much like Prader-Willi patients as they did Fragile X patients, meaning
that clinical expression in these individuals often included significant Prader-Willi
features like obesity and very small genitalia, while excluding macro-orchidism and
facial characteristics common to Fragile X syndrome. Indeed, it is important to keep in
mind that what clinicians call a disorder may be as much about defining how it should be
classified: ‘Prader-Willi-like’ Fragile X syndrome, as how it should not: Prader-Willi
syndrome.
Conclusion
This chapter examines the history of Prader-Willi syndrome, and its unanticipated
genomic and clinical overlaps with Angelman, as well as Fragile X syndromes. As I
have described, during the early-1980s, Prader-Willi syndrome came to exemplify the
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promises of a new ‘genomic’ nomenclature in postwar biomedicine. The association of
Prader-Willi syndrome with a visible deletion at the chromosomally defined genomic
location 15q11-13, even if the aberration was not seen in all patients, offered a
representative example of how chromosomal analysis could aid human and medical
geneticists in their attempts to better to delineate, diagnose, understand, prevent, and treat
human diseases. Indeed, Prader-Willi syndrome was pointed to as an important example
of biomedicine’s growing knowledge of the ‘morbid anatomy’ of the human genome, and
its central role in disease.
With the unanticipated identification of the chromosomally visible 15q11-13
deletion in patients not expressing the classical clinical features of Prader-Willi
syndrome, the exemplary status of the disorder was called into question, and ultimately
reconceived. The nosological system linking genetic diseases to discrete genomic
locations had shown great success throughout the 1980s (Hogan, 2013a). Nonetheless,
the visual association of both Prader-Willi and Angelman syndrome with the same
genomic location was not regarded as evidence that they were in fact historically distinct
forms of the same genetic disorder. Indeed, clinical expression unequivocally trumped
genomic localization as far as classification was concerned.
The genomic overlap between Prader-Willi and Angelman syndromes posed
complications for its accurate diagnosis and understanding in the clinic. As I
demonstrate throughout this dissertation however, findings such as this one effectively
turned human chromosomal analysis into unexpectedly productive experimental system.
Hans-Jorg Rheinberger’s description of experimental practices in biomedicine highlights
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the concept that the most productive experimental systems are those that continuously
produce unanticipated outcomes (Rheinberger, 1997). Such a situation, while of great
value in basic laboratory research, is seemingly at odds with the goals of clinical analysis,
which seeks to provide consistent and reliable results. In the long-term however,
unanticipated findings like the one described in this chapter may improve the clinical
diagnosis and understanding of disease. Central to the resolution of how Prader-Willi
and Angelman syndrome could be caused by the same genomic deletion, was the
application of knowledge about genomic functionality in mice to research on human
disease. This intersection, I suggest, was facilitated in part by the late-20th century
‘genomic’ conception of human disease, which placed disease analysis within the realm
of both basic biological and clinically targeted research. Indeed, during this era, the
human genome became a location where the conventions, questions, and interests of
clinical and basic genetics intersect and intermingle.
What does the chromosomal relationship between Prader-Willi and Angelman
syndrome mean for the researchers who study them and the families who are affected by
them? Pedagogically and genomically these two disorders likely will always be linked.
Indeed, clinicians still need to know about their common genetic deletion and differential
clinical outcomes, lest they should be misdiagnosed. Also, as the papers of Judith Hall
demonstrate, Prader-Willi and Angelman syndrome are an important teaching point more
generally, both as an example of the role of uniparental disomy and methylation in
human disease, and well as of the complex functionality of the genome more broadly.
Institutionally however, these two disorders remain quite distinct. As Charles Williams
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noted, “Years ago we thought about, should we have a joint meeting [between the PraderWilli and Angelman syndrome foundations] . . . really it never quite had a dynamic, it
just didn’t make sense” (Interview with Charles Williams, March 16, 2012). Though
these two disorders are linked chromosomally and genomically, for those affected by
them they are remain distinct. Indeed, while genomic overlaps like the one described in
this chapter are interesting and valuable findings in both the laboratory and the clinic,
they do not necessarily change the day-to-day experience of living with a genetic
disorder.
In the next chapter, I explore another instance of genomic overlap in the recent
history of human and medical genetics. While the two genetic syndromes examined were
clinically and historically distinct for more than a decade, the finding that they were
associated with the same chromosomal deletion was pointed to, in this instance, as
evidence that they were in fact two versions of the same genetic disorder. As in this
chapter, I will examine the implications of this finding for the naming, diagnosis,
understanding, and institutional organization of these two disorders in the years after they
became genomically associated. The contrasts between these two stories are meant in
part to highlight the ongoing power and influence of both laboratory and clinical
observation in the thinking and practices of postwar biomedicine.
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CHAPTER 4
A Single ‘Elephant’ in the Room: How DiGeorge and Velo-Cardio-Facial
Syndromes Become One Genomic Disorder
In this chapter, I focus on another instance of genomic overlap, though in this
case, one with a very different outcome. Just like Prader-Willi and Angelman
syndromes, DiGeorge and Velo-cardio-facial (VCF) syndromes were each initially
identified and historically diagnosed independently based upon clinical observations
alone. In the early-1990s however, it was demonstrated that many patients clinically
affected by DiGeorge and VCF syndromes possessed the same deletion in the
chromosomal band 22q11. This finding was not quite as surprising for clinicians as the
overlap between Prader-Willi and Angelman syndromes had been a few years earlier.
Indeed, going back to the mid-1980s, some clinicians had noted similarities between
DiGeorge and VCF syndrome patients. However, despite these commonalities, the
natural and clinical histories of these two disorders did not frequently overlap.
The established ‘look’ of a disease may be significantly impacted by its clinical
severity. If a disorder is generally lethal during early infancy, conceptions of clinical
appearance will tend to focus on its most visually obvious characteristics: like structural
birth defects or highly deadly attributes. In cases where patients are not so severely or
noticeably impacted at birth, and are expected to live for years or decades after diagnosis,
more subtle characteristics of the disease become relevant to its diagnosis and treatment,
as well as to the experiences of patients and their families. Into the 1980s, the differing
‘looks’ of DiGeorge and VCF syndrome were closely related to the age of patients when
first diagnosed. DiGeorge syndrome was diagnosed at birth and almost always proved
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deadly by age two. VCF syndrome, on the other hand, was generally only identified in
school-aged children based on non-life threatening symptoms.
In this chapter, I trace the various visual signs that were used to independently
identify DiGeorge and VCF syndrome, and which over time brought them together as one
clinical entity. The convergent histories of these two disorders highlight the problem of
‘ascertainment bias’ in genetics research. As many scholars have previously noted, there
is nothing certain or obvious when it comes to identifying disease categories. Indeed,
nosological categories in medicine are affected by the variable expression of disorders as
well as the institutional and professional infrastructures that divide clinical specialties and
assumptions. Thus, in analyzing clinical nosology, we must focus the collective ways in
which clinicians and researchers learn and agree to see, name, and standardize their
objects of study (Fleck, 1979; Daston, 2008).
Throughout this dissertation, I explore how the introduction of visual genetic
evidence has impacted the clinical categorization of diseases. As I show in this chapter,
while a common genetic marker has the power, in some cases, to make two diseases one
from etiological and ontological perspectives, the existing names and institutional
affiliations associated with the disorders will not always immediately follow suit. In fact,
to this day, a common name has not been universally accepted for describing DiGeorge
and VCF syndromes. It has not been the bodily presentation of disease that has gotten in
the way in this case, but rather the importance of maintaining certain disease
classifications, which expand beyond medical textbooks and diagnostic interactions to the
identity of research grants, foundations, institutions, and careers.
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The association of DiGeorge syndrome with a particular genomic location
occurred, as with Prader-Willi syndrome, through observational chromosomal analysis.
Translocations, and small deletions, involving the long arm of chromosome 22 eventually
came to be understood as an additional genomic and anatomical markers for DiGeorge
syndrome, as well as key pieces of genetic evidence linking the disorder to VCF
syndrome. Indeed, over time, a deletion in the chromosomal region 22q11 came to be
understood as the most significant and reliable indicator of the presence of this genetic
disease, now widely referred to as ‘22q11 deletion syndrome’. Unlike DiGeorge
syndrome, which was historically associated with severe birth defects and early infant
death, 22q11 deletion syndrome is now traced in family pedigrees, with parents being
retroactively identified as having a mild case of the disorder after their children are
clinically diagnosed. The natural history of DiGeorge, reconceived as 22q11 deletion
syndrome, now spans entire lifetimes, rather than being primary seen in infants and
young children. Indeed, the ‘look’ of 22q11 deletion syndrome is broader, and in some
cases may be quite distinct from, the severe clinical attributes initially associated with
DiGeorge syndrome.
This chapter traces the intersecting clinical and laboratory histories of DiGeorge
and VCF syndrome. As I have suggested throughout this dissertation, during the postwar
period, clinicians and geneticists increasingly looked to the human genome, at the
microscopically visible level of chromosomes, for new anatomical markers of disease. In
previous chapters, I have examined the use of genomic markers for the nosological
“splitting” off of unique clinical disorders. The converging histories of DiGeorge and
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VCF syndrome instead, offer an equally valuable example of how visible chromosomal
analysis has facilitated the categorical “lumping” of disorders as well. Indeed, in postwar
biomedicine, nosological categories have, in some cases, been broken down, rebuilt, and
even made more clinically variable, based on the association of existing disorders with
particular genomic locations (McKusick, 1969).

The Clinical Characterization of DiGeorge Syndrome
In 1965, Angelo DiGeorge, an endocrinologist at St. Christopher’s Hospital for
Children in Philadelphia, commented on a series of three newborns he had recently
observed who had been born without a thymus. The thymus is an organ located above
the heart, which plays an important role in the development of the immune response in
early infancy. DiGeorge noted that these children suffered from continuous infections
due to their lack of a thymus, among other problems, and died within the first two years
of life (DiGeorge, 1965; 1968). The infants had initially come to the attention of
clinicians because they also lacked or had under-developed parathyroid glands, which
play a key role in calcium regulation in the body. Absence of the thymus was actually
only recognized in these three patients upon autopsy. Indeed, as DiGeorge (1965) points
out, the finding that infants born with under-developed parathyroid glands also lack a
thymus is not all that surprising given that these two organs develop from the same
primordial structures, known as the 3rd and 4th pharyngeal pouches (Kretschmer et al,
1968).
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Two years later, DiGeorge and two of his colleagues in Philadelphia reported on a
similarly affected child. This child suffered from multiple infections due to an
inadequate immune response, and died at 17 months. As DiGeorge anticipated, upon
autopsy, the child was found to lack a thymus, as well as parathyroid glands. At the time,
there was no treatment for this condition. Indeed, DiGeorge was largely interested in
these children from a research perspective: they offered a unique opportunity to study the
nature of the human immune response (Lischner et al, 1967). The affected children also
had significant cardiac problems, due to occasional inborn heart defects, and because
their under-developed parathyroid glands were not able to regulate calcium levels, thus
disrupting proper heart function (DiGeorge, 1968).
DiGeorge inferred that these symptoms taken together likely represented a unique
clinical disorder. Whether or not this disorder was of genetic origin remained unclear. A
similar clinical presentation had previously been seen in mice in which it was inherited in
a recessive manner. However, none of the siblings or relatives of affected patients were
known to have similar clinical outcomes, suggesting that the disease occurred
sporadically in humans. By 1968, congenital lack of the thymus, and its clinical effects,
was already been referred to by some clinicians as ‘DiGeorge syndrome’, following the
suggestion of immunologist Robert Good. DiGeorge himself “demurred” though, noting
that such cases had previously been reported, as early as the first half of the 19th century
(DiGeorge, 1968; Lammer and Opitz, 1986, 114). The term DiGeorge syndrome,
nonetheless, was widely adopted by the clinical community soon thereafter (Kretschmer
et al, 1968; Dodson et al, 1969; Harvey et al, 1970).
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Many additional patients who appeared to be affected by DiGeorge syndrome
were identified in the published medical literature during the late-1960s and early-1970s.
These individuals showed previously unreported symptoms including seizures, palate
abnormalities, and developmental delay, as well as heart defects or murmurs (Kretschmer
et al, 1968; Dodson et al, 1969, Harvey et al, 1970, Freedom et al, 1972). Among the few
patients who lived past infancy, mild to moderate intellectual disability was seen (Conley
et al, 1979). At the time, clinicians were interested in the potential to treat DiGeorge
patients by using thymus tissue transplants to restore immune function. One group
reported doing so, with apparent success, using human fetal thymus tissue in 1968
(Cleveland et al, 1968). Steele et al (1972) also attempted such a transplant, which
seemed to be somewhat effective in restoring immune response. The long-term impact of
this treatment however, remained unknown, because this patient died of pneumonia nine
days later.
While thymus tissue transplants offered hope for DiGeorge patients, it was
becoming increasingly apparent during the 1970s that heart defects were also a common
cause of infant death in this population. Finley (1977) reported on seven DiGeorge
patients, all but one of whom died in the first weeks of life due to cardiac problems. As
these authors put it, “diagnosis of DiGeorge syndrome should be possible in the newborn.
The important features are not, however, related to immune deficiency, but rather to
severe congenital cardiovascular disease” (Finley, 1977, 637). While clinicians
continued to consider an underdeveloped or absent thymus to be the most important
anatomical marker of DiGeorge syndrome during the 1970s, the majority of DiGeorge
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patients at this time first came to medical attention, and were most likely to die form,
congenital cardiac problems (Conley et al, 1979). Indeed, two prominent, and deadly,
features defined the morbid anatomy of DiGeorge syndrome in the 1970s. As I describe
in the next section, during the 1980s, additional anatomical features came to be
associated with DiGeorge syndrome. Perhaps most important among these were visible
cytogenetic aberrations, often involving chromosome 22. Based on this chromosomal
marker, DiGeorge syndrome was associated with a particular chromosomal ‘address’, and
was listed in the earliest editions of Victor McKusick’s ‘morbid anatomy’ of the human
genome (McKusick, 1982).

Cytogenetic Analysis of DiGeorge Syndrome
Medical geneticist Albert de la Chapelle and his Finnish colleagues reported in
1981 on an extended family affected by DiGeorge syndrome. Four children of one
father, and a cousin of theirs on the same side of the family, had died of DiGeorge
syndrome as infants. The adult brother and sister, who were separately the parents of
these affected children, were both found to possess the same balanced translocation
involving chromosomes 20 and 22. The balanced translocation in these siblings was
passed down in an unbalanced manner, meaning that some genetic material was lost or
gained among individuals the next generation who were affected by DiGeorge syndrome.
Each of the children in this family who died of DiGeorge syndrome had a similar
unbalanced translocation, while healthy family members either had a balanced
translocation or normal chromosomes. The chromosomal rearrangement could not be
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traced back further however, because older family members refused to provide tissue
samples for this study, citing religious reasons (de la Chapelle et al, 1981).
The unbalanced translocation seen in affected family members caused a partial
trisomy of chromosome 20 and a partial monosomy of chromosome 22. This included
the deletion of the entire short arm of chromosome 22, as well as a portion of the long
arm (de la Chapelle et al, 1981). The clinical effects of trisomy 20 had previously been
described by Francke (1977), and did not resemble those of DiGeorge syndrome. From
this, it was inferred that the deletion of a portion of chromosome 22 was more likely to
play a causative role in the disorder. Existing evidence on such abnormalities was mixed
however, with a previous report of one patient with monosomy 22 appearing to show
DiGeorge syndrome features (Rosenthal et al, 1972), while another patient lacking one
copy of chromosome 22 did not (DeCicco et al, 1973).
Despite these confusing previous findings, de la Chapelle et al (1981) theorized
that DiGeorge syndrome in these cases was most likely associated with the deleted
portion of chromosome 22 in the patients his group had described. Previous individuals
who lacked the short arm of chromosome 22 had not shown similar clinical
characteristics. Therefore, de la Chapelle and colleagues pointed to the deleted portion
on the long arm of chromosome 22, noting, “the most likely location of the gene is at
22q11” (de la Chapelle et al, 1981, 255). These researchers however, could only account
for the familial patients that they had studied. DiGeorge syndrome was known to occur
both sporadically and in families, but no consistent chromosomal anomalies had
previously been reported (Steele et al, 1972; Raatikka et al, 1981).
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Summing up their report, the authors admitted, “As of yet we have no clue to the
nature of the postulated gene. Another point that remains to be clarified is the part played
by the remaining gene on the structurally normal chromosome 22 in our cases” (de la
Chapelle et al, 1981, 255). Indeed, the idea that the loss of one copy of one particular
gene played an etiological role in DiGeorge syndrome was purely hypothetical at this
time. These clinicians could only see that their DiGeorge patients were missing a rather
large portion of chromosome 22. How this visible anatomical aberration impacted the
genome was a point of speculation.
The next year, clinical geneticists in Philadelphia identified an additional
DiGeorge patient with chromosome 22 abnormalities. As Beverly Emanuel, a Ph.D.
geneticist at the Children’s Hospital of Philadelphia and University of Pennsylvania,
described it to me,

In that family [described by de la Chapelle], the children who wound up
missing the proximal part of chromosome 22 all had DiGeorge syndrome,
and it was almost like an ‘ah ha ‘ moment. We have a child here [in
Philadelphia] missing part of 22, who has DiGeorge, and they have a
family, with three affected, missing part of 22, who have DiGeorge
(Interview with Beverly Emanuel, November 9, 2011).

Clinicians at the Children’s Hospital of Philadelphia immediately contacted DiGeorge
and cytogenetist Hope Punnett across town at St. Christopher’s Hospital to ask if they
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had seen any similar chromosomal abnormalities in their own DiGeorge patients. As
Children’s Hospital of Philadelphia clinical geneticist Elaine Zackai described it, “We
went back to DiGeorge [and asked], ‘do you have any others that have chromosome
abnormalities?’ ‘Yes’ [he said]. Sure enough, it was the 22” (Interview with Elaine
Zackai, November 10, 2011).
The case identified at the Children’s Hospital of Philadelphia, along with two
described by DiGeorge himself, were published in the Journal of Pediatrics in August
1982. These three unrelated DiGeorge patients were each found to have lost the all of the
short arm of chromosome 22, as well as the 22q11 region on the long arm, due to
translocations involving 22 and another chromosome (3, 10, and 20). Based on their own
results, these authors agreed with de la Chapelle et al (1981) that the deletion of 22q11
was most likely involved in the clinical onset of DiGeorge syndrome (which the
Philadelphia researchers referred to as ‘DiGeorge anomalad’, a difference in naming that
I take up in the next section). Referring to the identification of a chromosomal deletion
associated with Prader-Willi syndrome a year earlier (discussed in chapter 3), the
researchers noted the possibility that DiGeorge syndrome may also be caused by a small
deletion that could be made visible using high-resolution cytogenetics. Of more
immediate importance, in two of the cases reported, the unbalanced translocation in
affected children seemed to result from a balanced translocation in one of the parents.
This suggested that there was a significant recurrence risk for DiGeorge syndrome in
these families (Kelley et al, 1982).
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An addendum to the Kelley et al (1982) report identified an additional family
impacted by DiGeorge syndrome due to translocations involving chromosomes 22 and 4.
A full report on this family was submitted the next year, and subsequently published in
1984. A sibling of this affected patient had previously died in infancy due to congenital
heart problems, and was later found to lack a thymus as well. Chromosomal studies
however, had not been performed. The authors even inferred that the mother likely had a
mild form of DiGeorge syndrome herself, as her immune cell count was low, and because
she showed the same unbalanced translocation as her affected son. Indeed, it was
becoming clear that the same visible abnormality of chromosome 22 could lead to a wide
range of clinical outcomes (Greenberg et al, 1984).
The extent and specifics of this potential causative link between chromosome 22
aberrations and DiGeorge syndrome remained unclear throughout the 1980s. Multiple
cases where reported during this time in which, among family members who all appeared
to have the same visible chromosome 22 translocation, only some were clinically affected
with DiGeorge syndrome (Augusseau et al, 1986; Bowen et al, 1986). In addition,
DiGeorge-like symptoms were also identified in a few patients with other visible
abnormalities, such as deletions on chromosomes 10 and 18 (Greenberg et al, 1988). As
Children’s Hospital of Philadelphia genetic counselor Donna McDonald-McGinn
summed it up to me, “They did chromosomes [on DiGeorge patients] and in 25% they
could see a visible piece [of chromosome 22] missing. But from 1982 to 1992, they
didn’t know what to do with the other 75%” (Interview with Donna McDonald-McGinn,
November 10, 2011). Indeed, like with the history of Prader-Willi syndrome described in
169

chapter 3, similar chromosomal abnormalities appeared frequently enough in DiGeorge
patients to suggest a genomic location for the disorder. However, their visual presence or
absence alone could not be relied upon diagnostically.

Searching for the ‘DiGeorge Gene(s)’
How were chromosome 22 abnormalities mechanistically linked to DiGeorge
syndrome? As Emanuel explained it to me, “At the time, and this is kind of interesting,
the thinking in the field was, somewhere on 22 there’s a DiGeorge gene, and probably the
patients with the translocation were just putting us into the right region. The idea was
they all involve 22. So, missing the ‘DiGeorge gene’, on chromosome 22 was going to
give you the syndrome” (Interview with Beverley Emanuel, November 9, 2011). How
the DiGeorge gene was actually disrupted in patients with chromosome 22 translocations,
and why this led to such a range of clinical outcomes remained unclear. Nonetheless, the
chromosomal band 22q11 had been widely adopted as the genomic address where the
cause of DiGeorge syndrome resided.
In 1984, researcher Frank Greenberg and colleagues suggested that, “some cases
of DiGeorge syndrome might have an interstitial deletion of 22q11, a situation analogous
to that of Prader-Willi syndrome, and interstitial deletions of 15q11-12” (Greenberg et al,
1984, 318). Indeed, the 15q deletion associated with Prader-Willi syndrome identified by
Ledbetter et al (1981) was seen as a potential model for other genetic disorders that were
associated with chromosomal translocations, and thereby might be caused by small
deletions. The authors however, admitted that even if an interstitial 22q11 deletion did
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exist in many or all DiGeorge patients, it might well be too small to identify
microscopically on banded chromosomes, even with the use of new high-resolution
cytogenetic techniques. To this point, Greenberg and colleagues (including David
Ledbetter) had never seen such an interstitial deletion in DiGeorge patients (Greenberg et
al, 1984), nor had any other DiGeorge researchers (Rohn et al, 1984).
Clinical geneticist Roy Schmickel, of the University of Pennsylvania, included
DiGeorge and Prader-Willi syndrome among what he called ‘contiguous gene
syndromes’ in a 1986 publication in the Journal of Pediatrics. Contiguous gene
syndromes are associated with a broad and variant array of clinical outcomes. Schmickel
suggested that this might be the result of multiple adjacent genes being deleted in one
genomic region. The size of the deletion in this region, and thereby the number of genes
lost, suggested Schmickel, might be the basis for clinical variation. As Schmickel notes
in his discussion, “these genes many be quite independent and no more related than
apples and Appalachian Mountains; the loss of an encyclopedia page could remove both
entries. The organization of genes may be as arbitrary as that of words” (Schmickel,
1986, 236). As a result, the loss of multiple genes in a genomic deletion may have wide
ranging effects on the body, and thereby cause a diverse array of clinical outcomes.
Schmickel was a mentor of Emanuel at the University of Pennsylvania, and
encouraged her to study the chromosomal basis of DiGeorge syndrome, “Roy Schmikel
said, ‘Bev, you know, you ought to study DiGeorge syndrome, I think there’s something
there’ . . . And I said, ‘but the reality is, so many of these kids with DiGeorge die in the
neonatal period, how are we going to study them?’ and he said, ‘I think you’re just going
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to find out that it is really interesting’ (Interview with Beverly Emanuel, November 9,
2011). As Emanuel noted, the natural history of DiGeorge syndrome remained difficult
to define in the 1980s, since few affected individuals older than childhood were known.
Indeed, only recently had surgical interventions for heart defects succeeded in allowing
most patients to survive infancy. As Schmickel and Emanuel clearly recognized
however, DiGeorge syndrome offered a unique opportunity to study the genomic impact
of multiple genes being lost due to a deletion.
As Schmikel wrote his 1986 piece on contiguous gene syndromes however, the
prevalence of 22q deletions in DiGeorge patients remained unclear. In 1988 Greenberg
reported on the use of high-resolution chromosomal analysis in 27 DiGeorge patients.
Chromosomal abnormalities were identified in five, including a visible 22q11 interstitial
deletion in one. This was the first report of a visible cytogenetic deletion in a DiGeorge
patient, which was seen without a chromosomal translocation. The parents of this
individual showed no such deletion, suggesting that it occurred spontaneously during the
reproductive process, on the maternally inherited copy of chromosome 22 (Greenberg et
al, 1988). A second report of a microscopically visible 22q11 deletion in a DiGeorge
patient came the next year (Mascarello et al, 1989).
The lack of visibly identifiable 22q11 deletions in DiGeorge patients suggested
that most of these aberrations, if they existed, were likely too small to see, even using
high-resolution cytogenetic techniques. During the late-1980s, molecular techniques
began to be applied to the identification of such deletions. In a 1987 abstract conference
abstract printed in the American Journal of Human Genetics, Emanuel and her colleague
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Wendy Fibison, identified a molecular DNA probe specific to the 22q11 region that did
not bind one copy of chromosome 22 in DiGeorge patients, but bound to both copies in
normal individuals. This finding suggested that the molecular probe was specific to the
DiGeorge deleted region (Fibison and Emanuel, 1987).
From here, additional molecular studies conducted over next five years helped to
better define the size and prevalence of the 22q11 deletion in DiGeorge patients. The
impacts of molecular analysis will be further discussed later in this chapter. Before
returning to this narrative however, the next section explores broader discussions about
the clinical nature and categorization of this disorder, which was named after DiGeorge
and associated with chromosome 22 abnormalities. In addition, I describe the parallel
clinical history of VCF syndrome, during the years before it was genetically linked to
DiGeorge ‘syndrome’.

DiGeorge ‘Syndrome’?
Throughout the 1980s, clinicians and researchers raised various questions about
the disorder named after DiGeorge. Was it a syndrome, or something else? Definitions
of what defines a syndrome vary. Medical geneticist John M. Opitz and colleagues
lamented in a 1979 account of the history of the term ‘syndrome’ that, “Through
indiscriminate use, lately also by sociologists and political commentators, the word
‘syndrome’ has become so debased that few know how to use it correctly anymore”
(Opitz et al, 1979, 98). Clinician and geneticist Kurt Hirschhorn has suggested to me that
identifying syndromes is sometimes, “Tricky business,” noting that, “The conception of a
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syndrome is simply that, once it’s described, you have the possibility of recognizing it
and accepting the fact that the same syndrome can have manifestations that are absent or
present” (Interview with Kurt Hirschhorn, January 26, 2012). Indeed, as Opitz et al
(1979) note, ontological thinking is central to how clinicians conceive syndromes: the
expression of syndromes may be variable within individuals, but nonetheless a syndrome
is a real world entity, that can be delineated and diagnosed.
In a letter to the editor of the Journal of Pediatrics, medical geneticist John Carey
called into question the designation of DiGeorge as a ‘syndrome’ (Carey, 1980). Noting
that the disorder was regarded instead as an ‘anomalad’ in the 1976 edition of Smith’s
Recognizable Patterns of Human Malformation (Smith, 1976, 374), Carey suggested that
its associated clinical features may represent a discrete developmental defect, rather than
a syndrome. Carey offered the term ‘DiGeorge malformation complex’, to describe a set
of related embryological defects that may be features of many different syndromes. He
went on to note that, if additional expressions, such as abnormal facial features, were
seen along the with heart and immune system defects associated with the DiGeorge
‘malformation complex’, then these visual characteristics taken together may constitute a
DiGeorge ‘syndrome’. In fact, the 2006 edition of Smith’s Recognizable Patterns of
Human Malformation has separate entries for the DiGeorge ‘sequence’ or ‘malformation
pattern’, and what some call DiGeorge ‘syndrome’ (Jones, 2006, 298, 714).
During the 1980s, some clinicians and researchers used the terms DiGeorge
‘malformation complex’ and the DiGeorge ‘anomalad’ in their published papers (Kelley
et al, 1982; Keppen et al, 1988). Goldberg et al (1985), perhaps in following with the
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1982 edition of Smith’s Recognizable Patters of Human Malformation (Smith, 1982,
470), referred to the disorder as ‘DiGeorge sequence’, as did Swiss medical geneticist
Albert Schinzel in a 1988 paper on chromosomal syndromes. As Schinzel put it, “The
DiGeorge sequence is a localised defect of development and therefore not a syndrome. It
can occur as an isolated defect or as a component of a variety of syndromes” (Schinzel,
1988, 458).
A sequence is defined as a chain of physiological abnormalities resulting from
one primary defect, which leads to a number of secondary and tertiary effects. In the case
of DiGeorge syndrome the primary defect occurs during the embryonic development of
the 3rd and 4th pharyngeal pouches and the 4th branchial arch, which develop into the
parathyroid, thymus, and heart. On the other hand, a syndrome involves a number of
symptoms that occur together, and usually have a common etiology, but are not the result
of a chain reaction of events (Cohen, 1982). As a result, sequences are localized
disorders (Schinzel, 1988), while syndromes more universally affect the body.
In a 1986 paper, Developmental specialist Edward J. Lammer, writing with Opitz,
referred to this disorder as the ‘DiGeorge anomaly’ saying, “without detracting in the
slightest from [Angelo] DiGeorge’s discovery, a change in our conception of the
condition is necessary because this so-called syndrome is not an etiologically unique
‘syndrome’ at all, but rather a causally non-specific and heterogeneous complex
polytropic developmental field defect” (Lammer and Opitz, 1986, 115). By calling the
disorder a ‘developmental field defect’ the authors implied that DiGeorge is associated
with “a group of embryonic cells and primordial that share some morphogenic property
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that causes them to develop abnormally together” (Lammer and Opitz, 1986, 116). The
DiGeorge ‘anomaly’ is caused by an embryonic abnormality, Lammer and Opitz note,
which may have various etiologies. Indeed, the disorder was associated with aberrations
on chromosomes 1, 8, 10, and 22, and also linked to fetal alcohol exposure.
During the 1980s then, while many clinicians were seeking to associate DiGeorge
syndrome with a specific chromosomal abnormality, multiple others doubted its status as
a ‘true’ syndrome (Opitz et al, 1979) with a clear etiological cause. While translocations
involving the long arm of chromosome 22, and even a small interstitial deletion at 22q11
(Greenberg et al, 1988; Mascarello et al, 1989) were considered to be relevant genomic
markers associated with this disorder, in the majority of cases no chromosomal aberration
was seen. The cause of DiGeorge syndrome remained unclear, as did its nosological
status as a clinical syndrome. During the 1990s, the identification of a genetic link
between DiGeorge and a previously distinct clinical disorder, VCF syndrome, would both
further clarify and confuse its diagnosis and classification.

The Clinical Identification of Velo-cardio-facial Syndrome
In 1978, Robert Shprintzen and colleagues at the Center for Cranio-Facial
Disorders of Montefiore Hospital in New York City reported on what they believed to be
a newly identified clinical syndrome. Ten school-age children and two newborns had
been referred to the center due to various palate problems, and showed “very similar
patterns of symptoms” (Shprintzen et al, 1978, 56). Elaborating on these similarities, the
authors noted, “Perhaps the most striking feature of these patients was the similar facies
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of all twelve” (Shprintzen et al, 1978, 57). The children all had large, wide noses,
flattened cheeks, narrow eyes, and a long face, among other features. Nine of the twelve
patients had heart defects, some had been surgically corrected, eleven showed learning
disabilities (the twelfth was an infant with developmental delay). IQ scores suggested
borderline to mild intellectual disability (Shprintzen et al, 1978).
The most noticeable similarities among these patients were oral and nasal
(velopharyngeal) abnormalities, heart defects, and distinct facial characteristics, which
led to the name Velo-cardio-facial (VCF) syndrome for this disorder. Another syndrome
had previously been called Cardio-facial syndrome (Yurchak and Fallon, 1976),
characterized by ‘elfin’ facial features, heart defects, and intellectual disabilities.
However, the authors of this paper suggest that the mouth and nasal features as well as
the facial characteristics of patients with VCF syndrome were distinct from those with
Cadrio-facial syndrome (Shprintzen et al, 1978).
The cause of VCF syndrome remained unclear at this time. There did not seem to
be an environmental or genetic common denominator among all twelve patients. Among
them however, there was one instance of familial transmission, with the mother and
sibling of a patient showing similar clinical effects (Shprintzen et al, 1978). A 1981
follow-up report accounted for 39 patients with VCF syndrome. Most had been referred
to clinicians because of their hypernasal speech, which is associated with palate clefting.
Among these patients, four instances of familial transmission of VCF syndrome were
noted. This suggested that the syndrome might be inherited in a Mendelian dominant
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manner. Chromosomal analysis performed on these familial patients however, showed
no visible abnormalities (Shprintzen et al, 1981).
In 1985, a conference abstract published in the journal Clinical Genetics by the
Shprintzen group noted a phenotypic overlap between the DiGeorge ‘sequence’ and VCF
syndrome. A patient diagnosed as having VCF syndrome suffered multiple infections,
and was found to have the type of immune dysfunction common in DiGeorge patients.
Upon review of other VCF syndrome patients, it was found that many were judged by
their parents to have frequent infections, while others were shown to have specific
immune dysfunction. In addition, clinically diagnosed DiGeorge patients were seen to
share the ‘look’ of facial features similar to those affected by VCF syndrome. The
disorders were also associated with the same developmental defect of the third and fourth
branchial arches (Goldberg et al, 1985, A54).
Based on four instances of familial transmission, among 39 patients reported in
early-1981, VCF syndrome was regarded by Shprintzen and colleagues as likely
following an autosomal dominant inheritance pattern (Shprintzen et al, 1981). The 1982
edition of Smith’s Recognizable Patterns of Human Malformation, lists this disorder as
Shprintzen syndrome, and notes that it is a “Probable autosomal dominant” (Smith, 1982,
194). Familial transmission of DiGeorge syndrome had been noted previous in a number
of cases, though the inheritance pattern remained unclear in the early-1980s (de la
Chapelle et al, 1981; Raatikka et al, 1981). A 1984 paper, published in the Journal of
Pediatrics, by researchers from Norfolk, Virginia and Philadelphia, reported on a family
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that showed an autosomal dominant inheritance pattern for DiGeorge syndrome, with no
visible chromosomal abnormalities (Rohn et al, 1984).
Among other similarities, this genetic inheritance pattern further strengthened
suspicions that DiGeorge and VCF syndromes were related. As the Shprintzen group
noted in their 1985 conference abstract, “VCF should be considered in any familial
instance of DGS [DiGeorge sequence]” (Goldberg et al, 1985, A54). While the genomic
cause of inherited DiGeorge in VCF syndromes remained unclear at this time, the
presence of abnormalities in the chromosomal band 22q11, identified in a number of
DiGeorge patients using observational cytogenetic analysis, suggested a viable starting
place for molecular studies seeking to identify a genetic etiology.

Molecular Analysis of DiGeorge Syndrome Patients
In 1991, Peter Scambler, and colleagues in London and Stockholm, began to use
molecular probes to examine DiGeorge patients whose chromosomes appeared normal
under the microscope. A report of this research, published in the journal Genomics in
1991, noted that five of six individuals examined had submicroscopic deletions in the
22q11 region. Among these patients however, there was a wide variety of clinical
outcomes, from mild to severe cases of DiGeorge syndrome. There did not seem to be a
correlation between the size of the 22q11 deletion and the severity of the clinical
outcome. The researchers therefore hypothesized that DiGeorge syndrome was likely
caused by the loss of just one gene, common to all of the deletions found (Scambler et al,
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1991), instead of being a ‘contiguous gene syndrome’, associated with the disruptions of
multiple genes in the 22q11 region (Schmickel, 1986).
The next year, Deborah Driscoll and colleagues at the University of Pennsylvania,
identified a 22q11 deletion in each of 14 DiGeorge patients tested using molecular
probes. Five of these patients had microscopically visible 22q11 deletions as well. The
deletions were determined to be both maternally and paternally inherited, ruling out
instances of imprinting, as had been identified in the cases of Prader-Willi and Angelman
syndromes. These findings provided further evidence that a 22q11 deletion was the
etiological cause of DiGeorge syndrome in most clinical cases. The genomic deletions
identified all involved the loss of at least 500,000 DNA base pairs (a large deletion on the
molecular level, but much too small to be seen microscopically), suggesting that multiple
genes were impacted (Driscoll et al, 1992).
Familiar with previous reports about the clinical overlaps between DiGeorge and
VCF syndromes, Driscoll and Emanuel were interested in using their molecular probes to
scan for the 22q11 deletion in patients diagnosed with the latter syndrome as well. As
Emanuel recounted to me, “We were very eager to figure out whether there was a
connection, because we thought there probably was, and we talked to people in our own
cleft clinic here and at CHOP [Children’s Hospital of Philadelphia] and asked, ‘have you
ever seen any of those patients here with VCFS?’ . . . We made an arrangement to go into
the cleft clinic to see if we could detect any of these, VCFS patients, and sure enough
they were there” (Interview with Beverly Emanuel, November 9, 2011). Similarly,
Driscoll told me that, once they were able to identify patients in the cleft clinic who were
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likely affected with VCF syndrome, and test them for the 22q11 deletion, the link to
DiGeorge syndrome became obvious, “We found that it is really essentially one and the
same: it is the same disorder” (Interview with Deborah Driscoll, November 29, 2011).
Based on this additional research, near the end of their report, Driscoll and
colleagues note, “Our observation of deletion of loci from within the DGCR [DiGeorge
Critical Region] in several patients with velo-cardio-facial (Shprintzen) syndrome
(authors’ unpublished results) may explain the overlapping phenotypic features observed
in DGS [DiGeorge syndrome] and velo-cardio-facial syndrome” (Driscoll et al, 1992,
931). This was the first time that VCF syndrome had been associated with a specific
chromosomal abnormality or genomic location. Clearly, this genetic link expanded the
awareness of DiGeorge and VCF syndrome among cleft palate clinics, while also
creating the opportunity to improve laboratory diagnosis. Beyond this, Driscoll and
colleagues hypothesized that further work might reveal the basis of the differential
clinical outcomes associated with these historically distinct syndromes (Driscoll et al,
1992).
Peter Scambler and David Kelly in London reported similar findings in a Lancet
article also published in 1992: deletions in the 22q11 region were found in five additional
VCF syndrome patients. These authors interpreted their findings as evidence that
DiGeorge and VCF syndromes were indeed etiologically related (Scambler and Kelly,
1992). A larger follow-up the next year by Driscoll and colleagues analyzed 76 patients
diagnosed with either DiGeorge or VCF syndrome. Including their previous results,
Driscoll et al (1993) reported that the 22q11 deletion could be identified molecularly in
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88% of DiGeorge patients and 76% of VCF patients. Many of these individuals were
referred by outside clinicians, suggesting that diagnoses may not have been consistent:
some of these patients may not have been affected by DiGeorge or VCF syndrome. In
this latter study, the Driscoll and colleagues used a new laboratory technique:
fluorescence in situ hybridization (FISH). FISH uses fluorescently labeled DNA probes
instead of radioactive ones, which allow for easier, quicker, and safer laboratory analysis.
Also in 1993, another paper from Scambler and Kelly, this time with Shprintzen
and Rosalie Goldberg as co-authors, reported on 12 additional VCF syndrome patients
who each possessed the 22q11 deletion. These clinicians noted that the deletions
molecularly identified in both DiGeorge and VCF syndrome patients were very closely
linked to one another, and indeed might be identical. It seemed as if the physical
genomic deletion itself was not directly responsible for the somewhat different clinical
manifestations associated with these two disorders. Rather the two syndromes, “Could be
part of a spectrum of abnormalities which many be caused by monosomy [the deletion of
one genomic copy of] 22q11. Chance events during morphogenesis could be responsible
for much of the difference in phenotypes [clinical outcomes]” (Kelly et al, 1993, 311).
Indeed, the molecular analysis of increasing numbers of patients suggested that DiGeorge
and VCF syndrome were each associated with the exact same, or at least closely
overlapping, genomic abnormality on chromosome 22.
In a retrospective look at the diagnosis of these two disorders, Greenberg said of
the common deletion found in many DiGeorge and VCF syndrome patients, “This
suggests that the two disorders represent a spectrum of the same gene defect . . . patients
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with suspected or confirmed DGA [DiGeorge anomaly] should be evaluated for features
of VCFS” (Greenberg, 1993, 806). Indeed, with the identification of 22q11 deletions in
patients diagnosed with each disorder, clinicians had identified yet another visible bodily
marker shared by DiGeorge and VCF syndromes. And, since this was a chromosomal
marker, it was understood to have potential etiological and diagnostic implications. By
the mid-1990s, based on their common genomic location and aberration, DiGeorge and
VCF syndromes were increasingly understood as being two historically distinct forms of
one genetic syndrome.

Bringing Together DiGeorge and VCF Syndrome
As noted at the beginning of this chapter, the association of DiGeorge and VCF
syndrome with the same genomic location, designated by the chromosome band 22q11, is
in many ways similar to the overlap between Prader-Willi and Angelman syndromes
described in chapter three and elsewhere (Hogan, 2013). In the historical case of PraderWilli and Angelman syndromes, clinicians immediately discounted the hypothesis that
the two disorders were one and the same. As I have described so far in this chapter, the
historical trajectory of DiGeorge and VCF syndromes was quite the opposite. Indeed,
clinicians took the common 22q11 deletion as definitive evidence that the two disorders
were in fact historically distinct forms of one clinical syndrome. However, while the
etiological sameness of these two disorders was widely accepted in the mid-1990s,
discussions and disagreements were ongoing (and continue, as Navon and Shwed (2012)
have recently described) concerning what to name this, now joint, disorder.
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One early designation came from Wilson et al (1993), who suggested the acronym
CATCH-22 syndrome. The name was meant to remind clinicians of the main features of
DiGeorge and VCF syndromes: Cardiac defects, Abnormal facial features, lack of or an
underdeveloped Thymus, Cleft palate, and Hypocalcemia (low calcium levels due to
underdeveloped parathyroids), all associated with chromosome 22 abnormalities. The
authors of this paper went on to note, “We think that these conditions are all part of one
clinical spectrum and the diagnostic label depends upon the age of presentation and the
predominant clinical manifestation” (Wilson et al, 1993, 865). Indeed, DiGeorge
syndrome tended to be diagnosed primarily in infants with heart defects and immune
deficiency, whereas VCF syndrome was most often identified in school age children with
distinct speech anomalies and learning disabilities. The goal of the term CATCH-22 was
not to replace these two historical designations, but to bring them together under one
clinical and diagnostic heading (Wilson et al, 1993).
Clinician Judith Hall commented at this time that the designation CATCH-22
would prove helpful for remembering what symptoms tend to occur together with the
22q11 deletion. She also suggested, “CATCH 22 is a wonderful model for what is to
come over the next 10 years of human genome work” (Hall, 1993, 802). Indeed, Hall
recognized that this complicated situation, in which multiple clinically defined disorders
were found to be associated with the same genomic location and aberration, was likely to
become increasingly common in the coming years. Such situations would force clinical
researchers to consider more complex explanations for why and how the same genomic
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defect can produce a range of clinical outcomes. This would include various gene
interactions, environmental inputs, and epigenetic effects (Hall, 1993).
A collaboration of clinical geneticists from the US and Australia, including
Driscoll and Emanuel, responded to the suggestion of CATCH-22 in a letter to the editor
of the Journal of Medical Genetics. These researchers pointed out that the designation
CATCH-22 could be misleading for families, since those impacted by the 22q11 deletion
often did not show all of the clinical features captured by the acronym. This was
particularly relevant in familial cases where the diagnosis of a child with a mild form of
the disorder also served as an indicator that future siblings could be more severely
affected. If such a diagnosis was missed, that warning would be lost as well (Lipson et
al, 1994). Indeed, this problem is central to why syndrome delineation and diagnosis is
such, “Tricky business” (Interview with Kurt Hirschhorn, January 26, 2011). While a
syndrome in general may be associated with a large set of outcomes, and an affected
individual may only be impacted by some symptoms, and thus overlooked.
Julie Leana-Cox and colleagues at the University of Maryland also opposed the
use of ‘CATCH-22’, but for a different reason. These clinicians saw the term as having
negative connotations due to its association with the 1962 Joseph Heller book of the same
name. Similar to the instance of ‘Happy Puppet syndrome’ (described in chapter 3),
CATCH-22 was seen as, “inappropriate for use when counseling family members”
(Leana-Cox et al, 1996, 315). Rather than CATCH-22 syndrome, Leana-Cox and
colleagues supported simply combining the disorder’s two historically distinct
designations: DiGeorge/VCF syndrome, “It calls attention to the phenotypic spectrum
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using historically familiar names” (Leana-Cox et al, 1996, 315). Still other clinicians
during the mid-1990s suggested naming the syndrome after its common, and newly
defining, genomic feature: the (sometimes microscopically visible) 22q11 deletion
(McDonald-McGinn, 1997). For their part, the Leana-Cox group liked that the name
‘22q11 deletion syndrome’ was neutral, when compared to the pejorative ‘CATCH-22
syndrome’. Nonetheless, they opposed the designation because it failed to communicate
any of the common the clinical features of the disorder (Leana-Cox et al, 1996;
Wulfsberg et al, 1996).

Just One Elephant in the Room?
In a second 1996 paper, also published in the American Journal of Medical
Genetics, Leana-Cox, writing with Eric Wulfsberg and an Italian colleague, once again
addressed the issue of naming, this time making reference to the parable of the blind men
and elephant. The parable, it turns out, comes up relatively often in the medical literature
when clinicians make the argument to their colleagues that two previously distinct
disorders should instead be thought of as one (Hirschhorn, 1975; Kassirer, 1986; Tobin;
1987). In this classic story, multiple blind men are asked to describe the characteristics
of an elephant, based on touching it alone. Each man focuses on just one portion of the
elephant, leading one to claim that an elephant is like a wall, and another to compare it to
a fan, and a third to think of an elephant as tree-like. Being blind, none of the men can
see the elephant for what it truly is, as one continuous whole. Instead, they continuously
argue about the elephant’s defining features, based on their own limited experience.
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Using this parable, Leana-Cox and Wulfsberg suggested that a similar situation
had played out over the clinical history of DiGeorge and VCF syndromes. Due to their
own specialties and patient populations, clinicians had defined and diagnosed the same
syndrome in different ways, and had failed to see that each of these designations was part
of a greater whole. With the identification of the common 22q11 deletion in the early1990s however, it became clear to clinicians that DiGeorge and VCF syndromes were
indeed two historically distinct forms of just one genetic syndrome (Wulfsberg et al,
1996). Driscoll later put it to me this way,

I think what we realized, is that so much of genetics is based on your
ascertainment bias [what population of patients you see] . . . you can’t
always define syndromes based on phenotype. We came to appreciate that
they are so highly variable. When we thought about DiGeorge syndrome,
we thought immune deficiency, hypocalcaemia, and heart defects: that’s it.
Many of these were so severe they never survived. Whereas here [in
patients initially diagnosed with VCF syndrome] we have this much
milder phenotype, with mostly learning difficulties and cleft palate, and
those were how those children were ascertained. Maybe they had a heart
defect. What we realized is really they were all one and the same, and it
was kind of an ‘a-ha’ moment that you have (Interview with Deborah
Driscoll, November 29, 2011).
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Indeed, this ‘a-ha’ moment was akin to a number of formerly blinded clinicians suddenly
being made to see: the common presence of the 22q11 deletion had brought them all
together.
McDonald-McGinn and colleagues at the Children’s Hospital of Philadelphia
made a similar argument in an editorial response to the Wulfsberg and Leana-Cox paper.
The researchers even provided their own drawn image of ‘the blind men and the
elephant’ to make their point (Figure 9). The depiction shows multiple clinicians, all
focused on different portions of the same elephant, and failing to appreciate its singular
presence. The elephant in their drawing is also shown wearing a banner with the number
22 on it, designating the common genomic location and aberration that ties DiGeorge and
VCF syndromes together. Indeed, just as Wulfsberg and Leana-Cox had argued, the
presence of 22q11 chromosomal deletions in patients with both of these syndromes
represented convincing evidence for clinicians that there had been just one ‘elephant’ in
the room all along.
Velo-cardio-facial as the One True Syndrome
While clinicians widely agreed in the mid-1990s that DiGeorge and VCF
syndrome were two historically distinct forms of one clinical syndrome, they continue, to
the present day in fact, to disagree about what it should be called (Navon and Shwed,
2012). As Shprintzen (1998, 5) suggested, paraphrasing Cohen (1982, 158), “Geneticists
would rather share their toothbrushes than their terminology.” Indeed, Shprintzen
remains one of the primary holdouts in the effort to agree on a common name for these
two syndromes. One grouping of clinicians have agreed upon 22q11 deletion syndrome,
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while Shprintzen and others maintain that VCF syndrome, a name that Shprintzen and his
colleagues coined in their 1978 paper, represents the most descriptive and accurate name
for this disorder.

Figure 9 Drawing referencing the relevance of the parable of the blind men and the
elephant to the case of DiGeorge and VCF syndromes (McDonald-McGinn et al, 1997).
Reprinted with permission from John Wiley & Sons, Inc.

In a 1994 letter to the editor of the Journal of Medical Genetics, Shprintzen also
pointed to the parable blind men and the elephant, noting that previously DiGeorge was
primarily diagnosed in patients initially presenting with heart defects, and VCF syndrome
in individuals with facial and palate abnormalities. In line with other clinicians and
researchers (Carey, 1980; Lammer and Opitz, 1986; Schinzel, 1988, Shprintzen (1994,
1998) did not consider DiGeorge to be itself a syndrome, and instead acknowledged only
the existence of the DiGeorge ‘sequence’. He went on to suggest that VCF syndrome had
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been associated with over 40 clinical features, and among them were those attributed to
the DiGeorge sequence.
As a result, according to Shprintzen (1994), DiGeorge sequence should be
thought of as a possible outcome of VCF syndrome. Its etiology however, was
heterogeneous: the DiGeorge sequence had been associated with multiple chromosomal
abnormalities. In response to the finding of Driscoll et al (1993) that the 22q11 deletion
was only seen in 76% of VCF syndrome cases, Shprintzen argued that any patient
thought to have VCF syndrome, who did not have the 22q11 deletion, was clinically
misdiagnosed. He also noted that Scambler and colleagues identified a 22q11 deletion in
all of the VCF syndrome patients they tested (Kelly et al, 1993). As opposed to
DiGeorge sequence argues Shprintzen, “There is simply no valid evidence to suggest that
velocardiofacial syndrome is aetiologically heterogeneous” (Shprintzen, 1994, 424). As
Shprintzen saw it, while the DiGeorge sequence had multiple causes, VCF was the one
‘true’ syndrome because it was always associated with the 22q11 chromosomal deletion.
Pointing to a singular genetic etiology helped to establish the ontological status of VCF
as a ‘syndrome’.
In a 1998 paper titled “The Name Game,” Shprintzen further explicates his
position, distinguishing between the meaning and medical implications of sequences and
syndromes, and providing arguments for why ‘VCF syndrome’ remained most
appropriate for naming the clinical disorder associated with 22q11 deletions. First,
Shprintzen noted that he an his colleagues, in their 1978 paper, were the first to suggest
that VCF represented a newly delineated clinical syndrome, an argument that Angelo
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DiGeorge had never made in his own publications during the late-1960s. Second, no
earlier studies of syndromes with similar features as VCF syndrome fully addressed all of
its clinical manifestations. Third, while the DiGeorge sequence had been found to be of
heterogeneous origin, no other cause of VCF syndrome besides 22q11 deletions had ever
been identified (Shprintzen, 1998). Taken together, argued Shprintzen, the term VCF
syndrome had priority of in terms of timing, clinical scope, and etiological clarity.
Shprintzen has since presented still more arguments for the designation VCF
syndrome. In a 2008 history of VCF syndrome, he noted that his chosen name is,
“descriptive, geographically nonspecific, free of eponyms, and much easier to write and
say than 22q11.2 deletion syndrome” (Shprintzen and Golding-Kushner, 2008, 16).36
Shprintzen also notes in the same paragraph that most other syndromes associated with
such genomic abnormalities are not named after their chromosomal designations. In a
second 2008 publication, Shprintzen noted, “VCFS is simply easier to say and write and
communicate than any other labels and its use should therefore be encouraged”
(Shprintzen, 2008, 4). Shprintzen’s arguments for his chosen name therefore extend
beyond issues of priority, to a consideration of communicative simplicity.
Clearly the name VCF syndrome is important to Shprintzen in a way that
DiGeorge syndrome never was to the clinician after whom it was named. While
Shprintzen has dedicated his career to VCF syndrome research, Angelo DiGeorge rather
quickly moved on to other interests. Shprintzen has published regularly on VCF
syndrome, especially after it became associated with 22q11 in the early-1990s.
36

22q11.2 represents an additional level of cytogenetic specificity made possible by
high-resolution analysis.
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DiGeorge, on the other hand, who died in 2008, did not publish on DiGeorge syndrome
again after 1969, though he did remain interested in keeping up with ongoing research
concerning the disorder (Interview with Beverly Emanuel, November 9, 2011). Indeed,
Shprintzen’s professional identity is much more closely tied to VCF syndrome, the
disorder he named in 1979, than DiGeorge’s ever was in the disorder named after him.
Perhaps as a result, to this day, VCF syndrome advocates maintain their own
website, hold separate annual research conferences, and have a specific research institute,
the Velo-Cardio-Facial International Center located at the State University of New
York’s Upstate Medical University in Syracuse. At the same time, the 22q11.2 Deletion
Syndrome Foundation also has its own website, annual conferences, and institutions, such
as the 22q Center located in the Children’s Hospital of Philadelphia. The 22q foundation
has an ongoing “Same Name Campaign” aimed at bringing together patients, families,
advocates, and clinicians impacted by or interested these historically distinct syndromes,
under one name (Interview with Donna McDonald-McGinn, November 10, 2011).
I have no interest in taking a side in this debate. However, I do think that this
ongoing difference of opinion over naming demonstrates that the identification of a
common genomic location, in some cases, does not provide sufficient force to meld
together the existing social networks and institutions built around two historically distinct
syndromes. For the remainder of this chapter, I will refer to this disorder as
DiGeorge/VCF syndrome, a name that captures its historical duality, but one that
proponents from both the Velo-Cardio-Facial International Center and 22q11.2 Deletion
Syndrome Foundation would likely oppose.
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A Gene for DiGeorge/VCF Syndrome?
Just like most cases of Prader-Willi and Angelman syndrome, DiGeorge/VCF
syndrome is associated with the deletion of genetic material, specifically from
chromosome 22. Since humans have two copies of chromosome 22, the genes deleted in
the 22q11 region among DiGeorge/VCF patients continue to exist on the non-deleted
copy of the chromosome. Unlike Prader-Willi and Angelman syndromes however, the
deleted region of 22q11 is not affected by genetic imprinting in any way: all genes in this
region are believed to be functional on the remaining single copy present in
DiGeorge/VCF syndrome patients with the deletion (Driscoll et al, 1992). Over 35 genes
are present within the genomic area that is most frequently deleted in DiGeorge/VCF
patients (Kobrynski and Sullivan, 2007). One of more of these genes may play a role in
the clinical expression of the disorder when a copy of it is lost due to a 22q11 deletion.
During the late 1990s, a number of ‘candidate genes’ were identified in the 22q11
region, which could be associated with the DiGeorge/VCF syndrome etiology (Budarf
and Emanuel, 1997; Lindsay and Baldini, 1998). Based on studies in mice, in which
targeted segments of the 22q11 region were deleted, Elizabeth Lindsay of the Baylor
College of Medicine, along with American and British colleagues, highlighted the gene
Tbx1 in 2001 (Lindsay et al, 2001). Researchers from Columbia University in New York
also published on Tbx1 the same month (Jerome et al, 2001). The loss of Tbx1 in mice
seemed to cause heart abnormalities, suggesting that it might also play a significant role
in the clinical outcomes of DiGeorge/VCF patients. Researchers continued to believe
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however, that Tbx1 alone probably is not entirely responsible for the wide-ranging
clinical expression of this disorder (Kobrynski and Sullivan, 2007).
Others have similarly suggested that the clinical expression of DiGeorge/VCF
syndrome is too variable for it to be explained by one gene mutation alone (Schinke and
Izumo, 2001). In 2003, Hisato Yagi and colleagues in Japan reported in the Lancet on
five patients diagnosed with DiGeorge/VCF syndrome who did not have a 22q11
deletion, but did have a mutation specific to the Tbx1 gene. The clinical expression of
these patients remained variable, but most showed the major features of this disorder,
including distinctive heart, thymus, parathyroid, palate, and facial abnormalities. These
patients however, did not show the mild intellectual disability normally associated with
the disorder. The authors of this paper also proposed that the variability of expression
among the five patients they studied suggested that additional environmental and
developmental factors likely influence clinical outcomes (Yagi et al, 2003).
Indeed, going back to the mid-1990s, clinicians and geneticists have been aware
that individuals with the same exact 22q11 deletion can have quite variant clinical
outcomes. This has been made particularly apparent by the identification of identical
twins with widely variable expression of DiGeorge/VCF syndrome. For instance, in
1995 Goodship, Scambler, and colleagues reported on twins who had the same 22q11
deletion, and showed some similar features of this disorder. However, only one twin had
the heart defect characteristics of DiGeorge/VCF syndrome (Goodship et al, 1995). In
1998, Yamagishi and colleagues in Japan reported a similar case. In this instance, the
identical twins both had the same 22q11 deletion, and each showed the distinct facial
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features of the DiGeorge/VCF syndrome, but only one twin expressed other clinical
indicators of the disorder, including a heart defect (Yamagishi et al, 1998). As clinical
geneticist Eli Hatchwell noted in a letter to the editor responding the report by Goodship
et al (1995), a number of genetic mechanisms might lead to such an outcome. For
instance, the deletion of 22q11 from one chromosome may uncover recessive mutations
present on the other copy of 22q11. It is also possible that a second abnormality,
somewhere else in the genome, may represent a ‘second hit’ facilitating certain clinical
outcomes (Hatchwell, 1996).
As Emanuel has described to me, there are a number of factors, such as the
genomic background and chance events embryonic during development that may impact
clinical outcomes. In addition, she noted that, “We don’t know for example, and we’re
trying to pick away at it: what about the non-deleted allele? There are some 40 genes
there. Are there particular forms of those genes that affect whether you do or you don’t
develop a heart defect or neuropsychiatric behavior differences, etc” (Interview with
Beverly Emanuel, November 9, 2011). Emanuel is pointing here to the same issue that
Hatchwell did previously: when an individual only has one copy of a particular gene
because of a deletion, there is always the possibility that a mutation may be uncovered on
the remaining chromosomal copy that will influence clinical outcomes. This also ties
back in with the ongoing discussion over the extent to which DiGeorge/VCF syndrome is
a ‘contiguous gene syndrome’: one in which a variety of impacted genes in one particular
genomic region, 22q11, contribute to clinical expression.
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While Tbx1 appears to play an important role in causing this disorder, it seems
likely that other genes in this region are significant in at least some cases. Researchers
generally agree that the size of the 22q11 deletion does not correlate with the severity of
clinical outcomes (Carlson et al, 1990), but this does not discount the possibility that
larger deletions at least increase the probability that other mutant gene effects could arise.
Indeed, despite its association with the 22q11 deletion, DiGeorge/VCF syndrome
continues to pose significant challenges when it comes to clinical, and in particular
prenatal, diagnosis. In at least 10-15% of cases, children inherit the 22q11 deletion from
one of their parents (in most cases the deletion occurs de novo during the reproductive
process). Most of the parents passing down the mutation have had such mild effects that
they were never diagnosed themselves, and did not need any clinical interventions. If
they possess the deletion, a parent has a 50% chance of passing it on to each additional
child they have. The severity of its clinical impact however, remains impossible to
predict (Driscoll, 2001).
Indeed, there is no way to know another fetus found prenatally to have the 22q11
deletion will be more severely affected than their existing sibling, have an almost entirely
normal life like their previously undiagnosed parent, or fall somewhere in between. This
continued uncertainty greatly complicates the diagnostic process. As Emanuel put it to
me,

We have a lot to learn. The good news is that we understand a fair amount
of the syndrome, i.e. we know it’s due to the deletion. But the good news
196

from the scientific perspective is that there are still many, many questions
to ask in answer. And you can look at it from the reverse, the bad news is
that we don’t know the answer, but the good news is that someone is
interested in finding the answers (Interview with Beverly Emanuel,
November 9, 2011).

Indeed, while clinicians face many challenges when it comes to offering reliable and
reproducible diagnoses, this uncertainty continues to offer researchers with interesting
and potentially valuable questions and opportunities. Variations of the 22q11 deletion
and genomic region found in patients diagnosed with DiGeorge/VCF syndrome, or not,
offer additional opportunities to identify new genomic mutations and interactions that
play a central role in the clinical expression of this disorder, as well as in human disease
and biology more broadly.

Conclusion
In this chapter, I explore the clinical and laboratory history of two previously
distinct disorders that have since come to be understood as one. As I demonstrate here,
the ‘look’ of a particular clinical disease may be impacted by a variety of genetic, social,
and institutional factors. Historical distinctions between DiGeorge and VCF syndrome
seem to have resulted from the different medical specializations, and related patient
populations, of those who first described the disorder. Angelo DiGeorge identified the
syndrome, later named after him, based on his experience with severely impacted
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newborns at a children’s hospital, while Robert Shprintzen primarily saw school-aged
patients who were brought to his clinic due to their speech and palate abnormalities.
Indeed, before the two disorders were linked, the natural history of DiGeorge syndrome
was widely assumed to end by age two, and that of VCF syndrome largely seemed to go
unnoticed until age four or five.
Though the identification of the 22q11 deletion in both subsets of patients
represented an important turning point in the history of DiGeorge/VCF syndrome, it was
certainly not the first indication that these disorders were somehow linked. The openness
to identifying a wide array of potential symptoms associated with VCF syndrome led the
Shprintzen group to notice the impact of immune system abnormalities in their patients,
and link this to existing accounts of DiGeorge patients. Based on this recognition, when
a genomic deletion was found in most individuals diagnosed with DiGeorge syndrome in
1992, it seemed an obvious next step to also look for it in patients who showed signs of
VCF syndrome, even if they were not previously diagnosed with this disorder.
Ultimately, the 22q11 deletion was pointed to, by way of the parable of the blind men and
the elephant, as proof that when it came to differentially diagnosing DiGeorge and VCF
syndromes, there had always in fact been just one ‘elephant’ in the room.
The nosological status of the clinical disorder Angelo DiGeorge first identified –
‘syndrome’ or ‘sequence’ – has remained a point of contention. However, following the
introduction of laboratory testing for the 22q11, it has been clearly established that
individuals who have the ‘look’ described by DiGeorge, as well as this genomic
aberration, are affected by a distinct syndrome. Indeed, while the clinical attributes of
198

DiGeorge/VCF syndrome in an individual, or their child, remains the primary indication
for genetic testing, the genomic deletion itself has become so central to the diagnosis of
this disease that its absence would almost certainly overturn a clinical diagnosis.
As Shprintzen has argued, if the 22q11 deletion is not present in a patient, then
the clinical diagnosis of VCF syndrome was almost certainly incorrect (Shprintzen, 1994,
1998). And similarly, as McDonald-McGinn has told me, “It’s the 22q, the only thing
that everyone has in common is that deletion. Even if it’s a smaller deletion it’s the same
thing” (Interview with Donna McDonald-McGinn, November 10, 2011). The move
towards a more universal use of ‘22q11 deletion syndrome’ instead of DiGeorge and
VCF, only further re-enforces the clinical boundaries of this category. At least in terms
of diagnosis, this genomic finding, of a 22q11 deletion, now seems to be privileged in the
clinic over bodily expression.
This said, while clinicians and researchers have agreed for 15 years now that
DiGeorge and VCF syndrome are the same clinical disorder, a universally agreed about
upon name for this disease has not been reached. In this chapter, I have noted the various
institutional and professional reasons why a common name is so difficult to establish.
Organizations have been created, research dollars spent, and careers built around the
historical names of these clinical disorders. The identification of a common genomic
abnormality may have quickly impacted how individuals are diagnosed with this
disorder, but it has failed to so rapidly alter how the clinicians, researchers, patients, and
families interested in and affected by DiGeorge/VCF syndrome identify themselves and
promote their causes. Indeed, in merely attempting to refer to this syndrome in my own
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scholarly analysis of it, I cannot help but make myself subject to the politics that swirl
around it.
The outcome of the instance of genomic overlap discussed in this chapter may
appear on its surface to have been more easily and simply resolved than in the case of
Prader-Willi and Angelman syndromes. My goal in this chapter however, has been to
demonstrate the various complications that remain when two disorders become one.
Beyond just institutional and professional debates, the association of DiGeorge and VCF
syndromes with the 22q11 deletion has also done little to explain or predict the great
clinical variability of this disorder. While it is easy to diagnose DiGeorge/VCF syndrome
prenatally, or during early childhood, it is impossible to predict how the disorder will
ultimately be expressed.
During the 1980s, many hoped that the association of DiGeorge syndrome with
aberrations at the genomic address 22q11 would lead to the identification of a single
mutant gene for this disorder. However, as recognition of the clinical variability of this
syndrome increased, particularly following its genomic link with VCF syndrome, many
researchers began to assume that one gene alone could not explain the complicated ‘look’
of this disorder in the clinic. A number of theories since have been applied to explaining
the variable expression of DiGeorge/VCF syndrome, including the idea that it is a
‘contiguous gene syndrome’, and the related concept that the 22q11 deletion unmasks
mutant genes in some patients.
While clinical diagnosis would certainly benefit from the resolution of some of
these uncertainties, their genomic implications do continue to drive valuable research in
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human and medical genetics. The concept that this disorder could be explained by oneto-one correlations between gene mutations and clinical outcomes has now been largely
overshadowed by the recognition of multiple-dimensional genomic functionality in this
and other disorders. However, we should not discount the continued importance of the
chromosomally defined genomic region 22q11 over the past 30 years, and in the present
day understanding of DiGeorge/VCF syndrome. While the mechanism of this disease is
complex and unclear, the 22q11 deletion remains an important visual genomic, and
anatomical, marker of this disorder, which has undoubtedly improved the diagnosis,
understanding, and significance of it in the laboratory and the clinic.
Indeed, the ‘look’ of this disorder is very much rooted in the types of visual
evidence that clinicians and researchers choose to highlight and give epistemic priority.
These standards are established and reinforced by the collective ways in which these
biomedical professionals learn and agree to see their objects of study. These research
objects have taken various forms in postwar biomedicine, including the clinically
presented body, and microscopically visible human chromosome set. As this chapter
described, the established ‘look’ of a disease may vary among different institutions,
medical specializations, and over time as new evidence is introduced and re-conceived as
being increasingly important and reliable.
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CHAPTER 5
The Lasting Impacts of Chromosome Level Thinking and Analysis
In 2011, during the early days of my dissertation research, I interviewed Beverly
Emanuel, a medical genetics researcher at the University of Pennsylvania and Children’s
Hospital of Pennsylvania. As our conversation was drawing to a close (and after I had
already turned off my tape recorder), Emanuel was reflecting on her career, which has
largely been defined by her research focus on a particular sub-region on the long arm of
chromosome 22. As Emanuel mused, she held her thumb and 1st finger about a
centimeter apart and spoke of how amazing it was that something so small could be the
focus of an entire (quite productive and rewarding) career. Now, she knew as well as I
did that the genomic region she works on is much smaller than the space between her
fingers; in fact, it is almost imperceptibly small. That bit of space between her fingers
however, was real to her in terms of how she understood chromosome 22 in her head.
Visualized as an ideogram, the chromosome was a tangible entity, maybe a few inches in
length. Small portions of this chromosome have been the focus of many a life’s work.
Most of the genomic entities and processes that Emanuel and thousands of other
postwar medical geneticists dedicated their lives to studying were too small to ever be
directly seen. However, as this dissertation has sought to demonstrate, the work objects
of these researchers were far from invisible to them. In line with generations of
biomedical researchers before then, these individuals relied on painstaking observation,
and standardized ways of seeing and communicating, in practicing their trade. Nicholas
Rose (2007, p. 12) and others (Clarke et al, 2010) have suggested that a new “style of
202

thought” (Fleck, 1979), the “molecular gaze” has “supplemented, if not supplanted” the
longstanding centrality of the ‘clinical gaze’ in biomedicine. In this dissertation however,
I demonstrate that an increasing focus on the ‘genomic basis’ of disease has not undercut
the centrality of observational approaches in genetics in biomedicine. Rather, I suggest
that the postwar period is perhaps best defined by the rise of a ‘genomic gaze’, which
integrates molecular understandings of disease with visible and tangible genomic markers
and conventions.
What is the point of retaining chromosome level conceptions and depictions of the
human genome in an era when clinicians and researchers have a complete DNA reference
sequence at their fingertips? Why has an ‘antique’ nomenclature developed in the 1970s
for the visual description of chromosomes remained a prominent set of landmarks in the
post-Human Genome Era? The answers to these questions are particularly perplexing
when one considers that chromosomal banding nomenclature and genomic sequence data
are incommensurable languages: banding boundaries can, at best, be located within a
100,000 DNA base pair range (Interview with David Haussler, February 29, 2012). In
this chapter, I examine the forces and considerations that have helped to maintain the
importance of chromosome level thinking and nomenclature, and reflect on why older
languages of description based on chromosomal analysis remain intact in the face of
newer, more exacting options. Following this, I offer a series of broader conclusions that
tie together the various case studies examined in this disseration.
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From Sequencing to Browsing
The official announcement of the completion of a rough draft of the human
genome took place on June 26th 2000 at the White House. The draft DNA sequence itself
however, was not made publically available until over a week later on July 7th, when the
genome was for the first time posted on the Internet by the University of Santa Cruz
Genome Bioinformatics Group. As David Haussler put it to me, “that was the day that
the world got the first glimpse of the human genome”. On that day however, the draft
was little more than 2.7 billion letters, “It was nothing more than a waterfall of As, Ts,
Cs, and Gs. So you had people counting how many times GATTACA appeared in it, or
looking for secret biblical messages . . . it was something you could use for wallpaper”
(Interview with David Haussler, February 29, 2012).
In order to make the human genome sequence more accessible to the thousands of
clinicians and geneticists who expected to be begin using it for diagnosis and research,
multiple genome ‘browsers’ were built during the second half of 2000. This included the
Map Viewer, created by the National Center for Biotechnology Information (NCBI) at
the NIH campus, the Ensembl Genome Browser, sponsored by the Wellcome Trust
Sanger Institute and the European Molecular Biology Laboratory (EMBL), and the
University of California, Santa Cruz (UCSC) Genome Browser (Wolfsberg et al, 2002).
These browsers served as portals to the raw human genome sequence data, and provided
the online software and annotations necessary to make the information useful to those
who accessed it. As Haussler put it, in reference to the online release of the initial human
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genome draft in July 2000, “In terms of usefulness it wasn’t until this browser was built
that people could actually use it” ((Interview with David Haussler, February 29, 2012).
The UCSC Genome Browser and others, made analyzing the human genome a lot
like browsing a bookshelf. These data portals offered a top down view of the genome,
with the human chromosome set as the primary unit of analysis. One can jump straight to
a particular gene or genome region, or begin with a specific chromosome and zoom-in
from there. When I began my interview with Haussler at UCSC, he immediately asked
me for my favorite gene, so that he could search for it in the Genome Browser. I picked
SNRPN, a gene associated with Prader-Willi syndrome. Haussler typed this into the
search mechanism, and the browser immediately brought us to a region near the
centromere on the long arm of chromosome 15.
The UCSC genome browser has a horizontal orientation, with a series of
customizable data tracks appearing on the screen. In its default mode, one is shown the
nucleotide number of the region in question (the DNA nucleotides on each chromosome
are numbered from 1 into the hundreds of millions, beginning at the farthest point from
the centromere on the short arm). Below this, the expanse of the gene and its coding
regions are shown, and continuing downward a number of additional data tacks are
shown, including the sequence homologies with a number of other organisms. Above all
of this information, featured prominently at the top of the page is a banded ideogram of
the chromosome being explored: in the case of SNRPN this was chromosome 15. A red
box (or line depending on how zoomed in the tracks are) shows the location and extent of
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chromosome 15 being viewed. SNRPN falls into the chromosomal band 15q11.2, and
appears to be quite close to the boundary with the next visible band, 15q12 (Figure 10).

Figure 10 Output impage from the UCSC Genome Browser, showing the prominient
position of a chromosome 15 ideogram above all other genetic tracks. "The UCSC
Genome Browser, http://genome.ucsc.edu", Human genome assembly Feb. 2009.
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Chromosomal ideograms have a similarly prominent position in the other major
genome browsers. In Ensembl, one begins with a vertically oriented view of all 24
human chromosomes, the “whole genome”, and from here can click on a particular band,
or drag the cursor and select a larger region of one chromosome. From here, Ensembl
offers a similar experience as the UCSC Browser, with a horizontal ideogram of the
chromosome being examined above and a series of data tracks below. The NCBI Map
Viewer also has a number of common experiential features. For instance, one begins by
choosing a chromosome from a vertical depiction of 24 unbanded chromosomes. The
interface is noticeably different at the chromosome level however, because it is vertically
oriented, with a chromosomal ideogram on the far left, and a series of data tracks to the
right. The NCBI depiction of chromosomes is more in line with early genomic
representations, which depict chromosomes vertically with their short arm on top. In the
era of widescreen computers however, horizontal depictions of ideograms may become
more standard.
Initially, UCSC and NCBI provided their own, slightly different assemblies of the
human genome. However, it was quickly decided that for clarity, there should be one
reference genome sequence shared by all browsers, for which the NCBI assembly was
chosen (Wolfsberg et al, 2002). Each browser continues to have its own annotational and
organizational strengths. The Ensembl browser specializes in highlighting protein
structure and function, while the UCSC Browser is more focused on the genetic code
itself. Human geneticists therefore often go to the USCS browser first, and then jump
into the Ensembl browser for protein analysis (Interview with David Haussler, February
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29, 2012). The NCBI Map Viewer is particularly closely integrated with OMIM, and
tends to highlight genes and their chromosomal positions.
The official publication of the draft genome sequence came in issues of Science
and Nature in February 2001. By agreement, papers concerning the results from the
publically funded Human Genome Project appeared in Nature, and those from Craig
Venter’s competing private venture, which also finished its draft in June 2000, were
published in Science. The primary collaborative paper from the public project in Nature
highlighted the newly constructed UCSC and Ensembl genome browsers (Lander et al,
2001). Published along side a series of related papers on different aspects of the genome
project and its preliminary results, was a foldout map depicting the genome at the level of
chromosomes. A vertical, microscopic image of each chromosome was placed next to a
series of horizontal data tracks. Similar to the genome browsers, these tracks broke down
each chromosome into cytogenetic banding units and nucleotide base pair distances.
Known genes were also listed along each chromosome.
When I walked into his office at UCSC, Haussler had the Nature foldout
displayed prominently on his wall. I asked why the contributors to the Human Genome
Project’s primary publication decided to plot the large mass of information that they had
sequenced and compiled in this very visibly oriented format. Haussler responded,

People needed to have something tangible, they wanted a fold out. It was
a monumental achievement, so you wanted something you could
physically touch and look at to get an idea of the scope of the work.
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Previously you would publish a paper in Nature based on five years work
of locating one of those genes, and Figure 1 would be the chromosomal
ideogram and your location of your gene. And that was an incredible
achievement, and I think this made a statement of, wow, look at the scale,
all at once, all those genes (Interview with David Haussler, February 29,
2012).

Having spent a decade sequencing and assembling the entire human genome, it remained
the case that the best way to capture and make apparent the broad implications of this
great accomplishment was to visually depict it a much lower level of resolution. Even on
this poster sized, foldout figure, each linear inch represented 10 million DNA base pairs.
In this sense, the figure certainly conveyed the immensity of the data set that had been
obtained.
This foldout published along with the initial Human Genome Project publications
in early-2001 is representative of continuity of conceptions about the genome before and
after the completion of a draft sequence. Clinician and research understandings of the
genome as a visible, tangible entity did not immediately fade away or become irrelevant.
Rather, they remained central to the thinking and practices of post-HGP era genetics and
biomedicine. In the next section, I trace this continuity more extensively through my
interviews with geneticists.

Cytogenetic Thinking and Analysis in the Era of Whole Genome Sequencing
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One of the publications found in Nature along side the initial paper on the
completed human genome draft sequence, reported on a large project to integrate
cytogenetic landmarks into the genomic DNA sequence (Cheung et al, 2001). 7600
probes had been utilized in an attempt to correlate the chromosomal banding
nomenclature with the draft sequence of the human genome. Each probe was
fluorescently tagged, and under the microscope, which chromosome and band it annealed
with noted, along with the relative ordering of each probe. The probes were associated
with specific genomic fragments, and so their location in the draft sequence was also
known. The goal of all this was to correlate two existing physical maps of the genome:
one based on observational analysis of the human chromosome set going back to the
1970s, and the newly completed draft DNA sequence.
To improve the accuracy of the genome browsers, researchers wanted to know
where boundary lines should be drawn between each consecutive chromosomal band
within the genome sequence. Realistically, these data sets are incommensurable. Asked
how closely the banding boundaries could be associated with the reference sequence,
Haussler told me that the estimations were within, “100,000 bases at best, and that’s
assuming fairly dense mapping, in the optimum conditions. In sparse places, it is a
million bases” (Interview with David Haussler, February 29, 2012). Indeed, where one
chromosomally visible band ends and another begins primarily has to do with the
physical compaction of chromosomes, a process that is only indirectly related to the DNA
codes itself (areas with fewer genes tend to be less compacted and appear as lighter Gbands).
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Knowing the approximate correlation between chromosomally visible bands and
the genomic code is of value in part for research purposes. As Cheung et al (2001, p.
954) put it in their 2001 report, “To proceed from cytogenetic observation to gene
discovery and mechanistic explanation, scientists will need access to a resource of
experimental reagents that effectively integrates the cytogenetic and sequence maps of
the human genome”. Often times, as is described throughout this dissertation, the first
indicator of the genomic location of a disease etiology comes from the identification of a
chromosomal abnormality in a number of similarly affected individuals. A better
correlation between chromosomal band and genomic sequence location can help to target
the search for genes in that region, potentially involved in the disorder. In a similar study
reported in 2003, and based on 9000 probes, UCSC postdoctoral researcher Terrence
Furey made a similar argument about the importance of linking the chromosomal banding
and genomic sequence maps, “The integration of the cytogenetic map with this draft
sequence provides cytogeneticists with the necessary link to this molecular-based
resource. Given a chromosomal abnormality in a diseased cell where the affected region
has been cytogenetically mapped, the corresponding area in the draft sequence can be
easily determined, and then investigated for potential disease genes” (Furey and Haussler,
2003, p. 1037).
In practice however, correlating the cytogenetic banding map to the draft human
genome sequence was about more than helping to target the molecular search for new
disease genes. From a conceptual perspective, the chromosomal banding map offer
clinicians and researchers a way to find themselves in the genome, and to communicate
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genomic locations to their patients and colleagues. As medical geneticist David
Ledbetter has put it to me, “It’s hard to talk about a gene using genome sequence
coordinates, because how do you visualize that, how do you wrap your brain around
genome sequence coordinates?” (Interview with David Ledbetter, March 21, 2012). Here
Ledbetter is referring to the system by which each nucleotide in the human genome
reference sequence is numbered on each chromosome from 1 into the hundreds of
millions. So, for instance, one can refer the gene SNRPN as being located on
chromosome 15 between the nucleotide coordinates 25,217,650 and 25,224,945, or as
being with the visible band labelled 15q11.2. The first method is more exacting
quantitatively, but it does not give one a sense of where they are in the genome or on
chromosome 15.
Many other clinicians and geneticists have offered similar accounts of how their
conceptions of the genome remain grounded in the human chromosome set. As medical
geneticist Beverly Emanuel put it,

If you go to any of the sequence websites, like the [UCSC] Genome
Browser, and you focus in, there is an ideogram that is still there . . .
because for so long we have used that information in that way, and it does
help to put that in a perspective, as opposed to a long string of numbers. A
long string of numbers, from 17 to 20 million, doesn’t necessarily put you
into a visual of where in the genome it is (Interview with Beverly
Emanuel, November 9, 2011).
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Chromosome bands offer a better sense of location and nucleotide numbers do. In
addition, banding nomenclature locations also help to historicize a disorder and its
genomic association. Medical geneticist Kurt Hirschhorn described the important of
chromosomal context to me in this way, once again referencing the UCSC Genome
Browser, “Some of this is historical, a number of difficulties have been described by
virtue of a chromosome and a position in a chromosome. So, if you want to understand
what the background of the whole thing is, you really need to see the chromosome. And
I think they have done a very good job of that at Santa Cruz” (Interview with Kurt
Hirschhorn, January 26, 2012).
Chromosomal locations are also more useful than genomic coordinates when
communicating with patients. As medical geneticist Uta Francke noted to me, “It’s hard
to visualize just DNA . . . if you talk to parents, or people who are affected with a
chromosomal imbalance, it helps a lot to show them a picture of a chromosome, and say
look, this is the piece that is now translocated. It gives them some coordinate numbers”
(Interview with Uta Francke, February 27, 2012). Indeed, it is much easier to offer
patients a visual representation of a genomic abnormality than a sequence level,
quantitative account. Deborah Driscoll offered a similar narrative of how she uses
chromosome level explanations to counsel patients,

We have come a long way [with molecular genetics], and I think it has
really changed the way we can counsel families, but visually you still
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think of a chromosome. It is kind of where the DNA lives, the genes live,
so that’s how I think of it. When I talk to patients, I talk about
chromosomes, and then what I try to do is explain to them what is a gene
(Interview with Deborah Driscoll, November 29, 2011).

Along similar lines, many of the clinicians and geneticists I interviewed told me
that those who work with the human genome have a communal sense of its geography
based on the chromosomal banding nomenclature initially developed in the 1970s.
Indeed, one cannot know the entire genome at the level of resolution that the DNA
reference sequence provides. But geneticists are quite used to visualizing the genome
under the microscope as a karyotype. Referring to Victor McKusick’s ‘morbid anatomy’
of the human genome, Reed Pyertiz suggested to me, “I think if you had psychoanalyzed
people back then and tried to get them to express what image flashed in their mind when
they thought of the genome that [McKusick’s chromosome level gene and disease maps]
would be it . . . I still have tucked away the notion of the karyotype . . . but now I think of
a cloud, it’s just a mass of data” (Interview with Reed Pyeritz, April 18, 2012). Indeed,
even in the era of whole genome sequencing, it is difficult for geneticists to conceive of
the human genome without referring back to the chromosomes.
While the human genome reference sequence is an impossibly large and repetitive
data set, chromosomal nomenclature offers researchers and clinicians with a satisfying
sense of place. Medical geneticist Dorothy Warburton has suggested to me that she
thinks of the genome as a familiar neighborhood, full of landmarks that make navigating
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it easy and intuitive. To remove these landmarks, and replace them only with
consecutive numbering she told me, is to take away the native elements that make a
neighborhood recognizable Interview with Dorothy Warburton, May 11, 2011).
Ledbetter expressed a similar feeling that chromosomal locations offer him a sense of
place and context,

If I am in a seminar or talking with somebody and they start talking about
a gene, the first question I ask is, what chromosome is it on, where does it
live? And, it is sort of like saying, where are you from? Just the
geography of where somebody lives or comes from just helps you . . . If a
gene is on chromosome 18 or it is on chromosome 16, I’m not really
asking because I want to know what the individual gene neighbors are. I
just can’t imagine a gene without thinking where it is in the genome
(Interview with David Ledbetter, March 21, 2012).

As Ledbetter went on to explain, there really is not an explicit functional purpose for
knowing on which chromosome a gene is located. Indeed, genomic proximity does not
suggest that there is a functional relationship or interaction among gene functions or
products.
Knowing where a gene is located in the human genome however, may offer
context more generally about what other genetic entities or regulatory elements are in the
area, which could be relevant in cases involving chromosomal aberration or genomic
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imprinting (as in the instance of Prader-Willi and Angelman syndrome). In this sense,
chromosomal banding offers a set of signposts that may help to guide one through the
genome. As Robert Nicholls put it in our interview, “for me the chromosome correlation
is a guidepost as to the underlying genes or regulatory sequences” (Phone Interview with
Robert Nicholls, April 5, 2012). Driscoll similarly referred to cytogenetic banding
nomenclature as “the signposts along the genome” (Interview with Deborah Driscoll,
November 29, 2011). In fact, the genome offers many useful signposts (expressed
sequence tags, ESTs, and restriction enzyme sites have been used in this way). However,
chromosomal ideograms offer a broadly shared, visual language for describing the human
genome, which is known to geneticists worldwide, thereby making it highly useful for
positional communication.
Indeed, while the human genome may in many ways be an expansive cloud of
data, as Pyeritz described it to me, in the post-HGP era, clinicians and geneticists
continue to rely on familiar landmarks and low-resolution chromosomal representations
of the human genome as they communicate about and interact with it. Chromosomal
ideograms offer a tangible landscape within which clinicians and geneticists situate and
contextualize their research, and offer a useful visual referent as they counsel patients on
the genomic basis of a particular disorder. While genetic analysis now regularly takes
place at the level of DNA sequence analysis, chromosomal level thinking and
representation continue to be an important starting point for conversation.
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Concluding Remarks
This dissertation is a contribution to the ongoing observational turn in the history
of postwar genetics and biomedicine. In recent years, scholars have made significant
contributions to our understandings of the visual practices of human and medical
geneticists since the 1950s (Martin, 2004; Lindee, 2005; de Chadarevian, 2010;
Santesmases, 2010). As part of this, historians of science have sought to better
understand how the human genetic complement and chromosome set have been seen and
standardized as a scientific object by genetics researchers. To this body of literature, I
add a historical analysis of evolving conceptions and depictions of the human genome
since the 1960s, an entity that has become increasingly central to the thinking, practices,
and promotion of biomedical research over the past 30 years.
Each of the case studies presented in this dissertation seek to capture the
development of a new nosolgical and diagnostic system in postwar biomedicine, in which
clinical disorders have come to be understood as having a genomic basis. As I describe,
the visible chromosomal markers associated with each of these disorders played a central
role during the 1970s, 80s, and 90s in shaping their clinical delineation, diagnosis,
understanding, and treatment. These visible genomic markers, specifically the fragile X
site, 15q11-13, and 22q11 deletions, have served as an influential basis for delineating
and naming a new disorder, identifying a relationship between two diseases that were
otherwise clinically distinct, and ontologically (though not institutionally) unifying two
previously separate syndromes into one.
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As these case studies are meant to demonstrate, the ideal of one-to-one
correlations between genetic mutations and diseases was often complicated during the
postwar period by the unanticipated and confusing behavior of visible chromosomal
markers. While a source of frustration for many clinicians and patients, such ambiguous
findings attracted the attention of many more basic genetics researchers. Indeed,
chromosomal analysis proved to be a very productive experimental system for human
geneticists throughout the postwar period. As I describe, sustained observational analysis
of chromosomes in patients impacted by various genetic disorders led to new, more
complex, understandings of genomic functionality in the decades before the completion
of the Human Genome Project. Far from a one-dimensional dataset, chromosomal
analysis offered a window into the multi-level functionality of the genome.
Many of the disorders examined in this dissertation represented important (and
sometimes short-lived) exemplars of particular forms of genomic disease in the postwar
period. For example, Fragile X and Prader-Willi syndrome have long been, and remain,
important teaching cases in human genetics and biomedicine. The deletion of the
chromosomal region 15q11-13 was pointed to throughout the early-1980s as
representative of how the loss of specific genomic information could cause a discrete
clinical outcome, and since 1990 with the demonstration of genomic imprinting, has been
used as a means for demonstrating the multi-dimensional functionality of the human
genome. Likewise, the fragile X site similarly represented in the early-1980s a visible
chromosomal feature that could be used to delineate a particular form of intellectual
disability, which it in the 1990s was presented to clinicians and geneticists as the basis of
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a new genomic mechanism, trinucleotide repeat expansions, which turned out to explain
the unusual inheritance pattern of multiple genetic disorders.
As Angela Creager has suggested, exemplars are much more than fixed textbook
renderings of established scientific theory. In fact, existing exemplars are constantly
being renegotiated within productive experimental models (Creager, 2002). The case
studies presented in this dissertation demonstrate that throughout the 1980s,
chromosomal analysis remained an important and productive experimental system for
human and medical geneticists, which brought about new exemplary understandings of
the structure and function of the human genome and its role in disease. While during the
1980s, clinicians and geneticists had high expectations for the value of new molecular
approaches to doing genetics, and for the potential of DNA sequence level mapping of
the human genome, this did not undercut their willingness to take advantage of existing
cytogenetic tools.
Particularly in the clinic where the treatment of individual patients could not be
put on hold pending new techniques or understandings, researchers developed new
approaches for better understanding genetic diseases through a process of bricolage.
Using whatever tools were currently had available they built what was at once a
technological and experimental system. As I have described throughout this dissertation,
the questions and findings of the clinic often shaped more basic genetics research, and
vice versa. The trading zone of problems, interests, and information between the
laboratory and clinic, I argue, was greatly facilitated during the 1970s and 1980s by
adoption of common conventions for describing the genomic basis of disease among
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basic and clinical geneticists. These conventions were perhaps best embodied by the
standardized chromosomal ideograms discussed throughout this dissertation.
Chromosomal ideograms offered idealized representations of what chromosomes
looked like under the microscope, and at the same time tangible entities within which
known cartographic and anatomical features of the human genome could be
systematically represented. In this sense, following the distinction first made by Charles
Pierce (1982), these ideograms were both iconic and indexical representations. Iconic
images are those that capture the likeness of an object, such as a photograph of someone,
whereas indexical representations point to something unseen within them, such as dark
clouds suggesting an impending rainstorm.37 Along these lines, ideograms roughly
approximated what chromosomes looked like under the microscope, and at the same time
have been used to represent the basic landscape and anatomy of the unseen DNA
sequence of the human genome, which is compacted within them.
As I describe throughout this dissertation, the combined iconic and indexical
status of chromosomal ideograms in postwar genetics and biomedicine was central to
evolving notions of the human genome as a standardized object of research and analysis
in the laboratory and the clinic. As iconic representations, ideograms helped clinicians
and geneticists to distinguish and communicate about chromosomes and their visible
anomalies. During the 1970s and 1980s, these ideograms also increasingly took on an
indexical role as the framework upon which the genetic and disease related components

37

For me on this distinction:
http://www.cs.indiana.edu/~port/teach/103/sign.symbol.short.html. See also, Lukas
Rieppel’s (2012) recent paper on the museum exhibition of fossilized dinosaurs.
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of the human genome were mapped. Over this period, these ideograms evolved both
visually and conceptually, coming at once to represent the human chromosome set
iconically and the human genome indexically.
Chromosomal characteristics that could be seen under the microscope and were
represented on ideograms, such as dark and light bands, fragile sites, and deletions, were
used as a basis for understanding unseen genomic structures and functionality. Light
bands on ideograms suggested areas of the human genome with a much higher density of
genes, while bands that were absent in patients diagnosed with particular disorders were
assumed to contain the etiological basis for certain clinical outcomes. In this way,
ideograms were used to represent knowledge about both the normal and pathological
human genome.
Keating and Cambrosio (2003) have argued that central to postwar biomedicine
has been a material and institutional realignment of the normal and the pathological, in
the form of what they call biomedical platforms. In this dissertation, I suggest that
McKusick’s ‘morbid anatomy’ of the human genome captures a similar conceptual
realignment, through its iconic use of normal chromosomal ideograms to point,
indexically, to the genomic basis of hundreds of genetic disorders. Indeed, as the case
studies presented here demonstrate, when diseases come to be understood as having a
genomic basis, they may draw the attention of more basic genetics researchers, who are
not interested in a particular disorder, so much as what it might reveal more broadly
about the structure and function of the human genome. This continuity of in the
questions and interests of basic biological and applied clinical researchers, I argue, has
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been facilitated in part by shared conventions for mapping the human genome using the
standardized banding patterns provided by chromosomal ideograms.
Chromosome level depictions of the human genome embody particular modes of
thinking and sets of approaches that have been central to the development of
contemporary biomedicine. Indeed, understandings of the human genome as visual,
tangible, and anatomical have helped to facilitate a broad communication, exchange of
interests, and sense of common relevance among the diverse array of individuals who are
involved in biomedical research. Each day, in meetings, clinics, and laboratories,
biomedical professionals look to chromosomal depictions of the human genome, and see
in them iconic and indexical representations of what has been accomplished so far, and
what territory remains to be explored. Mindful of this, as historians of science and
medicine continue to probe the material and conceptual underpinnings of postwar
biomedicine, I hope that they will keep an eye open to its visual cultures, which have
been integral to the postwar success of genetic medicine – scientifically, clincally, and
socially.
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